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Abstract 
Computational design, synthesis, and biological evaluation of small molecule anti-cancer 
therapeutics 
Matthew Ernest Welsch 
 
It’s estimated that as many as 80% of the existing potential cancer targets are considered 
to be ‘undruggable’ [1]. The vast majority of these targets engage in protein-protein interactions 
(PPIs) [1]. Within this class are the RAS GTPases (HRAS, KRAS (4A and 4B), NRAS), which 
are the most frequently mutated oncoproteins in human cancer- present in 30% of all 
malignancies [11]. Despite efforts to target RAS spanning over 30 years, there still exists no 
direct therapeutic agent. The focus of this work has been using in silico tools to develop general 
approachs for designing inhibitors of PPIs and applying them to the RAS family of GTPases. 
Two parallel approaches are described. The first uses pharmacophore screening with a model 
derived from the residues on the effector proteins that have been established through 
mutagenesis studies to be functionally important for binding affinity to RAS. The second is a 
process we have termed PAINT- Process for Assembling ligands for Intractable Targets. This 
approach first entails the docking of fragments into multiple sites on a target engaging in protein-
protein interactions. The fragment docking results are analyzed for enriched molecular 
architectures and are then used for the basis of combinatorial in silico libraries. A library is 
designed in one site and then the top scoring compounds are selected and used to extend into 
adjacent sites in iterative docking and design process. The design, organic synthesis, biochemical 
evaluation, evaluation in cells, and in vivo testing are described herein.  
	  
The second portion of this thesis describes the structure-activity relationship studies and 
optimization of two experimental cancer therapeutics discovered in the Stockwell lab. The first is 
the small molecule erastin, which elicits a novel, iron dependent form of cell death in cancer 
cells called ferroptosis. The ability to study ferroptosis in vivo has been limited by the suboptimal 
physiochemical properties and potency of erastin. Described in this work is the systematic 
synthetic modification of the erastin structure that resulted in the improvement of its 
physiochemical properties, selectivity, potency, and metabolic stability. The second molecule, 
J9, reverses resistance to glucocorticoid therapy in T-cell acute lymphoblastic leukemia (T-
ALL). The improvement of both the potency and selectivity of this compound was achieved 
using this process.  
The hope of this work is that the strategies implemented can be applied to other small 
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Chapter 1: Introduction 
I. The ‘druggable’ genome and protein-protein interactions as drug targets 
The ‘druggable genome’ is a concept used to describe the segment of the total human 
genome that is amenable to modulation by exogenous small molecule drugs [1]. The advent of 
technologies, such as high throughput protein crystallography, have facilitated the delineation of 
a large repertoire of protein structures and insight into the forces that govern receptor-ligand 
interactions [2]. According to analyses performed the on structures in the protein data bank, it is 
estimated that only about 12% of proteins in the human proteome fall within this ‘druggable’ 
category [3]. Moreover, the quantity of existing drugs is focused on a small subset of targets. For 
example, G protein coupled receptors constitute an astonishing 19% of the established druggable 
genome [4]. The primary difficulty in targeting the vast remaining portion of human proteome is 
due to the absence of cavities with sufficient properties for the tight binding of small molecules 
[1,3-4].  
The majority of these perceived “undruggable” targets participate in protein-protein 
interactions (PPIs) [1,3]. PPIs play an integral role in biological processes and genome-wide 
computational methods estimate more than 300,000 potential protein interaction pairs exist [4,6]. 
Small molecule inhibitors for this largely untapped reservoir of challenging targets could treat 
innumerable diseases and be used as tools to help illuminate biological signaling networks. Such 
tools would provide a wealth of information about human biology and the molecular 
underpinnings of disease. PPIs are considered by many to be the final frontier of drug discovery 
[5].  
The chemical modulation of PPIs was historically thought to be an intractable problem 
because the contact surface area of a small molecule-protein interaction is approximately one 
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fifth to one tenth that of a typical PPI [3,5].  While a small molecule attaining higher binding 
affinity than a protein while making less surface contacts seems implausible, emerging 
technologies and innovative strategies have led to a number of PPI modulators progressing to 
clinical development [4-5,7]. This more tractable subset of PPIs is comprised of those that 
consist of a short α-helical domain that can be inserted into a hydrophobic grove of an 
interacting partner [7]. Successful attempts at inhibiting interactions of this type include the p53-
MDM2 interaction by nutlins, the BCL2 family inhibitor obatoclax, the ARF-SEC7 inhibitor 
BFA, among others [4,7]. A much more challenging class of PPIs are those that are mediated 
though β-strands [8]. Interactions of this type gain a substantial portion of their binding affinity 
by forming an extended β-sheet between the two interacting proteins. The interface of these 
interactions typically lacks cavities conducive to the binding of a small molecule inhibitor [8]. A 
protein family that enables a number of a different cellular signaling modules through 
interactions of this type are the RAS family of GTPases, considered by many to be the most 
highly sought after target in the history of cancer biology [9].  
 
II. The RAS family of GTPases 
IIa. Prototypical members  
The canonical members of the RAS GTPases (HRAS, NRAS, and KRAS (4A and 4B)) 
play a central role in a number of signal transduction pathways [10-11]. They function as binary 
switches, transitioning from their active GTP-bound state to their inactive GDP-bound state, a 
transition that is reciprocally regulated by guanine exchange factors (GEFs) and GTPase 
activating proteins (GAPs) [10-11]. GTP binding causes RAS to undergo a conformational 
change that enables it to interact with a number of proteins involved in signaling pathways 
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related to cell growth and proliferation. Mutations resulting in impairment of the GTPase 
catalytic activity or the prevention of GAP binding result in the constitutive activation of RAS 
and lead to the malignant phenotype [11].  Mutations of this type are found in 20-30% of all 
human cancers [11], with particularly high rates occurring in three of the top four lethal 
malignancies in the United States—pancreatic (90%), colon (45%), and lung (35%) [10].  
 
IIb. Other RAS family members 
The RAS superfamily can be divided into five major subfamilies: RAB, ARF, RAN, 
RHO, and RAS [17]. These subfamilies facilitate a number of processes within the cell: signal 
transduction (RAS), gene expression (RAS, RHO), cytoskeletal organization and cell motility 
(RHO), vesicle trafficking/budding (RAB, ARF), microtubule reorganization and 
nucelocytoplasmic transport  (RAN) [17,18]. The RAS subfamily can be further divided into 
groups consisting of: RAP (RAP1A, RAP1B, RAP2A, RAP2B and RAP2C), RHEB, RAL 
(RALA and RALB), RRAS (RRAS, TC21 and MRAS), and the canonical members of RAS 
(HRAS, NRAS, KRAS 4A and KRAS 4B) [17].  RHEB (RAS homology enriched in the brain) 
elicits its effect primarily through TORC1, which causes enhanced growth and translation. 
RRAS, a less understood member, is known to enhance integrin mediated adhesion and signaling 
though PLCε [19]. In contrast to the majority of GTPases effector proteins, RAP1 and RAP2 
have domains that discriminate between these two isoforms [20]. RAP is known to regulate 
functions such as cell-cell junction formation, cell adhesion, exocytosis as well as establishing 




III. Post-translational processing of RAS 
The prototypical members of the RAS family (HRAS, NRAS, KRAS 4A and KRAS 4B) 
are ubiquitously expressed in all cells with the exception of KRAS 4A, which is found only in 
the lung, liver, and kidney [22]. They exhibit high degree of sequence homology between 
isoforms (~90%) [23]. The variability is primarily in the C-terminal hypervariable region, 
possessing only 10-15% conservation, and the differences dictate posttranslational modification 
through both palmitylation and prenylation [23].  
This area contains a CAAX motif (C=cysteine, A=aliphatic residue, and X=serine or 
methionine) that is prenylated after translation. All the RAS isoforms can be farnesylated at the 
cysteine of the CAAX motif, while NRAS and KRAS (4A and 4B) can also undergo 
geranylgeranylation [23, 24]. Addition of the prenyl moiety localizes RAS to the ER where the 
AAX portion is cleaved by RAS converting enzyme 1 (RCE1) and the cysteine undergoes 
methyl esterification by isoprenylcysteine carboxymethyltransferase (ICMT). Once methylated, 
palmitoylation occurs at an additional cysteine on NRAS and HRAS that subsequently directs 
these enzymes to the golgi apparatus [23]. They are then depalmitoylated at the golgi and the 
delta subunit of phosphodiesterase 6 (PDE6) binds to the hydrophobic farnesyl moiety and 
enables localization to the plasma membrane [25]. KRAS 4B, the more ubiquitous spliced form 
of KRAS, does not undergo palmitoylation. Instead, following methylation at ER, the farnesyl 
moiety is bound by PDE6 and is localized to the plasma membrane, where it associates to the 
cytoplasmic face via its farnesyl group and a poly-lysine sequence near the C-terminus [25]. This 
alternative localization mechanism is the basis of the different signaling modalities of the RAS 
isoforms [23-25].  
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The idea of non-redundant functions of these isoforms was proposed based on the 
observation that certain isoforms are exclusively mutated in cancers of different tissue types [26]. 
Moreover, studies involving RAS knockout mice resulted in embryonic lethality with a 
homozygous KRAS 4B isoform knockout in contrast to the normal growth and viability 
observed with the HRAS and NRAS homozygous knockouts [26].  
 
IV. Upstream signaling of RAS  
The wild-type RAS proteins are activated through guanine exchange factors (GEFs) [21, 
30-31].  There are four subfamilies of GEF proteins currently known: SOS, RASGRP, and 
CNRASGEF [21]. SOS is ubiquitously expressed, while RASGRP and CNRASGEF are 
predominately expressed in the haematopoietic cells and the central nervous system, respectively 
[21]. The SOS facilitated activation of RAS is mediated through signaling at receptor tyrosine 
kinases (RTKs) [21, 30]. 
 
IVa. Receptor tyrosine kinases (RTKs) 
Signals transmitted to the cell surface are detected at receptor tyrosine kinases (RTKs), 
such as EGFR or PDGFR.  These signals result in autophosphorylation at their tyrosine residues 
[30]. The SRC homology 3 (SH3) domain of the adaptor protein GRB2 then binds to the 
phosphorylated tyrosines, and son of sevenless (SOS) is then brought in close proximity to 





IVb. Son of sevenless (SOS) 
SOS is a guanine exchange factor that is responsible for catalyzing the exchange of GDP 
to GTP in RAS GTPases [30, 31]. The two isoforms of SOS, SOS1 and SOS2, are ubiquitously 
expressed in mammalian cells. Both consist of the CDC25 and RAS exchanger motif (REM), 
which are required for their activity [30]. The interaction of RAS with SOS occurs primarily at 
the CDC25 domain, with an α-helix from SOS inducing a conformational shift of the switch I 
region of RAS and expansion of the nucleotide-binding pocket [31]. The side chain of L938 of 
SOS is inserted into the pocket and blocks the magnesium from interacting with the phosphates. 
In addition, E942 of SOS blocks the critical hydrogen bond between S17 of RAS and the alpha 
phosphate of GDP [31]. The net effect of these events is an alteration of the chemical 
environment of the nucleotide-binding site that dramatically reduces affinity of GDP, causing it 
to diffuse out and allowing for the binding of GTP [31].  In its GTP-bound state RAS is able to 
interact with a number of ‘effector’ proteins and cause the activation of several signaling 
cascades [31].  
 
IVc. GTPase activating proteins (GAPs) 
The inactivation of RAS proceeds through two mechanisms: intrinsic GTP hydrolysis and 
by GTPase activating protein (GAP) mediated hydrolysis. GAPs inactivate RAS via accelerating 
the otherwise slow intrinsic rate of GTP hydrolysis. A GAP arginine residue is positioned into 
the GTP binding site and acts to neutralize the negative charge of the GTP phosphates [32]. The 
hydrolysis is further catalyzed by the stabilization of Q61 of RAS, which lowers the pKa of a 
water molecule situated in the p-loop [32]. This water molecule then engages in a nucleophilic 
attack on the beta phosphate, expelling the gamma phosphate and yielding GDP [32]. Mutations 
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in the RAS proteins, particularly at amino acids G12 and G13, prevent GAPs from binding and 
results in its constitutive activation [32].  
 
V. Signaling downstream of RAS  
Va. Rapidly accelerated fibrosarcoma (RAF) kinase pathway 
The first RAS effector to be discovered, and also the best studied, are the RAF kinases 
(CRAF, ARAF and BRAF) [40].  BRAF is the most frequently mutated RAF isoform and is 
found altered in approximately 70% of human melanomas [40]. RAF isoforms associate with the 
switch I region of RAS via their n-terminal RAS-binding domain (RBD) and with the switch II 
region of RAS through their c-terminal cysteine rich domain (CRD) [41,42]. This binding event 
to GTP-bound RAS disrupts the N-terminal auto-inhibition segment of RAF and localizes it to 
the plasma membrane for further phosphorylation and dephosphorylation events that lead to its 
optimal active state [42].  
Following RAS mediated activation; RAF phosphorylates the two isoforms of MEK 
(MEK1 and MEK2), whose only known substrates are ERK1 and ERK2 [41]. ERK has as vast 
array of substrates, which affect cell differentiation and proliferation. Of particular importance is 
the activation of the transcription factors ETS-1, ETS-2, and CMYC; whose overexpression 
contributes to the oncogenic transformation of cells [43].   
 
Vb. Phosphatidylinositol 3-kinase pathway 
Another well-studied RAS effector is phosphatidylinositol 3-kinase (PI3K), which is also 
mutated in a number of different cancers including glioblastoma, breast, colorectal, gastric, acute 
leukemia, hepatocellular and lung [44, 46]. It consists of two domains - p85 and p110 [44]. In the 
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inactive state the p85 regulatory domain inhibits the catalytic activity of the p110 kinase domain 
[44]. Upon association of the p85 domain with RAS, the p110 unit becomes active and PI3K can 
phosphorylate the 3’-hydroxyl group of phosphatidylinositol-(4,5)-bisphosphate (PIP2) to 
produce phosphatidylinositol-(3,4,5)-triphosphate (PIP3) [45]. This product then binds to the PH 
domain of PDK1, PDK2 and AKT. The binding of PIP3 recruits these cytosolic proteins to the 
plasma membrane where AKT is phosphorylated at T308 and S473 by PDK1 and PDK2, 
respectively [46]. While phosphorylation of T308 is sufficient for catalytic activation of AKT, 
the second phosphorylation at S473 allows for maximal activity [46]. In a similar manner to 
ERK, AKT has a number of different substrates. Mutations of AKT1, such as E17K, have also 
been found in a number of cancers and result in constitutive localization to the plasma 
membrane, which promotes hyperphosphorylation [46]. Additionally, amplification of AKT1 has 
been found in some gastric carcinomas [46]. 
 
Vc. RAL dissociation stimulator (RALGDS) 
RAS-like (RAL) GTPases were identified from a screen for genes related to RAS. 
Guanine exchange factors for RAL were discovered shortly after from a screen of a library of 
mouse cDNA [47].  Further investigation of this library also identified that RALGDS has 
sequence homology to the REM and CDC25 domains, characteristic of REF-GEFs [47].  In a 
manner similar to RAS, GTP-bound RAL interacts with a number of downstream effector 
proteins. The best-characterized interaction is SEC5 and EXO84, two components of the 
octameric exocyst complex. This complex regulates exocytosis through tethering post-golgi 
secretory vesicles to the plasma membrane prior to exocytic fusion [48]. This process plays a 
functional role in tumor cell invasion [48].   
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VI. Early stage drug discovery and applications towards targeting RAS and RAS signaling 
pathways 
VIa. Target selection 
 The analysis of differences between normal and abnormal cells is the initial step in 
selecting a suitable target for pharmacological inhibition. In the case of cancer, targets are 
selected on the basis of their ability to induce selective lethality over normal cells.  
 
i. Oncogene addiction 
The concept of oncogene addiction is the situation in which the survival of the cell 
becomes dependent on a single altered gene [12]. Inhibition of the protein product of these 
mutated genes has been shown not only to lead to a reversal of the malignant phenotype but also 
to tumor regression, making it desirable for pharmacological inhibition [13]. The addiction to 
mutated RAS is a prototypical example of this phenomenon. The high prevalence of mutations 
and frequent essentiality in a number of different malignancies has made RAS a highly sought 
after cancer target [9,10]. 
 
ii. Synthetic lethal screening 
The difficulty in discovering a direct inhibitor for RAS, and other challenging targets, has 
motivated a number of creative alternative approaches, such as synthetic lethal screening [14]. 
Synthetic lethality arises when the presence of two altered proteins results in cell death, in 
contrast to cells consisting of the individual alterations where no deleterious phenotype is 
observed [14]. A major utility of this approach is finding a more druggable target for the 
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treatment of a particular disease when the desired target is not amenable to pharmacological 
inhibition [14]. A number of different screens using RNAi in RAS mutated cells have been 
performed to find a gene that exhibits a synthetic lethal interaction with RAS [9]. One notable 
example is STK33, a much more druggable kinase that was identified from an shRNA screen of 
KRAS mutated cells compared to wild-type (wt) [15]. Unfortunately, inhibition of STK33 by a 
small molecule did not reproduce this synthetic lethal interaction [16]. Moreover, this result was 
not reproducible with small interfering RNA (siRNA), highlighting the limitation of this 
approach [16].  
 
VIb. Helix stapling  
i. Overview 
The most common type secondary structure at protein-protein interfaces is the α-helix 
[33]. It was discovered that the binding affinity of short α-helical segments engaging in PPIs 
could be improved through the use of chemical braces [33]. These “helix staples” encompass one 
or two turns of the helix (i, i+4 and i+7), and typically consist of 8 and 11 hydrocarbon chains, 
respectively. Stapling increases helicity and improves affinity by decreasing the entropic cost of 
binding [33]. This technique as also been shown to reduce degradation by proteases and increase 
the blood half-life of a peptide from 30- to 60-fold [33, 34]. Stapled helices have been shown to 
out-compete the endogenous protein in a number of different cases, however the issue of cell 





ii. Application of helix stapling to disrupting the RAS-SOS interaction 
In an effort to disrupt SOS mediated RAS activation a cell permeable synthetic α-helix 
based on the interacting portion of SOS was developed [35].  The helix was based on the stretch 
of amino acids (residues 929-944) interacting with the switch I of RAS and included a synthetic 
hydrogen bond surrogate installed to improve helicity and stability. Substitutions of non-
interfacial residues were made with amino acids that had a higher helical forming propensity. 
The synthetic helix bound to nucleotide-free RAS with a KD of 28 µM and to GDP-bound RAS 
at 158 µM [35]. It also successfully abrogated RAS signaling in EGF-stimulated HeLa cells [35]. 
While this constituted a major advancement towards inhibiting RAS proteins, it would be 
primarily applicable only to cancers in which proteins upstream of RAS are mutated/activated. 
Further improvement of affinity is also warranted before therapeutic translation.  
 
VIc. High-throughput screening and chemical genetics 
The practice of discovering a small molecule with the ability to modulate a desired 
biological process remains a slow, expensive, and largely serendipitous undertaking [49]. The 
most widely implemented approach involves physically screening large libraries of small 
molecules to elicit a particular biological response. An assay is first designed such that it can be 
executed in high throughput, and molecular libraries are then screened for their ability to 
provoke the desired effect. Initial identified “hits” undergo iterative cycles of medicinal 
chemistry in order to improve their potency, as well as a number of important physiochemical 
properties to maximize the chance of a successful clinical candidate.  
 These types of screens can be classified into two general types: forward and reverse 
chemical genetics [49]. In forward chemical genetics compounds are screened for a particular 
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phenotypic response. Once a “hit” eliciting the desired effect is found, the target is then 
elucidated using a variety of different methods. The most widely used approach for target 
identification is affinity chromatography, where the small molecule “hit” is attached to a solid 
phase and cell lysate incubate with this immobilized molecule in order to isolate the target. 
Target identification is considered the “bottle neck” of forward chemical genetics [49] and its 
labor-intensive nature has caused this approach to decrease in popularity, particularly in the 
pharmaceutical industry.  
In contrast, reverse chemical genetic screens are performed against a target with an 
established role in a particular biological process [49], such as RAS. Compounds are typically 
screened initially for their ability to bind to the purified target. Subsequent validation and 
medicinal chemistry on the initial hits then warrant the advancement of the molecule to cell and 
in vivo assays.   
 
VId. Strategies for designing a chemical library for a screen: focused library vs. diversity 
oriented library 
Two orthogonal synthetic approaches for designing compounds for screening purposes 
are: target-oriented synthesis and diversity-oriented synthesis [50]. The former, also called 
focused library synthesis, has been more widely used in drug discovery. This involves using 
retrosynthetic analysis to devise how to construct a chemical library against a preselected set of 





i. Privileged structures as a focused library approach 
Certain scaffolds are enriched within different classes of biological targets. Evans coined 
the term “privileged structure” in the late 1980s to describe structures of this type when he 
observed enrichment of the benzodiazepine nucleus [51]. Since then, in both academia and 
industry, numerous libraries have been synthesized around these types of structures and have 
yielded a number of bioactive ligands and marketed drugs. One example of the implementation 
of “privileged structures” has been towards the discovery of kinase inhibitors [52]. All kinases 
use ATP as their substrate and designing libraries based on the purine scaffold have yielded 
numerous hits against various kinases, among other desirable targets [52]. While a number of 
therapeutically useful compounds have been discovered using this approach, complete specificity 
for one target has not been achieved in the case of kinase inhibitors due to their highly 
homologous ATP binding sites.   
 
ii. Application of privileged purine library for targeting proteins downstream of RAS 
A number of downstream proteins of RAS function as kinases. Laufer et al. reported the 
synthesis of a 2,6,9 -6,8,9 substituted purine library that they used in a screen against a panel of 
kinases [53]. Among hits with several different kinases, the screen yielded an inhibitor against 
the RAS effector CRAF and its downstream protein MEK. An additional hit was discovered 
using this library against AKT, a part of the RAS-PI3K signaling axis [53].  
 
iii. Application of a focused library around GDP 
Hunter et al. [54] reported a KRASG12C selective inhibitor by focusing their design 
around the endogenous binder GDP. Their strategy exploited the reactivity of the cysteine 
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residue in the mutant, and they targeted the nucleotide-binding site directly. A chloroacetamide 
moiety was attached to the beta phosphate of GDP, which positioned it for nucelophilic attack by 
the cysteine and displacement of the chlorine through an SN2 reaction [54]. Crystallographic 
data with the inhibitor bound confirmed the mode of binding, along with showing that switch I 
and II had adopted their inactive conformations. To see if it would be possible for the inhibitor to 
out compete GDP and GTP under more physiological conditions, labeling efficiency was 
measured with the nucleotides at the typical cellular concentration of 1.5 mM (200 fold excess to 
the analog). Selective labeling of KRASG12C was achieved in fewer than 36 h. While this analog 
was ineffective in live cells due to its inability to permeate the cell membrane, labeling was 
observed by mass spectrometry performed MiaPaca-2 (KRASG12C) cell lysates [54]. This study 
demonstrated that a guanine nucleotide competitive inhibitor is possible, however a much more 
drug-like molecule would be required for therapeutic applications. 
Focused library synthesis has been an extremely effective approach for discovering new 
hits against targets with known ligands. However, it will be difficult to discover new drugs with 
efficacy against new, more challenging targets using these existing libraries. 
 
iv. Diversity oriented synthesis (DOS) 
With an average small molecule consisting of 30 atoms, chemical space is estimated to 
contain roughly 1060 stable configurations [55]. It is possible that the current libraries simply do 
not posses the requisite structures for the binding of these more challenging targets. Screening 
libraries based on the same small set of privileged scaffolds probes the depth of chemical space 
while ignoring its breadth. Development of libraries with a diverse set of less-explored core 
structures offers a first step into the nearly incomprehensible vastness of chemical space. Though 
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such exploration will certainly yield many molecules with no biological significance, it also 
represents one of the most promising methods for medicinal chemists to discover molecules with 
new properties that make them active against targets previously deemed intractable [50]. Further 
exploration into chemical space could unveil molecules with the properties necessary to bind to 
previously unattained target types [50].  
Diversity-oriented synthesis (DOS) entails the efficient construction of as many 
structurally distinct molecular architectures as possible [50, 55]. In contrast to the focused library 
synthesis, the goal is not to synthetize one particular target type, thus standard retrosynthetic 
analysis cannot be applied [50,55]. The logic behind this approach is that as such a library will 
be used for general screening purposes in a diverse array of biological assays, and maximizing 
molecular diversity would increase the hit rate. A typical synthetic route for DOS uses 
sequential, complexity-generating reactions where distinct branching points (common starting 
material that can undergo reactions with different reagents) are used to maximize the number of 
possible structural outcomes [50, 56].  While complexity is not essential for diversity, it is 
thought to confer a higher degree of target specificity. Using DOS to access new areas of 
chemical space could be one possible direction for discovering drugs against previously 
unattainable targets. 
 
VIe. Fragment-based screening 
Fragment-based screening is a method that exploits the idea of using a larger degree of 
chemical diversity. As the name implies, this approach involves smaller compounds than what 
would typically be a marketed drug (molecular weight less than 300 g/mol, compared to 500 
g/mol) [36]. The goal is to identify low affinity binders that could than be further elaborated into 
16	  
a more potent molecule specific to the desired target. The library size is substantially lower 
(~103) than conventional high-throughput screening (~106-107) as a result of less enumerable 
combinations of atoms in small molecules [36]. Thus, fragments are applicable in more assays, 
less time consuming to screen, and thus more cost effective [36]. By using smaller molecules, 
there is a higher probability of obtaining compounds with ideal physiochemical properties, as 
typical HTS generally produces larger, more lipophilic molecules that are difficult to optimize 
for clinical studies. Moreover, the vast majority of commercial HTS collections are filled with 
compounds that have been optimized for conventional targets (i.e. kinases, GPCRs, ect.) [36]. 
The fragment-based approach has resulted in several compounds in clinical trials [36].  Abbott 
and co-workers implemented a notable example of this in a series of inhibitors they designed 
against the BCl-2 family of anti-apoptotic proteins [36].  These were the result of synthetically 
stitching together three fragments that eventually yielded ABT-737, a high-molecular weight 
(975 Da) inhibitor in phase II clinical trials [36].  
 
i. Application of fragment screening to finding RAS-SOS inhibitors 
Two reports of small molecule RAS-SOS inhibitors were published in 2012 using an 
NMR-based fragment screen as an initial assay to find molecules capable of binding to RAS 
[37,38]. These papers report hits containing indole scaffolds binding in the same site on RAS 
located near L56. The lead compound described by Maurer et al., DCAI (KD of 1.5 mM), was the 
only fragment that exhibited activity in cells. It was shown to attenuate the amount of RAS-GTP 
in EGF-stimulated HEK-293T cells [37].  Efforts to further elaborate these fragments to a more 
potent inhibitor were unsuccessful.  
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ii. Application of fragment screening to finding a KRAS mutant selective inhibitor 
Later that year, a paper describing a mutant specific compound was published [39]. This 
strategy exploited a nucelophilic cysteine residue present only in the KRASG12C mutant, located 
in a shallow pocket between switch I and switch II. Ostrem et al. implemented a tethered screen 
of 480 disulfide-containing fragments against GDP-bound KRASG12C [39]. Changing 
electrophiles from disulfides to carbon-based acylamides and vinyl sulphonamides conferred a 
substantial increase in binding affinity. GTP and GDP titration experiments in the presence of 
the inhibitor indicated a shift in nucleotide preference of inhibitor bound KRASG12C to favor 
GDP by roughly 4-fold. Crystallographic data revealed that the inhibitor occupied the area 
required for G60 to make a hydrogen bond with the gamma phosphate of GTP, which is critical 
for the preferential GTP affinity of the mutant. Ostrem et al. then demonstrated the ability of 
their most potent inhibitor to prevent the RAS-RAF interaction selectively at 100 µM in H1792 
cells (KRASG12C) as compared to H358 (wt KRAS). The lethality in a panel of KRASG12C vs. 
non-KRASG12C mutant cancer cell lines did not show a very strong degree of selectivity. For 
example H23 (KRAS G12C) did not have any statistically significant difference compared to any 
of the non-KRASG12C mutant lines [39]. This can be attributed, in part, to possible off-target 
effects of the reactive electrophilic groups. While their most effective compound warrants further 
optimization prior to clinical translation, this constitutes a substantial advancement towards a 
RAS therapeutic.  
 
VIf. In silico screening 
The idea of computationally simulating protein structures and the chemical interactions 
that mediate their affinity for a small molecule drug was conceptualized as early as the mid-
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1970s [57]. The hope was that drugs can eventually be designed de novo, based solely on 
receptor structure, and that would free the pharmaceutical industry from random small molecule 
screening and tedious medicinal chemistry. While this notion has yet to be fully attained, 
substantial advances in the field of computationally driven drug design have been made since the 
1970s and are widely used in the pharmaceutical industry and academia.  
 
i. Molecular docking 
 Molecular docking entails the computational screening of in silico libraries of molecules 
against a target macromolecule [58]. Each compound is positioned in a defined area of the 
receptor and the binding orientation or  “docking pose” is predicted along with the structures 
being ranked by their binding affinity or “docking score”. Scoring functions can be classified 
into three major categories: empirical, force field based, and knowledge-based [58].  
The most widely used scoring function is empirical, which relies on the assumption that 
the affinity can be estimated as the sum of relatively simple individual energetic parameters: 
hydrogen bonds, electrostatics, hydrophobic, and Van der Waals interactions [58]. A common 
empirical scoring function is Chemscore which takes into account all of the aforementioned 
types of binding energy [58, 59]. Chemscore has been used as a starting point for other, more 
advanced algorithms, such as glide [60].  
In force field based scoring functions, the sum of two energies is quantified: internal 
ligand energy upon binding and ligand-receptor energy [58]. These are described by the Lenard-
Jones potential energy function and by a Coulombic formulation, which accounts for Van der 
Waals and electrostatics, respectively [58]. 
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As the name implies, knowledge-based scoring functions rely on analyses performed on 
known ligand-receptor structures [58]. Interactions between the ligand and the receptor are 
broken down to individual atom interactions, with the overall docking score amounting to the 
sum of each ligand atom-receptor atom interaction [58]. The major limitation of this approach is 
that less common interactions in crystal structures, such as cation-π interactions, are poorly 
predicted with this scoring function [61]. Each docking algorithm can be more or less accurate 
depending on the receptor and the ligand. A common way to account for these discrepancies is 
utilizing consensus scoring, where ligands are selected that score well with multiple algorithms 
[62] 
Binding affinity in an aqueous environment is an extremely important parameter that 
plays a key role in affinity, which most programs don’t take into account [61]. The WaterMap 
application (Schrödinger, Inc.) for example, calculates the energetic favorability of the 
displacement of water molecules in a given site on a protein [63]. WaterMap has shown to be 
particularly effective when used with Schrödinger docking algorithm glide SP [63]. This 
application has been applied to the A2A receptor and was successfully able to rationalize the 
observed structure-activity relationship (SAR) of its tiazolylpurine ligands [64]. While programs 
such are WaterMap are extremely useful tools for drug discovery, they’re expensive, resource 
intensive, and not widely implemented as a result. 
 Another major consideration is that proteins do not exist as static structures [61]. A 
strategy that takes into account that proteins adopt multiple conformations in solution is 
ensemble docking [65]. In this approach a molecular dynamics simulation is run and frames of 
protein confirmations are extracted. The ligand library is then docked into the various frames of 
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the simulation and the top scoring ligands from each of the potential conformations are used 
[65]. 
As the induced fit model of enzyme function suggests receptors frequently change 
structure upon ligand binding. These changes can be very ligand specific, and the uniform, 
ridged treatment of a receptor with a given ligand library does not accurately represent actual 
binding events. Sampling protein conformations is a major obstacle of in silico screening due to 
receptor size and complexity [61].  Strategies, such as induced fit docking, exist that allow for a 
degree of receptor flexibility when docking a set of ligands [66] 
The prediction of covalent interactions of ligand with the receptor is another major 
limitation. With the recent renewed interest in covalent drugs [67], a high throughput way of 
predicting both reversible and irreversible covalent ligand-receptor interactions would be a 
useful tool. Recently there has been progress in producing a more high-throughput method with a 
program called DOCKovalent [68]. This uses the non-covalent program DOCK3.6 to 
exhaustively search for poses of the ligand with respect to the covalent bond that will be formed, 
and second screen is done to each for rotamers of the nucleophile [68].  
With the ever-increasing number of published high-resolution macromolecule structures 
and improved accuracy of in silico tools, this technology is poised to change drug discovery in 
the coming years.   
 
ii. Disrupting the RAS-effector interaction using molecular docking 
The first reported small molecule RAS binder that inhibits its interactions with its 
downstream effector proteins was by Shima et al. [71].  They implemented an in silico screen of 
GTP bound MRASP40D against 40,882 commercially available compounds. This form was found 
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to have a previously unknown confirmation that possesses a more druggable, potential ligand-
binding site than those of the previously established conformations. The top 97 scoring 
compounds were evaluated in a RAS-RAF binding assay. The top hit, Kobe0065, bound to RAS 
with a KD of 46 µM. This compound displayed the ability to disrupt the RAS-RAF and RAS-
PI3K signaling pathways in HRASG12V transfected NIH3T3 cells, as well as demonstrated 
moderate activity in an SW480 mouse xenograft [71].  
 
iii. Ligand-based in silico screening 
A pharmacophore is the spatial orientation of chemical features (hydrophobic regions, 
hydrogen bond donors, hydrogen bond acceptors, and charges) that confer a molecule its 
bioactivity [69]. A pharmacophore model is constructed using knowledge of a ligand’s 
bioactivity, derived from its SAR profile that is obtained from testing a series of similar analogs. 
A pharmacophore screen of commercially available or synthetically accessible molecules can 
then be performed in order to discover molecules that match the desired features to improve 
affinity [69]. It can be applied as a pre-docking filter if there are desired interactions to be made 
with the receptor, as it is much less computationally resource intensive [70].  
 
VIg. ADMET property optimization 
 The major bottleneck of drug development isn’t finding a compound with high enough 
binding affinity to a target, but rather optimizing its absorption, distribution, metabolism, 
excretion, and toxicity (ADMET) characteristics [72]. It was estimated that the development of a 
new drug costs on average more than 800 million dollars, 75% of which is accumulated in the 
process of initial development of failed lead compounds [72].  A molecule’s ADMET profile is 
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due to a combination of various physiochemical properties that a molecule possesses. While 
these properties can be measured experimentally, the process is time consuming; instead, 
computational predictions are much more widely used [72].  
 
i. Physicochemical properties of successful drugs 
 Potential screening collections and synthetically feasible library candidates are typically 
filtered to fall within ideal ranges of the properties in order to maximize the chance of finding a 
successful clinical contender [72]. The mostly widely applied set of physiochemical parameters 
for selecting compounds for screening is “Lipinski’s rule of five” [73]. Upon analyzing the 
properties of marketed drugs, Christopher Lipinski observed that the vast majority of orally 
available drugs posses the following characteristics: logP<5, hydrogen bond donors ≤ 5, 
hydrogen bond acceptors ≤ 10, and molecular weight <500. This set of parameters was coined 
“Lipinski’s rule of five”, as they all occurred in multiples of five [73].  
Since the observations made by Lipinski a number of other physicochemical parameters 
have been applied more frequently as library filters. The entropic barrier of drug binding is 
associated with the number of rotatable bonds, and has been found to be less than 10 in the 
majority of successful drug candidates [74]. Lower polar surface area increases the 
bioavailability of drugs [74]. Molecules with more polar surface area have more trouble crossing 
the cell membrane, especially the epithelium of the intestines, in the case of oral administration. 
A common method to determine the oral bioavailability of drugs is the caco-2 permeability assay 
[75]. The caco-2 cell line is derived from human colon carcinoma and resembles intestinal 
epithelial cells in that they form a polarized monolayer [75]. The ability of a compound to cross 
the epithelium of the intestines, and therefore its oral bioavailability, can be estimated by 
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assessing transport across the monolayer [75]. Compounds that are too lipophilic have problems 
with aqueous solubility. This can greatly limit the type of biological assays that can be performed 
to characterize a potential hit compound [76, 77]. This can often be difficult to optimize, as 
hydrophobic interactions are usually the primary force that drives the binding of small molecule 
drugs to their targets [76].  
 
ii. Drug metabolism 
Another problem that arises from poor aqueous solubility is the issue of drug metabolism 
[77, 78]. Drug metabolizing enzymes act particularly strongly on hydrophobic compounds in 
order to make them more polar and to help facilitate excretion [78]. Cytochrome P450 isoforms, 
for example, have a hydrophobic binding pocket that enables the relatively non-specific binding 
of drugs, which can then be oxidized through their heme prosthetic group [79]. This can lead to 
drug hydroxylation, which can be sufficient to inactivate the drug, accelerate its excretion, or be 
used a chemical handle for a secondary modification by phase II drug metabolizing enzymes 
[79]. Phase II enzymes attach a highly hydrophilic group, such as glucoronic acid or a sulfate, to 
further enhance the rate of excretion. Metabolic transformations can also lead to the production 
of a reactive metabolite that can cause toxicity [80].  
 Computational methods also exist for predicting the susceptibility of a small molecule to 
metabolic transformations, such as P450 Site of Metabolism (Schrödinger, Inc.). This program 
calculates the intrinsic reactivity of a molecule and indicates sites that are prone to CYP450 
oxidation. Next, it performs induced fit docking into isoforms of CYP450 and predicts the 
accessibility of different portions of the molecule to the reactive heme group that catalyzes the 
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oxidation [81]. The net result is a summary of potential reactive sites and their susceptibility to 
CYP450 mediated metabolism.  
 
iii. Drug toxicity 
 Filtering for toxicity prior to experimental testing can be challenging. One approach is to 
filter for chemically reactive groups that have been linked to the toxicity of hits discovered in 
previous screens [72]. These so-called ‘toxicophores’ include chloroacetamides, Michael 
acceptors, and epoxides among others. Moieties with a high degree of electrophilicity become 
covalently bound to proteins by reacting with nucelophilic residues such as cysteine or lysine 
and, primarily in proteases, serine and threonine [67]. Additionally electrophilic groups can react 
with the thiol of glutathione, present in millimolar concentrations in the cell [79]. Despite these 
potential issues there has recently been resurgence in the interest in covalent drugs, with the 
thought that the toxicity would be minimal if enough target specificity is attained by the rest of 
the molecule [67].  
The human ether-a-go-go related gene (hERG) encodes a potassium channel that 
regulates cardiac action potential [81]. hERG is a particularly promiscuous binder and is 
commonly associated with drug toxicity [81]. A common computational approach to address this 
is utilizing pharmacophore modeling of known binders to predict the propensity of a molecule to 






VIh. Mouse models for studying cancer drugs 
i. Mouse tumor xenograft models 
 A number of different types of animal models exist for studying cancer and the efficacy 
of cancer drugs [84, 85]. The most widely used type for the initial assessment of a molecule’s in 
vivo activity is a mouse xenograft model [84]. In this model cell lines are cultured in vitro and 
injected into a mouse to develop into a tumor. To prevent the rejection of these foreign cells by 
the mouse’s immune system nude or NOD/SCID mice are typically used. Once a tumor reaches 
the desired size, therapeutic efficacy of a drug is assessed throughout the dosage period, usually 
by measuring tumor size [84].  
 While xenografts provide a good initial gauge of the in vivo activity of a cancer drug, 
they have several disadvantages [84]. Cells cultured in vitro are exposed to vastly different 
conditions than cancer forming in the body. For instance, they have much greater exposure to 
oxygen and the nutrient content of the media is very different to nutrients circulating in the blood 
stream. These cells have been adapted to grow outside an endogenous tumor microenvironment, 
which results in genetic changes that are not reflective of the stress that growth in a normal 
tumor environment would produce [84]. Several factors of the malignant phenotype, such as 
metastasis and angiogenesis, are impossible to reproduce in a simple xenograft model [84]. The 
use of immunocompromised mice also neglects the influence of lymphatic circulation and 
immune cells on cancer progression, and precludes the use of testing immunomodulators [84].  
As a result, there have been instances where a drug shows promise in a xenograft, but is much 
less effective in a more sophisticated model.  
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ii. Targeting post-translational processing of RAS as an example of the limitations of a xenograft 
model 
Farnesylation and palmitoylation have been rigorously pursed as drug targets for RAS 
and other GTPases [9, 10, 27, 28]. Farnesyltransferase inhibitors (FTI) have been developed as 
both farnesyl pyrophosphate (FPP) analogs and mimics of the CAAX motif on RAS [27, 28].  
Two such inhibitors, tipifarnib and lonafarnib, progressed to phase II clinical trials [27, 28]. 
While targeting farneseylation was effective with HRAS- KRAS (the most frequently mutated 
isoform) and NRAS were found to undergo geranylgernanylation (through GGTase I) as a means 
to compensate for the farnesyl transferase inhibition [28]. Combination treatment for both 
pathways was found to be too cytotoxic to be a viable strategy [28].  
 Following the disappointing outcome of the FTIs, targeting enzymes involved in RAS 
localization post-prenylation was then explored. Given the sizeable amount of farnesylated and 
gernylgernaylated proteins, targeting PDE6δ would appear to allow for a larger therapeutic 
window. A high throughput screen (HTS) was performed with biotinylated and farnesylated 
KRAS4B against a His-tagged PDEδ to find molecules that disrupt this interaction [29]. Several 
hits containing a benzimidazole scaffold were identified and optimized to bind in the low 
nanomolar range [29]. Preliminary evidence of their therapeutic utility was then demonstrated in 
a mouse xenograft of Panc-Tu-I cells [29]. Hopefully further evaluation in more sophisticated 
models will reveal that this is a viable target for RAS mutated cancers. 
 
iii. Patient-derived xenografts 
 An alternative to using standard cell lines is a patient-derived tumor xenograft. This 
methodology entails the surgical isolation of a fresh sample from a patient. Cells are then 
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cultured in vitro and implanted into a mouse. This model is thought to maintain the genetic and 
histological heterogeneity of a tumor and, as a result, more accurately predict the clinical 
efficacy of anticancer agents [84].  
 
iv. Genetically engineered mouse models 
 The lack of pre-clinical models that recapitulate the heterogeneity of tumors in patients is 
one of the most frequently cited reasons for the failure of new anticancer agents [84]. Genetically 
engineered models (GEMs) exist to overcome these significant limitations and more accurately 
mimic the molecular and pathophysiological features of cancer.  
 GEMs can be classified into two general categories: endogenous or transgenic [85]. 
While endogenous GEMs entail the expression or loss of expression of a gene on its endogenous 
promoter, transgenic involves the less specific insertion of the construct into the genome. Both 
cases are most commonly accomplished by either a direct injection or lentiviral transduction of a 
desired altered mouse embryonic stem cells. Following selection of stem cells containing the 
construct, they are subsequently injected into the blastocyst of a female mouse [85]. Mice are 
raised and bred until the desired genotype is achieved. 
  
v. CRE-lox system for tissue specific models  
CRE is a recombinase that excises a portion of DNA that is flanked by the short 
palindromic lox-P sequences [85]. This method is widely used to either inactivate or activate a 
particular gene in a GEM. In the case of inactivation, the gene of interest is flanked by lox 
sequences and is subsequently removed by CRE. In the case of gene activation, a stop codon 
flanked by lox sequences is situated between the gene of interest and the promoter [85]. CRE 
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expression removes the stop codon allowing for gene expression. Tissue specific activation or 
inactivation can be achieved through the linking of CRE to the promoter of a gene only 
expressed in a particular tissue type [85].  
 
vi. Inducible gene expression for temporal control 
Temporal regulation of gene expression is typically accomplished via an inducible target 
gene expression system under the control of an exogenous ligand [85]. The most common 
example of this is using the tetracycline operon where tetracycline (or the less toxic doxycycline) 
promotes or inhibits target gene expression [85, 86]. This can also be linked to the CRE-lox 
system to achieve both spatial and temporal control of a particular gene.  A model of this type 
can be very useful in studying the dependency of a gene in a particular cancer type, where tissue-
specific expression is turned on and off, and features of the malignancy are monitored. 
 
vii. Essentiality of KRAS in PDAC using genetically engineered mouse models 
The essentially of KRAS in the maintenance of pancreatic ductal adenocarcinoma 
(PDAC) was strongly supported through the use of genetically engineered mouse models with 
inducible oncogenic RAS [86]. In this series of experiments, temporal control of KRASG12D 
expression was accomplished using a tet-operator with a lox-stop-lox cassette between the 
promoter and the start codon. Pancreatic specific expression occurred through p48 linked CPE. 
To best recapitulate full malignant progression these mice were crossed with conditional p53 
knockout mice. All mice succumbed to PDAC between 8 and 22 weeks of doxycycline treatment 
at 3 weeks of age. To investigate the essentiality of oncogenic KRAS in PDAC progression 
following 9 weeks of induction, doxycycline treatment was abrogated. Extinction of KRASG12D 
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led to rapid tumor regression. MRI and PET/CT analyses of the tumor following one week of 
withdrawal resulted in a 50% reduction in tumor mass and complete loss of fluorodeoxyglucose 
uptake, respectively [86]; thus demonstrating a crucial role of RAS in PDAC. 
 
VII. Perspectives 
30 years after the discovery of the RAS family of GTPases they still remain elusive to 
pharmacological inhibition. Over the past three years several groups have identified compounds 
that bind to RAS proteins. Mauer et al. [37] described compounds that bind to RAS-GDP and 
prevent SOS-mediated nucleotide exchange. Treatment with an inhibitor of this type would be 
applicable in cancers that require activation of wild-type RAS through SOS for proliferation; 
mutated RAS remains unaffected by this class of compounds. Shima et al. [71] described 
compounds that inhibit the interaction of RAS with its effector proteins, and showed modest 
activity in a mouse tumor xenograft. Ostrem et al. [39] reported covalent inhibitors from a 
fragment screening approach, tethering, which selectively target KRASG12C by exploiting the 
reactive cysteine present in the mutant. While this represents an important advance for 
addressing some RAS malignancies it is only applicable to this specific mutant, present in only 
about one in eight KRAS mutated samples [82]. In the panel of cell lines tested with this 
compound, the selective inhibition of growth in KRASG12C cells ranged from three-fold 
inhibition in the most sensitive cell line, to no selectivity in the least. This narrow window may 
be attributable to the reactive electrophile present in the inhibitors. 
The definition of ‘druggability’ has been changing as a result of new and innovative 
approaches, particularly with targets engaging in protein-protein interactions [83]. While 
enormous progress has been made towards tackling α-helix mediated interactions [7], there are 
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few published instances of small molecule inhibitors of the more exigent β-strand mediated 
interactions [8]. This necessitates the development of new, generalizable approaches for 





















Chapter 2: Computational design, synthesis, and biochemical evaluation of small molecule 
RAS inhibitors 
The data presented in this chapter is part of a submitted manuscript: Welsch M.E., Kaplan A., 
Chambers J.M., Pagano N.C., Yang W.S., M.S. Martin, Badgley M.A., Olive K.P., Ferrando A., 
Stockwell B.R., Multivalent inhibitors of RAS GTPases designed using PAINT 
 
I. Introduction  
The major challenge with disrupting protein-protein interactions (PPIs) is the 
substantially lower surface area encompassed by a small molecule compared to that of a protein-
protein interface [3]. Alanine scanning mutagenesis experiments performed on the human growth 
hormone (hGH) and its receptor (hGHbp) lent credence to the idea that inhibiting PPI 
interactions may be possible by only encompassing a portion of the overall interface surface area 
[87]. Individual replacement of the 33 residues making contact at the hGH/hGHbp interface with 
alanine revealed certain residues contributed more substantially to the overall binding affinity 
than others [87]. In fact, two tryptophan residues accounted for more than 75% of the overall 
binding affinity. This was the first report of “hot spot” residues existing at a protein-protein 
interface [87]. Since then a number of different groups have performed both computational and 
experimental analyses on PPIs to map these functionally important residues [88]. With a wealth 
of knowledge available about the interaction of RAS with its effector proteins on the molecular 
level, we sought to analyze which interactions confer a larger amount of binding affinity with the 
hope of formulating information about these binding ‘hot spot’ residues into a targeting strategy 




II. Analysis of RAS protein-protein interactions 
Block et al. performed a thorough, quantitative structure activity relationship analysis of 
the CRAF-RAS interaction in vitro [89]. The activity of the CRAF mutants were then correlated 
to cellular function by using a luciferase reporter gene linked to three E74 binding sites. These 
sites have high affinity for ETS transcription factors, known to be associated with the activation 
of the RAS/RAF/MEK/ERK pathway. The most substantial loss of binding affinity to RAS was 
found with an R89L substitution on CRAF, which completely abrogated binding. This is 
compared to a dissociation constant of 130 nM in wild-type CRAF. Examining the co-crystal 
structures of HRAS and CRAF (PDB: 3KUD and 1G0N) indicated that this residue was 
interacting with the side chain of D38 and the main chain carbonyl of S39 on HRAS (Fig. 2.1a). 
A second residue on CRAF, making a direct hydrogen bonding interaction with D38, is T68 (Fig. 
2.1b). Even the small change of T68A resulted in a 10-fold loss in binding affinity. Mutations of 
two arginine residues in close proximity to E37 of RAS (R67A and R59A) resulted in a 16 and 
29-fold loss in binding affinity, respectively (Fig. 2.1c). The subtle alteration of V69A on CRAF, 
interacting with I36 on RAS (Fig. 2.1d), yielded a 7-fold loss in binding affinity.  
	  
Figure	  2.1	  |	  Interaction	  of	  CRAF	  with	  residues	  I36-­‐S39	  on	  RAS.	  (a)	  Interaction	  of	  the	  side	  chain	  of	  D38	  and	  carbonyl	  of	  
S39	  on	  HRAS	  (blue)	  with	   the	  side	  chain	  of	  R89	  of	  CRAF	  (yellow)	  (PDB:	  3KUD).	   (b)	  Side	  chain	  of	  T68	  (CRAF)	  hydrogen	  
bonding	  to	  D38	  (HRAS).	  (c)	  Interaction	  of	  R59	  and	  R67	  (CRAF)	  with	  E37	  (HRAS).	  	  (d)	  Interaction	  of	  V69	  (CRAF)	  with	  I36	  
(HRAS).	  
 To examine if interactions with this stretch of residues is functionally important with the 
binding to other effectors, the co-crystal structure of PI3Kγ and HRAS (PDB: 1HE8) was then 
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analyzed along with the structure-activity relationship data [90]. Consistent with the CRAF 
mutagenesis experiments, mutation of residue K251 on PI3Kγ, which interacts with D38, to 
either an alanine or a glutamic acid increased the dissociation constant of PI3Kγ from 2.9 µM to 
greater than 50 µM in both cases. T232D, interacting with the main chain carbonyl on D37 of 
HRAS, again showed this trend. This same drop in affinity was found in the F221S mutant, 
which interacts with I36 on HRAS. Of all 16 mutations performed in in this manuscript, these 
mutations represented 4/5 that resulted in a loss of binding affinity greater than 50 µM. While 
they did not perform mutagenesis on the residue interacting with S39 on RAS, the crystal 
structure indicates interactions with the side chain as well as the main chain amide and main 
chain carbonyl of S230 of PI3Kγ (Fig. 2.2).  
	  
Figure	   2.2	   |	   Interaction	   of	   residue	   S39	   of	   HRAS	   with	   residues	   T229	   and	   S230	   of	   PI3Kγ.	   Hydrogen	   bonding	  
interactions	  of	  the	  carbonyl	  oxygen	  and	  side	  chain	  hydroxyl	  of	  HRAS	  S39	  (blue)	  with	  the	  side	  chain	  hydroxyl	  groups	  of	  
T229	  and	  S230	  of	  PI3Kγ	  (grey),	  respectively	  (PDB:	  1HE8).	  
The RAS-RALGDS co-crystal structure (PDB: 1LFD) exhibited a similar pattern [91]. 
Loss of the hydroxyl group of tyrosine in the Y27F mutant resulted in an increase in the 
dissociation constant between RAS and RALGDS from 3.5 µM in the wild-type to 29 µM in the 
mutant (8.3-fold). This key difference with this substitution is the ability of the Y27 phenol 
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oxygen to make a hydrogen bond with the S39 hydroxyl. Loss of the R16 (RALGDS)-E37 
(RAS) interaction by a R16A substitution drops the affinity for RAS 29-fold. K28, interacting 
with D38 of RAS, when altered to an alanine a 29-fold loss of affinity was observed. While they 
did not report mutagenesis performed on I36 or the residue it interacts with on RALGDS, there is 
a valine within six angstroms, consisted with the pattern of the presence of hydrophobic residue 
(V69 on CRAF and F221 of PI3Kγ). I36 was also shown in experiments by Hall et al. to undergo 
a conformational change when transitioning from the GDP-bound to the GTP-bound form in 
which it adopts a solvent-exposed state (Fig. 2.3) (92). This conformational change could allow 
for some specificity for the active, GTP-bound form of RAS.  
	  
Figure	   2.3	   |	   Conformational	   change	   of	   I36	   as	   RAS	   transitions	   from	   the	   GDP	   to	   GTP-­‐bound	   state.	   (a)	   Change	  
undergone	  by	  I36	  transitioning	  from	  the	  GDP-­‐bound	  (yellow,	  HRASA59G,	  PDB:	  1LF0)	  to	  GTP-­‐bound	  state	  (blue,	  HRASA59G,	  
PDB:	  1LF5).	  (b)	  Shown	  is	   the	  same	  transition	  with	  a	  surface	  representation	  of	   the	  GDP-­‐bound	  state.	   In	  the	  active,	  GTP-­‐
bound	  state	  I36	  becomes	  more	  solvent	  exposed. 
III. Effector inspired pharmacophore strategy 
 Studies performed on RAS binding to its effectors indicated that a short stretch of four 
residues, I36-S39 (now referred to as the D38 site), provided a larger contribution to the overall 
binding affinity compared to the rest of the surface contact area, an apparent binding ‘hot spot’. 
Conceivably, if a small molecule could mimic the interactions of the effector proteins with these 
key residues on RAS then it could act as a competitive inhibitor. To try to encapsulate these 
a b
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interactions a pharmacophore model was designed using the chemical properties and shape of the 
portion of the effector residues making contact with the D38 site. This model then allows for the 
screening of large chemical libraries to find molecules that possess the properties necessary to 
interact with the D38 site. 
 
IIIa. Pharmacophore model design 
 From the aligned co-crystal structures of RAS and the effectors: F221 and T232 of PI3K, 
R16 of RALGDS, and T68 of RAF were extracted. These residues were then converted into a 
pharmacophore model using the program Rapid Overlay of Chemical Structures (ROCS, 
Openeye, Inc.). Analyzing the specific atoms engaging in interactions with RAS allowed editing 
of the model in ROCS such that only pharamacophore features making contacts with the side 
chains and amide backbone of residues 36-39 of RAS were selected. A summary of this process 
and the construction of the model are shown in Figure 2.4. 
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Figure	  2.4	  |	  Pharmacophore	  model	  construction	  from	  key	  effector	  interactions	  with	  RAS. (a) Co-crystal structures of 
HRAS (blue) with PI3Kγ (grey, PDB: 1HE8), the RAS-binding domain of CRAF (yellow, PDB: 3KUD), and RALGDS (red, 
PDB: 1LFD) aligned. (b) Example of the conserved interactions across the D38 site with the effectors. Each effector has either an 
arginine or lysine interacting with E37 on HRAS. (c) The selected effector residues that interact with residues 36-39 on HRAS. 
(d) Conversion of the selected effector residues into a searchable pharmacophore model. 
 
IIIb. Pharmacophore screen and in silico library design 
With a searchable model now in hand, a library consisting of ~4.7 million commercially 
available molecules was complied from the inventories of eight different vendors (Asinex, 
Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge, and TimTec). The high throughput 
screening capacity of this program precluded the use of any additional filters. A conformer 
library of the unique entries was then generated using Omega (Openeye, Inc) with a maximum of 
500 conformers per molecule. This conformer library was then screened against the 
pharmacophore model using ROCS (rapid overlay of chemical structures, Openeye Inc.). 
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The output of the screen ranked molecules by their similarity to the pharmacophore 
model using a tanimoto coefficient as a metric. This yielded largely inadequate matches 
(tanimoto <<0.8). In an effort to find improved matches, combinatorial in silico libraries of 
synthetically accessible molecules were designed to specifically match the properties in the 
model. 
To accomplish this goal, iterative cycles of in silico library design and pharmacophore 
screening were performed. The library that produced the best matches deconstructed the model 
to exist as three functional segments (Fig. 2.5).  These segments in the virtual library were 
derived from reagents that possessed hydrophobic rings and various combinations of hydrogen 
bond donors and acceptors. Computational calculations of the physiochemical properties showed 
that the vast majority of the hits from the pharmacophore screen were indeed compliant with 
Lipinski’s rules (selected examples shown in Table 2.1). A set of the closest matches (ranging 
from 0.85-0.97 Tanimoto coefficient) with ideal physiochemical properties was then synthesized 
(Appendix I, scheme A.1).  
	  
Figure	  2.5	  |	  In	  silico	  library	  design	  and	  the	  structure	  of	  two	  of	  the	  top	  hits.	  (a) Schematic representation of one of the in 
silico libraries designed to match the properties in the pharmacophore model. (b) Structures of the top compounds discovered 




Table	  2.1	  |	  Calculated	  physiochemical	  properties	  of	  31MEW78	  and	  31MEW79.	  Each	  of	  these	  properties	  was	  
calculated	  using	  MOE	  (chemical	  computing	  group	  inc.).	  
 
IIIc. Pharmacophore results summary and strategy for improving affinity 
The biochemical evaluation of the synthesized hits indicated that they bound to RAS and 
prevented it from interacting with CRAF and RALGDS at millimolar concentrations (see 
Appendix I). Unfortunately, the compounds were inactive when evaluated in RAS mutated 
cancer cell lines (data not shown). While the activity of the pharamcophore compounds was very 
modest, it was encouraging that they possessed any PPI inhibitory activity with the low 
molecular weight of the compounds and lack of druggable characteristics of the site targeted. It 
appears that this is an ideal region of the protein to target, but more contacts with the surface of 
the RAS protein are needed to confer enough binding affinity and specificity for further testing 
in cell culture and in vivo. 
Reanalysis of the RAS structure revealed that directly adjacent to the D38 site there exists 
two shallow pockets (Fig 2.6a-b). One site, situated between the switch I and switch II regions, is 
centered at A59 (A59 site). Towards the c-terminal end of the D38 site is another shallow cavity, 
which exists only in the active form of RAS. In transitioning from the inactive GDP-bound form 
to the active GTP-bound form, Y32 undergoes a conformational change where the side chain 
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bond with the gamma phosphate of GTP (92) (Fig. 2.6c-e). This site could be potentially 
exploited to selectively target the active form of RAS.  
	  
Figure	  2.6	  |	  Three	  sites	  targeted	  on	  KRASG12D.	  (a)	  KRASG12D	  (PDB:	  4DSN)	  with	  the	  switch	  I	  region	  shown	  in	  green	  and	  
the	  switch	  II	  region	  in	  purple.	  (b)	  Location	  of	  the	  three	  sites	  on	  KRAS	  targeted:	  D38	  site	  in	  yellow,	  A59	  site	  in	  blue,	  Y32	  
site	   in	   red.	   	   (c)	   Flip	   of	   Y32	   from	   the	   GDP-­‐bound	   to	   GTP-­‐bound	   forms	   for	   HRAS.	   HRASA59G	   bound	   to	   GDP	   in	   yellow	  
(PDB:1LF5)	  and	  HRASA59G	  bound	  to	  GTP	  in	  blue	  (PDB:	  1LF0).	  (d)	  Surface	  representation	  of	  the	  GDP-­‐bound	  form	  (yellow)	  
with	  the	  surface	  area	  occupied	  by	  Y32	  shown	  in	  grey.	  (e)	  Surface	  representation	  of	  the	  GTP-­‐bound	  form	  (blue)	  with	  the	  
surface	  occupied	  by	  Y32	  in	  grey.	  This	  conformational	  change	  unveils	  a	  pocket	  not	  present	  in	  the	  GDP-­‐bound	  form.	  
 
IV. PAINT – Process for Assembling ligands for Intractable Targets 
IVa. In silico fragment library screen  
 To accomplish this goal, we shifted gears from pharmacophore screening to molecular 
docking. The commercially available library used in the pharmacophore approach was filtered 
for ‘fragment like’ properties using the following filter criteria: LogP < 3, hydrogen bond 
acceptors ≤ 3, hydrogen bond donors ≤ 3, molecular weight < 300, aqueous solubility >0.5 mM 
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(chemical descriptors were calculated using MOE, Chemical Computing Group) [36]. This 
60,000-member fragment library was then docked (using Glide SP, Schrödinger inc.) into each 
of these sites, with the hope of gaining some insight from the docking results to formulate a 
targeting strategy.  
 Analysis of the composition of the top scoring molecules and their docking pose revealed 
some interesting patterns. A substantial portion of the top scoring fragments in the A59 site 
contained an indole scaffold. Many of these hits had the indole nitrogen oriented towards the 
D38 site, which could be used as a synthetic attachment point (Fig. 2.7a). In the D38 site, several 
aliphatic rings containing amine functional groups situated between two aspartic acids were 
observed (Fig. 2.7a-b). These amine groups could also be used as a second point of attachment to 
a group extending into the third and final site.  
 	   	  
Figure	   2.7	   |	   Examples	   of	   top	   scoring	  D38	   and	  A59	   site	   compounds.	   (a)	  Two	  of	   the	   top-­‐scoring	  existing	   fragments	  





IVb. Molecular library design 
Beginning with the D38-site, the chemical inventories of Sigma-Aldrich and Chem 
Impex were searched for molecules that possessed both an aliphatic group containing either an 
amine or a hydroxyl (for interacting with D38 and/or D33), as well as a carboxylic acid moiety to 
be used as a point of attachment to the A59 site by amine coupling. An in silico library of these 
structures was compiled replacing the carboxylic acid moiety with a methylamine amide to 
mimic the type of linkage that would occur to the adjacent A59 site. Two structures docked 
about an order of magnitude better than the other library members and were used to extend into 
the A59 site (Fig. 2.8). 
	  
	  
Figure	  2.8	  |	  Library	  of	  D38	  site	  compounds.	  These	  compounds	  were	  docked	  as	  methylamine	  amides	  to	  mimic	  the	  type	  
of	  linkage	  they	  would	  have	  in	  the	  final	  designed	  ligand.	  Examples	  of	  the	  two	  top	  scoring	  structures	  and	  locking	  pose	  on	  
the	  right. 
Next, an exhaustive search of commercially available indoles was performed. Libraries 
were designed based on synthetic combinations of groups to these various scaffolds, along with 














































transformations were utilized as the basis for points of diversity in order to accommodate a broad 
substrate range in the library and to minimize the degree of synthetic route optimization. These 
chemical reactions primarily consisted of: Suzuki couplings, nucleophillic substitutions, amine 
couplings, and reductive aminations. This process improved the docking score of the two-site 
binding compounds about an order of magnitude over the compounds docked into just the D38 
site (Fig. 2.10a). 
	  
Figure	  2.9	   |	   Examples	  of	  different	  docked	   in	  silico	  libraries	  with	   indole	   scaffolds.	  Moieties	  amended	  to	  the	  indole	  
core	  are	  indicated	  with	  the	  linkage	  to	  the	  D38	  site-­‐binding	  group.	  Scaffold	  6	  gave	  the	  highest	  scoring	  compounds	  and	  it	  
was	  then	  further	  elaborated	  to	  scaffold	  7.	  
	  
Figure	  2.10|	  Examples	  of	  compounds	  from	  the	  two-­‐site	  library	  docked	  and	  analysis	  to	  extend	  into	  the	  third	  site.	  































































binding	  moiety	  of	  34MEW43,	  which	  shows	  the	  interaction	  of	  the	  amine	  groups	  with	  the	  side	  chains	  of	  D38	  and	  D33.	  The	  
amine	  indicated	  was	  optimally	  positioned	  to	  extend	  into	  the	  adjacent	  Y32	  site.	  
Examining the contacts made by the D38 group motivated the extension strategy into the 
Y32 site. The top scoring ionization state consisted of the protonated amines interacting with the 
side chains of D33 and D38, with the amines oriented in the direction of the Y32 site (Fig. 
2.10b). Moieties were introduced in silico that could be attached via a reductive amination in 
order to retain the basicity of the amine required to obtain the docked ionization state. 
Synthetically accessible libraries of aldehydes that could be attached to the amine were designed, 
and again their attachment improved the docking score by about another order of magnitude.   
This approach proved to be dramatically more efficient computationally than the design 
of a single compound library that possessed all of the points of diversity encompassed by the 
PAINT approach. Figure 2.11b compares the size of the libraries that a single compound library 
would contain compared with that of the PAINT strategy. 
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Figure	   2.11	   |	   Example	   of	   a	   docked	   three-­‐site	   compound	   and	   schematic	   of	   the	   three	   site	   compound	   design.	   (a)	  
Docking	  pose	  and	  score	  of	  34MEW95.	  (b)	  Schematic	  of	  all	  of	  the	  points	  of	  diversity	  and	  number	  of	  reagent	  and	  scaffold	  
combinations.	   
With some concern about the high molecular weight of the two- and three-site molecules, 
the physiochemical properties of representative compounds were calculated in silico and 
compared to the non-natural product PPI inhibitor ABT-263, now in phase II clinical trials (Fig. 
2.12). Despite the molecular weight deviating from the ideal range, these compounds possessed 
ideal characteristics- especially when compared to ABT-263. Encouraged by this, a set of the 




Figure	  2.12	  |	  Comparison	  of	  drug-­‐like	  properties	  of	  the	  two-­‐and	  three-­‐site	  compounds	  to	  ABT-­‐263.	  The	  properties	  
in	  which	   the	   compounds	  are	  not	   compliant	  with	  Lipinski’s	   rule	  of	  5	   are	   indicated	   in	  blue.	   Instances	  were	   the	   two	  and	  
three-­‐site	  compounds	  outperform	  ABT-­‐263	  with	  other	  drug-­‐like	  properties	  is	  shown	  in	  red.	   
V. Synthesis of two-site and three-site compounds 
 The synthesis (scheme 2.1) began from an indole carboxaldehyde (1), which was 
alkylated with a BOC-protected amine linker at the indole nitrogen yielding 2. The alkylated 
indole was then brominated at the three position (3), which enabled a Suzuki coupling using 
various boronic acids to give 4. An alkylated piperazine (5) was then attached to the aldehyde via 
reductive amination that providing 6. The masked primary amine was then deprotected to 7, 
which allowed for a subsequent coupling of the D38 site moiety (8). This could then undergo 
two sequential deprotections using piperdine and HCl to yield one of the two-site compounds 
(31MEW44). To achieve a full three-site compound, one of the orthogonally protected amines in 
compound 9 remains masked to enable an extension into the Y32 site, which could be 
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Deprotection with HCl (or piperdine if the other free amine was used) then provides the full three 



































Scheme 2.1 | synthesis of 31MEW44 and 43MEW63. a) NaH (1.2 eq), NaI (1.0 eq), 0oC, then 3-(Boc-amino)propyl bromide (1.5 eq) 80oC, 
DMF, 12-36 h; b) Br2, -78oC, THF, 2 h; c) boronic acid (1.5 eq), Pd(PPh3)4 (5%), K2CO3, 80oC, dioxane/water (5:1), 36 h; d) piperazine (4.0 
eq), 0oC to 25oC, THF, 12 h; e) compound 5 (3.0 eq), ZnCl2 (0.1 eq), 60oC, 1,2-DCE, 3 h, then NaBH3CN (2.0 eq) in MeOH, 60oC, 3 h; f) HCl 
in dioxane (xs), 25oC, 12 h; g) Fmoc chloride (1.5 eq), Na2CO3 10% in H2O (5 eq), THF,  0oC to 25oC, 12 h; h) compound 8 (1.2 eq), EDIPA 
(1.2 eq), HBTU (1.2 eq), 0oC, 20 min, then compound 7, DMF, 25oC, 4 h; i) piperdine (6.0 eq) 25oC, DCM, j) HCl in dioxane (xs), 25oC 12 h.



















































































V. Biochemical evaluation 
Va. RAS pull-down 
To examine if these hits were capable of disrupting the RAS effector interactions, they 
were evaluated in both RAS-RAF and RAS-RALGDS pull-downs. The two top compounds 
prevented RAS from interacting with both CRAF and RALGDS in a dose-dependent manner at 
markedly lower concentrations than the pharmacophore compounds, supporting the hypothesis 
that multivalent ligands would be more effective at targeting RAS (Fig. 2.13). 
	  
Figure	  2.13	  |	  Disruption	  of	  RAS-­‐RAF	  and	  RAS-­‐RALGDS	  interactions	  by	  31MEW44	  and	  34MEW43.	  (a)	  Pull-­‐down	  of	  
GTP-­‐loaded	  KRASG12D	  with	  CRAF-­‐RBD	  agarose	  beads	  in	  the	  presence	  of	  31MEW44	  and	  34MEW43.	  (b)	  Pull-­‐down	  of	  GTP-­‐
loaded	  KRASG12D	  with	  GST-­‐tagged	  RALGDS	  using	  glutathione	  beads.	  	  
 
Vb. Quantification of binding  
 To quantify this interaction, the two-site compounds were evaluated by microscale 
thermophoresis (MST), which analyzes changes in the change in migration of fluorescently 
labeled molecule across a temperature gradient. This was performed using KRASG12D loaded 
with GppNHp, lysine labeled with NT-647-NHS-ester dye. The low aqueous solubility of 
34MEW43 prevented us from obtaining a full dose-response curve; its KD was estimated to be 
73 µM +/- 3 µM (Fig. 2.14a). Using this scaffold extension into the third and final Y32-site was 
performed (compound 34MEW95).  This three-site compound yielded an estimated KD of 32 µM 
+/- 1 µM (Fig. 2.14b); the low solubility of this even larger compound again prevented a full 
dose-cure and an accurate measurement of the dissociation constant. 31MEW44 showed the 
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highest binding affinity of all compounds tested with a measured dissociation constant of 9.0 µM 
+/-1 µM (Fig. 2.14a). Unfortunately, extension into the Y32 site of this 2-site inhibitor did not 
produce a significantly more potent binder (Fig. 2.14b). The higher affinity and more ideal 
physiochemical properties of 31MEW44 motivated more extensive characterization to be 
focused on this molecule. As a secondary method, the affinity was measured by isothermal 
titration calorimetery (ITC performed by Dr. Anna Kaplan, Fig 2.15a-b). This yielded a 
dissociation constant of 34 µM +/- 24 µM, within the range of the MST measurements.  
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Figure	  2.14	   |	  Docking	  scores	  and	  dissociation	  constants	  of	   two-­‐	  and	   three-­‐site	  compounds.	   (a)	  Docking	  scores	  of	  
synthesized	   2-­‐site	   compounds	   into	   KRASG12D	   (PDB:	   4DSN).	   Determined	   dissociation	   constants	   of	   2-­‐site	   compounds	   by	  
microscale	  thermophoresis	  with	  GppNHp-­‐bound	  KRASG12D	  from	  a	  16-­‐point	  dilution	  series	  of	  the	  indicated	  compound.	  (b)	  
Docking	   score	  and	  determined	  dissociation	  constants	  of	  3-­‐site	   compounds	  designed	  and	  synthesized	  based	  on	   the	   two	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Figure	   2.15	   |	   Isothermal	   titration	   calorimetery	   on	   31MEW44.	   (a)	   Isothermal	   calorimetery	   titration	   of	   KRASG12D-­‐
GppNHp	  into	  31MEW44.	  (b)	  Thermodynamic	  parameters	  of	  31MEW44	  binding.	  *This	  experiment	  was	  performed	  by	  Dr.	  
Anna	  Kaplan	  (Columbia	  University) 
Vc. Binding site characterization  
To examine the selectivity of 31MEW44 for the active GTP-bound form of RAS, 
KRASG12D was loaded with GDP and measured by MST. This resulted in a five-fold loss in 
affinity (KD= 45 µM +/- 3 µM, Fig. 2.16a), consistent with the idea that it’s selective for the 
active form. To support that 31MEW44 was binding in the predicted area; the mutants evaluated 
in the pharmacophore approach were used. They showed 3.5 to 21-fold loss of affinity 
(KRASG12D D38A KD= 33 +/- 2 µM and KRASG12D I36N KD = 200 µM +/- 20 µM, Fig. 2.16b), 
indicating a much greater degree of specificity than the pharmacophore compounds.  
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Figure	  2.16	  |	  Binding	  site	  specificity	  of	  31MEW44	  by	  microscale	  thermophoresis.	  (a)	  MST	  of	  the	  two-­‐site	  compound	  
31MEW44	   and	   its	   differential	   selectivity	   towards	   the	   active	   (GppNHp	   bound)	   form	   vs.	   inactive	   (GDP	   bound)	   form	   of	  
KRASG12D.	  (b)	  The	  effect	  of	  mutating	  residues	  within	  the	  docking	  site	  on	  KRASG12D	  on	  the	  affinity	  of	  31MEW44	  by	  MST.	  	   
To further characterize the binding site of the 31MEW44, 2D 1H-15N Heteronuclear 
Single Quantum Coherence (2D 1H-15N HSQC) experiments were performed on uniformly 15N-
labled KRASG12D protein (all protein NMR experiments performed by Dr. Anna Kaplan). The 
1H-15N HSQC spectra of the KRASG12D GDP-loaded protein and GppNHp-loaded protein were 
assigned using the previously published wild-type KRAS GDP assignments (93). Additional 3D-
1H-15N-1H-NOESY-HSQC and 3D-1H-15N-1H-TOCSY-HSQC experiments were performed on 
KRASG12D protein loaded with either GDP or GppNHp to verify these assignments (data not 
shown, experiment performed by Dr. Anna Kaplan). Consistent with the docking pose, dramatic 
shifts in amide resonances were observed in residues found in the switch I and II regions 
consistent with the predicted docking pose (Fig 2.17). Additional significant shifts were found in 
the residues surrounding P110. This area is a known allosteric site associated with movement of 




Figure	  2.16	  |	  Binding	  site	  characterization	  of	  31MEW44	  by	  1H-­‐15N	  HSQC	  NMR.	  (a)	  Significant	  residue	  changes	  (red)	  
by	   1H-­‐15N	  HSQC	  KRASG12D-­‐GppNHp	   in	   the	   presence	   of	   31MEW44	   (blue),	   proline	   shown	   in	   yellow.	   (b)	   Plot	   of	   chemical	  
shifts	  measured	  by	  1H-­‐15N	  HSQC.	  (c)	  Fully	  1H-­‐15N	  HSQC	  spectrum	  of	  GppNHp	  bound	  KRASG12D	  in	  the	  presence	  (red)	  and	  
absence	  (blue)	  of	  31MEW44.	  *This	  experiment	  was	  performed	  by	  Dr.	  Anna	  Kaplan	  (Columbia	  University). 
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Vd. GTPase selectivity 
 The high degree of sequence and structural homology among GTPases made selectivity 
for RAS a potential concern. This was first assessed in silico by docking 31MEW44, 34MEW43 
and 34MEW95 into the GTP bound form of: RHOA, RHEB, RAC1, RAB3A, RALA, and 
CDC42. The scores indicated 0.7 to 3 orders of magnitude lower affinity to these structures over 
RAS, suggesting they would be selective (Table 2.2). To test this experimentally, RHEB 
(provided by Michael Gaschler), RHOA and RALA (commercially available through Abcam) 
were GppNHp loaded and evaluated by MST. The results indicate 31MEW44 was indeed 
selective for RAS, as binding was not observed up to 187.5 µM of 31MEW44 (Fig. 2.18).   
   
Docking Score 
     PDB ID Protein 31MEW44 34MEW43 34MEW95 
4DSN KRAS G12D -GTP -9.33 -9.60 -10.0 
4LPK KRAS wt - GDP -6.10 -6.95 -7.62 
1AB2 RHO A - GTP -6.31 -6.98 -6.85 
1XTS RHEB - GTP -6.31 -7.64 -6.92 
3TH5 RAC1 - GTP -7.24 -7.69 -8.86 
3RAB RAB3A - GTP -6.66 -6.34 -7.05 
1U8Y RAL A - GTP -8.65 -8.34 -8.79 
2QRZ CDC42 - GTP -6.61 -5.57 -7.52 
	  
Table	  2.2	   |	  Docking	  scores	  of	  31MEW44,	  34MEW43,	  and	  34MEW95	  against	  a	  panel	  of	  GTPases.	   	  Molecules	  were	  




Figure	   2.18	   |	   GTPase	   selectivity	   of	   31MEW44	   by	   microscale	   thermophoresis.	   Shown	   are	   the	   normalized	  
thermophoretic	  traces	  of	  a	  16-­‐point	  dilution	  series	  of	  31MEW44	  with	  GppNHp-­‐bound	  KRASG12D,	  RHEB,	  RHOA,	  and	  RALA.	  
Only	  KRASG12D	  shows	  a	  thermophoretic	  change.	   
VI. Discussion  
The analyses performed in the pharmacophore approach allowed for the design of small 
molecules that bound to RAS and prevented interactions with its effectors. The low affinity of 
the pharmacophore hits motivated an alternative approach that entailed the design of ligands 
making multiple distinct contacts on the surface of RAS, the PAINT process. This process 
consisted of first docking fragment libraries across multiple shallow sites on the protein to find 
enriched architectures. These structures were then used as the basis for the design of 
synthetically accessible combinatorial in silico libraries. Top hits from a library docked into one 
site were extended into an adjacent site, where the linked scaffold was further elaborated on in 
another round of combinatorial in silico library design. A set of the top two site compounds was 
synthesized and demonstrated the ability to disrupt the RAS-RAF and RAS-RALGDS 
interactions through an in vitro pull-down assay at dramatically lower concentrations than the 
pharmacophore compounds. The binding affinity to RAS was then measured quantitatively 
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through microscale thermophoresis. Attempts at extending into the third, Y32 site, yielded an 
improvement in affinity for the hit compound 34MEW43; however, an accurate dissociation 
constant determination could not be achieved due to the aqueous solubility limits of the 
34MEW43 and the 3-site compound 34MEW95. The two-site compound 31MEW44 had the 
highest affinity of the potential inhibitors tested, as well as the most ideal physiochemical 
properties. More extensive characterization of this compound showed selectivity for the active 
form of KRASG12D as well as a loss of affinity when measured against mutants of residues in its 
predicted binding site. Comparing to the low molecular weight pharmacophore compounds, it 
appeared to have dramatically improved binding site specificity as the mutations resulted in a 
larger decrease in affinity despite the compound being roughly 2.5 times the molecular weight of 
pharmacophore compounds. Further confirmation of binding was shown by 2D 1H-15N HSQC 
NMR, where substantial changes in chemical shifts were observed in the area 31MEW44 was 
docked and functionally associated residues. When tested by MST against other GTPases, 
31MEW44 also showed selectivity towards RAS despite highly homologous structures and 
sequences. Thus, the PAINT approach constituted a dramatic improvement over the initial 











Molecular docking was performed using GLIDE (version 2012, Schrodinger, Inc). Modeling of 
proteins and ligands were performed using Molecular Operating Environment [MOE] (Chemical 
Computing Group). All chemical structures were drawn using ChemDraw Ultra version 10.0. 
(Perkin Elmer). All statistical analyses, EC50 determinations, and viability curves were produced 
using Prism 5.0c (GraphPad Software). 
 
In silico libraries 
Libraries of commercially available compounds were compiled from the inventories of Asinex, 
Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge and TimTec.   
A fragment subset of ~60,000 compounds of the unfiltered library was selected using the 
following filter criteria: LogP <3, hydrogen bond acceptors ≤ 3, hydrogen bond donors ≤ 3, 
molecular weight <300, aqueous solubility > 0.5 mM. Chemical descriptors were calculated 
using MOE (Chemical Computing Group) 
Designed libraries of synthetically accessible compounds were compiled using selected 
commercially available reagents from the inventory of Sigma-Aldrich and Chem-Impex using 
the Combigen application in MOE (Chemical Computing Group). 
	  
Molecular	  cloning,	  protein	  expression,	  and	  purification	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Human	  KRAS4B	   sequence	   containing	   the	   oncogenic	   Q61H	  mutation	   in	   pENTR221	   vector	  
was	  purchased	  from	  Invitrogen	  (Ultimate	  ORF	  Clone	  IOH9852).	  	  To	  generate	  the	  wild-­‐type	  
KRAS	   sequence,	   H61Q	   back	  mutation	  was	   introduced	   using	   QuickChange	   II	   site-­‐directed	  
mutagenesis	   (Agilent	   Technologies)	   and	   confirmed	   by	   DNA	   sequencing	   (GeneWiz,	   Inc.).	  
Wild-­‐type	  KRAS4B	   sequence	   encoding	   the	   catalytic	   domain	   (amino	   acids	  1-­‐169	   in	  KRAS)	  
was	   amplified	   by	   PCR	   and	   cloned	   into	  Nde	   I-­‐BamH	   I	   sites	   of	   pET-­‐15b	   vector	   (Novagen)	  
containing	   the	   N-­‐terminal	   His6	   tag.	   	   G12D	   point	   mutation	   was	   introduced	   using	  
QuickChange	   II	   site-­‐directed	   mutagenesis	   (Agilent	   Technologies).	   	   DNA	   sequencing	   was	  
performed	  to	  confirm	  the	  correct	  amino	  acid	  sequence	  of	  the	  construct	  (GeneWiz,	  Inc.).	  	  
	  
Mutagenesis	  of	   the	  KRASG12D	  plasmid	  was	  performed	  using	  a	  QuikChange	  XL	  site-­‐directed	  
mutagenesis	   kit	   from	   Agilent	   technologies,	   according	   to	   the	   manufacturer’s	   protocol.	  
Primers	   were	   designed	   using	   the	   Agilent	   QuikChange	   Primer	   Design	   application	   and	  
purchased	   from	   Integrated	   DNA	   Technologies.	  KRASG12D	  D38A	   forward	   primer	   5’	   ATA	   TGA	  
TCC	  AAC	  AAT	  AGA	  GGC	  TTC	  CTA	  CAG	  GAA	  GCA	  AGT	  AG	  3’,	  KRASG12D	  D38A	  	  reverse	  primer	  5’	  
CTA	  CTT	  GCT	  TCC	  TGT	  AGG	  AAG	  CCT	  CTA	  TTG	  TTG	  GAT	  CAT	  AT	  3’,	  KRASG12D	  I36N	   forward	  
primer	   5’	   CAT	   TTT	   GTG	   GAC	   GAA	   TAT	   GAT	   CCA	   ACA	   AAT	   GAG	   GAT	   TCC	   TAC	   AGG	   3’,	  
KRASG12D	  I36N	  reverse	  primer	  5’	  CCT	  GTA	  GGA	  ATC	  CTC	  ATT	  TGT	  TGG	  ATC	  ATA	  TTC	  GTC	  CAC	  
AAA	  ATG	  3’.	  DNA	  sequencing	  was	  performed	  to	  confirm	  the	  correct	  amino	  acid	  sequence	  of	  
the	  construct	  (GeneWiz,	  Inc.).	  
	  
Protein	  NMR	  (this	  protocol	  was	  developed	  by	  Anna	  Kaplan)	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For	   NMR	   studies,	   uniformly	   15N-­‐labeled	   KRASG12D	   protein	   with	   N-­‐terminal	   His6	   tag	   was	  
prepared.	  	  The	  KRASG12D	  construct	  was	  expressed	  in	  Escherichia	  coli	  BL21-­‐Gold	  (DE3)	  cells	  
(Stratagene)	   growing	   at	   37	   °C	   in	   M9	   minimal	   medium	   supplemented	   with	   100	   µg/mL	  
ampicillin,	  metals,	  30	  mg	  nicotinic	  acid,	  3	  mg	  p-­‐aminobenzoic	  acid,	  0.3	  mg	  biotin,	  0.5	  mg	  
thiamine	  hydrochloride,	  and	  0.6	  g	  15NH4Cl	  as	  the	  sole	  nitrogen	  source.	   	  When	  the	  OD600nm	  
reached	  0.9,	  protein	  expression	  was	   induced	  with	  1	  mM	   isopropyl	  β-­‐D-­‐thiogalactoside	  at	  
15	  °C	  overnight.	   	  Cells	  were	  pelleted	  and	   lysed	  by	  sonication	   in	  buffer	  containing	  10	  mM	  
Tris-­‐HCl,	  500	  mM	  NaCl,	  5	  mM	  imidazole,	  5	  mM	  MgCl2,	  pH	  7.5,	  0.5	  %	  CHAPS	  (w/v),	  1	  mM	  
PMSF,	  and	  1	  mM	  TCEP.	  Cell	   lysate	  was	  then	  centrifuged	  at	  15,000	  x	  g	   for	  45	  min	  at	  4	  °C.	  
KRASG12D	  was	  first	  purified	  from	  cell	  lysate	  using	  Ni	  Sepharose	  6	  Fast	  Flow	  beads	  (GE	  Life	  
Sciences)	   and	   then	   using	   gel	   filtration	   Superdex	   100	   column.	   	   The	   fractions	   containing	  
KRASG12D	   were	   pooled	   together	   and	   verified	   by	   SDS-­‐PAGE.	   	   Protein	   concentration	   was	  
determined	   using	   absorbance	   at	   280	   nm	   with	   extinction	   coefficient	   of	   11,920	   M-­‐1	   cm-­‐1	  
(calculated	  using	  MOE).	  Thrombin	  was	  added	  at	  5	  U/mg	  protein	  to	  cleave	  the	  N-­‐terminal	  
His6	   tag.	   	   The	   reaction	  was	   allowed	   to	   proceed	   overnight	   at	   4	   °C.	   The	   next	   day,	   protein	  
solution	   was	   passed	   over	   Ni-­‐Sepharose	   6	   Fast	   Flow	   beads	   (GE	   Life	   Sciences)	   and	  
flowthrough	   containing	   the	   15N-­‐labled	   KRASG12D	   protein	   without	   histadine	   tag	   was	  
concentrated	  and	  flash	  frozen.	  	  Purity	  was	  checked	  by	  SDS-­‐PAGE	  gel.	  	  	  
	  
To	   load	   a	   specific	   nucleotide	   onto	   15N-­‐labeled	   KRASG12D,	   the	   protein	  was	   first	   incubated	  
with	  10	  molar	  excess	  of	  EDTA	  for	  1	  h	  at	  rt,	  then	  buffer	  exchanged	  into	  HEPES	  NMR	  buffer	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(50	  mM	  HEPES	   pH	  7.4,	   50	  mM	  NaCl),	   and	   lastly	   supplemented	  with	   2	  mM	  MgCl2,	   2	  mM	  
TCEP,	  and	  10	  molar	  excess	  of	  GDP	  or	  GppNHp	  nucleotide.	  	  
For	  biochemical	   studies,	  KRASG12D	   construct	  was	  expressed	   in	  Escherichia	  coli	  BL21-­‐Gold	  
(DE3)	   cells	   (Stratagene)	   growing	   at	   37	   °C	   in	   LB	   media	   with	   100	   µg/mL	   ampicillin	   and	  
induced	  when	   the	  OD600nm	   reached	  1.0,	  with	  1	  mM	   isopropyl	  β-­‐D-­‐thiogalactoside	  at	  15°C	  
overnight.	   	  Protein	  purification	  was	  the	  same	  as	  for	  the	  15N-­‐labeled	  protein,	  except	  the	  N-­‐
terminal	  His6	  tag	  was	  not	  removed.	  	  	  
In	  vitro	  RAS	  pulldown	  
A	  20	  µM	  solution	  of	  KRASG12D	  in	  50	  mM	  HEPES,	  200	  mM	  sodium	  chloride,	  2	  mM	  TCEP	  with	  
1	   mM	   EDTA	   and	   1	   mM	   GTP	   was	   gently	   rotated	   at	   25	   oC	   to	   remove	   the	   endogenous	  
nucleotide.	  Magnesium	  chloride	  was	   then	  added	   to	  5	  mM	  and	   the	   resulting	   solution	  was	  
rotated	  at	  4	  oC	  for	  4	  h.	  The	  GTP-­‐loaded	  KRASG12D	  was	  then	  diluted	  to	  20	  nM	  and	  incubated	  
with	  the	  inhibitors	  and	  10	  µL	  of	  RAF1-­‐RBD	  agarose	  beads	  (EMD	  Millipore,	  CN:	  14-­‐278)	  or	  
100	  nM	  RALGDS	  (Abcam,	  CN:	  ab132590)	  with	  20	  µL	  of	  glutathione	  beads	  for	  2	  h.	  The	  beads	  
were	  separated	  from	  solution	  by	  centrifuging	  at	  1,500	  x	  g.	  They	  were	  then	  washed	  2	  X	  with	  
PBS	  before	  the	  addition	  of	  1X	  SDS.	  The	  quantity	  of	  RAS	  in	  the	  samples	  was	  then	  analyzed	  
using	  the	  western	  blotting	  procedure.	  	  	  
	  
Western	  blots	  
Samples	  were	  separated	  using	  SDS-­‐polyacrylamide	  gel	  electrophoresis	  and	  transferred	  to	  a	  
polyvinylidene	   difluoride	   membrane.	   Transfer	   was	   performed	   using	   the	   iBlot	   system	  
(Invitrogen).	  Membranes	  were	  treated	  with	  Li-­‐COR	  odyssey	  blocking	  buffer	  for	  1	  h	  at	  25	  oC,	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then	   incubated	   with	   a	   pan-­‐RAS	   antibody	   (cell	   signaling,	   CN:	   3965S)	   (1:1,000)	   in	   a	   1:1	  
solution	  of	  PBS-­‐T	  and	  Li-­‐COR	  odyssey	  blocking	  buffer	  overnight	  at	  4	  °C.	  Following	  3x5	  min	  
washes	   in	   PBS-­‐T,	   the	   membrane	   was	   incubated	   with	   a	   goat	   anti-­‐rabbit	   IgG	   antibody	  
conjugated	  to	  an	  IRdye	  at	  800CW	  (Li-­‐COR	  biosciences)	  (1:2000)	  in	  a	  1:1	  solution	  of	  PBS-­‐T	  
and	  Li-­‐COR	  Odyssey	  blocking	  buffer	  for	  45	  min	  at	  25	  oC.	  Following	  three	  5	  min	  washes	  in	  
PBS-­‐T,	  the	  membrane	  was	  scanned	  using	  the	  Li-­‐COR	  Odyssey	  Imaging	  System.	  	  	  
 
Microscale thermophoresis 
KRASG12D (250 µM) in 25 mM HEPES, 100 mM sodium chloride, 2 mM TCEP with 20 mM 
EDTA and 1 mM GppNHp was shaken at 220 rpm at 30 oC to remove the endogenous 
nucleotide. The solution was placed on ice for 2 min prior to the addition of 65 mM MgCl2. After 
an additional 10 min incubation on ice, 200 uL of a 10 uM solution of KRASG12D was combined 
with 200 uL of a 20 uM solution of NT-647-NHS-ester dye (from a 652.4 µM stock). The 
protein/dye mixture was rotated at 4 oC for 30 min, before being separated from the separated 
from the excess dye and buffer exchanged into 25 mM Tris, 100 mM sodium chloride, 2 mM 
TCEP, and 5 mM MgCl2 via a nap-5 column. The Compounds were arrayed across a 16-point 
dilution series consisting of 1.5% DMSO with 25 mM Tris, 100 mM NaCl, 2 mM TCEP, 5 mM 
MgCl2 and 0.05% tween-20. Thermophoretic movement of the fluorescently labeled protein with 
the inhibitors was performed using a Monolith NT.115 (Nanotemper Technologies). RALA and 
RHOA were purchased commercially from Abcam (RALA CN:ab102555, RHOA 
CN:ab101594). 
Isothermal titration calorimeter (this protocol was developed by Dr. Anna Kaplan) 
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ITC experiments were carried out at 25 ° C on MicoCal Auto-ITC200 system (GE Healthcare).  
Due to low solubility of 31MEW44 in aqueous buffers, for all ITC experiments the compound 
was loaded into the cell and the KRASG12D•GppNHp protein was loaded into the syringe. 
Working stocks of compound 31MEW44 were prepared in 100% DMSO at 20 mM.  450 µL of 
the compound solution was loaded into cell at 250 µM in ITC buffer (25 mM Tris pH 7.4, 1 mM 
TCEP, 100 mM NaCl, 5 mM MgCl2, 0.05% Tween-20) with final DMSO concentration at 
1.25% (v/v).  KRASG12D•GppNHp was buffer exchanged into same ITC buffer using Amicon 
Ultra 10 kDa size exclusion filter spin columns (buffer replaced with ITC buffer four times).  
Prior to loading 130 µL of KRASG12D•GppNHp into the syringe at 2.5 mM, DMSO was added to 
match the amount DMSO present in the cell.   ITC titration experiments were carried out at 25° 
C with 19 injections, 2 µl per injection, and 180 seconds between each injection.  Reference cell 
power was set to 5 µcal/sec.  Control experiment was performed where ITC buffer was titrated 
into compound 31MEW44 alone to account for heat released due to dilution.  This background 
was subtracted from test data before final dissociation constant was obtained.  Data were 
analyzed using one-site binding model in Origin 7.1 software. The dissociation constant, Kd, was 
calculated according to equation Kd = 1/Ka.  Gibbs free energy, ∆G, was calculated from 
equation ∆G = -RTlnKa . -T∆S was calculated from equation ∆G = ∆H-T∆S.  All other 
parameters, Ka, n, ∆H, were determined directly from the titration data.    
 
Synthesis of chemical materials 
General information. All reactions were carried out under a nitrogen atmosphere under 
anhydrous conditions unless indicated otherwise. Anhydrous methylene chloride (DCM), 
tetrahydrofuran (THF) and N,N-dimethylformamide (DMF) were purchased from Sigma-
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Aldrich. Reactions were magnetically stirred and monitored by thin layer chromatography 
carried out by Merck pre-coated 0.25 mm silica plates containing a 254 nm fluorescence 
indicator. Flash chromatography was performed on a Teledyne combiflash companion automatic 
flash chromatography system. Preparative thin layer chromatography was performed on 1 mm. 
Proton nuclear magnetic resonance spectra (1H NMR, 300 MHz, 400 MHz, 500 MHz) and 
proton decoupled carbon nuclear magnetic resonance spectra (13C NMR, 100 MHz, 125 MHz) 
were obtained on a Bruker DPX 300, 400, or 500 MHz instruments in deuterochloroform 
(CDCl3) with residual chloroform as internal standard. Other deuterated solvents that were used 
include d4-MeOD and d6-DMSO. 
Abbreviations: DIPEA = diisopropylethyl amine, DCE = 1,2-dichloroethane, EtOAc = ethyl 
acetate, HBTU = O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate, 
HCl = hydrochloric acid, MeOH = methanol, MgSO4= magnesium sulfate, NaHCO3 = sodium 
bicarbonate, Na2SO4 = sodium sulfate, NH4Cl = ammonium chloride, Pd(PPh3)4 = 
Tetrakis(triphenylphosphine)palladium(0), rt = room temperature, TFA = trifluoroacetic acid, 




tert-butyl 3-(5-formyl-1H-indol-1-yl)propylcarbamate (2) 
To a solution of 1H-indole-5-carbaldehyde (1) (3.5 g, 24 mmol) in DMF (100 mL) at 0 oC, 









5 min. The mixture was stirred for 45 min at 0 oC before the sequential addition of 3-(Boc-
amino)propyl bromide (8 g, 33.6 mmol) and sodium iodide (3.6 g, 24 mmol,). The solution was 
warmed to 80 oC and stirred for 48 h. Upon completion, the reaction was diluted with saturated 
aqueous NaHCO3 and extracted 3 times with EtOAc. The combined organic layers were washed 
with brine, dried (Na2SO4), concentrated, and the crude material was purified by combiflash 
0→50% EtOAc in hexanes to yield tert-butyl 3-(5-formyl-1H-indol-1-yl)propylcarbamate (2)  
(3.4 g, 47% yield). 1H NMR (400 MHz, CDCl3) δ 10.05 (s, 1H), 8.18 (d, J = 1.5 Hz, 1H), 7.81 
(dd, J = 8.7, 1.6 Hz, 1H), 7.26 (d, J = 3.1 Hz, 1H), 6.75-6.60 (m, 1H), 4.54 (s, 1H), 4.25 (t, J = 
6.9 Hz, 2H), 3.17 (d, J = 7.2 Hz, 2H), 2.08 (p, J = 6.9 Hz, 2H), 1.47 (s, 8H). 13C NMR (101 MHz, 
CDCl3) δ 192.4, 156.1, 139.2, 129.8, 129.3, 128.4, 126.6, 121.8, 109.8, 103.6, 79.5, 44.1, 38.0, 




tert-butyl 3-(3-bromo-5-formyl-1H-indol-1-yl)propylcarbamate (3) 
To a solution of tert-butyl 3-(5-formyl-1H-indol-1-yl)propylcarbamate (2) (1.8 g, 5.95 mmol) in 
THF (120 mL) at -78 oC, Br2 (0.367 mL, 7.1 mmol) was added dropwise over about 5 min. The 
resulting mixture was stirred at -78 oC for 2 h. Upon completion, the reaction contents were 
poured onto a solution of ice (~300 g), water (200 mL), ammonium hydroxide (1 mL, 12 M), 










extracted 3 times with EtOAc, the combined organic layers were washed with brine, dried 
(Na2SO4), concentrated, and the crude material was purified by combiflash 0→50% EtOAc in 
hexanes to yield tert-butyl 3-(3-bromo-5-formyl-1H-indol-1-yl)propylcarbamate (3) (1.2 g, 53% 
yield).1H NMR (400 MHz, CDCl3) δ 10.09 (s, 1H), 8.12 (d, J = 1.5 Hz, 1H), 7.86 (dd, J = 8.7, 
1.5 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.30 (s, 1H), 4.57 (s, 1H), 4.23 (t, J = 6.9 Hz, 2H), 3.18 (d, 
J = 6.8 Hz, 2H), 2.08 (p, J = 6.7 Hz, 2H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 191.2, 
155.3, 137.9, 129.0, 127.9, 126.5, 124.1, 121.6, 109.4, 91.2, 43.5, 37.1, 29.8, 27.6, 27.5. HRMS 




tert-butyl 3-(5-formyl-3-(4-(trifluoromethoxy)phenyl)-1H-indol-1-yl)propylcarbamate (4) 
To a solution of tert-butyl 3-(3-bromo-5-formyl-1H-indol-1-yl)propylcarbamate (3) (1.49 g, 3.91 
mmol) in dioxane (30 mL), 4-(trifluoromethoxy)phenylboronic acid (1.20 g, 5.87 mmol), 
Pd(PPh3)4 (0.225 g, 0.195 mmol), and a solution of potassium carbonate (1.08 g, 7.82 mmol in 
H2O (7.82 mL)) were added sequentially. The resulting mixture was heated to 80 oC and stirred 
for 48 h. Upon completion, the reaction was diluted with saturated aqueous NaHCO3 and 
extracted 3 times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, 











3-(5-formyl-3-(4-(trifluoromethoxy)phenyl)-1H-indol-1-yl)propylcarbamate (4) (1.3 g, 72%). 1H 
NMR (500 MHz, CDCl3) δ 10.03 (s, 1H), 8.35 (s, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.64 (d,J = 8.4 
Hz, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.40 (brs, 1H), 7.30 (d, J = 8.4 Hz, 2H), 4.25 (t, J = 6.9 Hz, 
2H), 3.20-3.16 (m, 2H), 2.08 (p, J = 6.8 Hz, 2H), 1.43 (s, 9H). 13C NMR δ (125 MHz, CDCl3)  
192.3,  156.2, 147.9, 140.0, 133.3, 130.0, 128.8, 127.5, 126.2, 125.1, 122.7, 121.6, 117.9, 110.3, 






To a solution of piperazine (9.66 g, 112.1 mmol) in THF (180 mL) at 0 oC, a solution of 2,6-
dichlorobenzyl bromide (4.52 g, 18.8 mmol) in THF (20 mL) was added dropwise over 10 min. 
The resulting mixture was slowly allowed to warm to rt and stirred for 24 h. Upon completion, 
the THF was removed, the crude material was resuspended in DCM and water, and extracted 2 
additional times with DCM. The combined organic layers were dried (Na2SO4), filtered, and 
concentrated. The crude material was purified by combiflash 0→20% MeOH in DCM to provide 
1-(2,6-dichlorobenzyl)piperazine (5) (4.1 g, 88% yield). 1H NMR (500 MHz, d4-MeOD) δ 7.37 










2.59 (dd, J = 5.0, 4.9 Hz, 4H). 13C NMR (125 MHz, d4-MeOD) δ 138.1, 135.0, 130.6, 129.6, 






To a solution of tert-butyl 3-(5-formyl-3-(4-(trifluoromethoxy)phenyl)-1H-indol-1-
yl)propylcarbamate (4) (324.4 mg, 0.7 mmol) and 1-(2,6-dichlorobenzyl)piperazine (5) (267.4 
mg, 1.1 mmol) in DCM (4.5 mL) was added sodium triacetoxyborohydride (442.5 mg, 2.1 
mmol). The resulting mixture was stirred at 25 oC for 6 h. Upon completion, the reaction was 
diluted with water and extracted 3 times with DCM. The combined organic layers were dried 
(Na2SO4), concentrated, and the crude material was purified by combiflash 0→5% MeOH in 
DCM to yield tert-butyl 3-(5-((4-(2,6-dichlorobenzyl)piperazin-1-yl)methyl)-3-(4-
(trifluoromethoxy)phenyl)-1H-indol-1-yl)propylcarbamate (454.5 mg, 94% yield). 1H NMR (400 
MHz, d4-MeOD) δ 7.93 (d, J = 1.0 Hz, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.54 (s, 1H), 7.45 (d, J = 
8.5 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.23 (dd, J = 8.5, 1.2 Hz, 1H), 
7.20 (dd, J = 8.6, 7.5 Hz, 1H), 4.22 (t, J = 6.9 Hz, 2H), 4.01 (s, 2H), 3.75 (s, 2H), 3.05 (t, J = 6.6 



















MHz, d4-MeOD) δ 178.1, 158.5, 148.4, 138.4, 138.0, 136.0, 134.5, 130.8, 129.6, 129.5, 128.7, 
127.5, 125.6, 123.2, 122.5, 116.5, 111.3, 80.0, 62.9, 56.7, 53.0, 51.7, 44.8, 38.8, 31.3, 28.8, 22.9. 






To a solution of tert-butyl 3-(5-((4-(2,6-dichlorobenzyl)piperazin-1-yl)methyl)-3-(4-
(trifluoromethoxy)phenyl)-1H-indol-1-yl)propylcarbamate (6) (998.5, 1.4 mmol) in dioxane (10 
mL) a solution of HCl (4 M in 1,4-dioxane) was added (3 mL, 12.0 mmol) and the resulting 
solution was stirred at 40 oC for 18 h. Upon completion, the dioxane was removed and the crude 
material was resuspended in methanol and an excess of potassium carbonate was added (~2 g). 
The slurry was stirred at rt until basic. then filtered and concentrated. The crude product was 
purified by preparative TLC (20% MeOH in DCM) to provide 3-(5-((4-(2,6-
dichlorobenzyl)piperazin-1-yl)methyl)-3-(4-(trifluoromethoxy)phenyl)-1H-indol-1-yl)propan-1-
amine (7) (652.0 mg, 76% yield). 
1H NMR (400 MHz, d4-MeOD) δ 7.80 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.50 (s, 1H), 7.41 (d, J = 
















2H), 3.56 (s, 2H), 2.71 (t, J = 7.1 Hz, 2H), 2.57 (brs, 4H), 2.43 (brs, 4H), 2.05 (p, J = 7.1 Hz, 2H). 
13C NMR (125 MHz, d4-MeOD) δ 148.3, 138.1, 137.8, 136.4, 135.1, 130.5, 129.64, 129.56, 
129.3, 127.8, 127.3, 125.4, 122.4, 121.9, 121.0, 116.4, 110.7, 64.5, 57.2, 53.9, 53.7, 44.7, 39.4, 






HBTU (505.7 mg, 1.3 mmol) was added to a solution of 4-amino-1-(tert-
butoxycarbonyl)piperidine-4-carboxylic acid (620.6 mg, 2.5 mmol)  and DIPEA (0.25 mL, 1.4 
mmol) in DMF (9 mL) at 0 oC and stirred for 30 min. A solution of 3-(5-((4-(2,6-
dichlorobenzyl)piperazin-1-yl)methyl)-3-(4-(trifluoromethoxy)phenyl)-1H-indol-1-yl)propan-1-
amine (7) (652.0 g, 1.0 mmol) in DMF (5 mL) was added. The reaction was stirred for an 
additional 72 h and allowed to warm to 25 oC. Upon completion, the reaction was quenched with 
saturated aqueous NaHCO3 and extracted 3 times with EtOAc. The combined organic layers 
were washed with water and brine, then dried (Na2SO4) and concentrated. The crude material 



















yl)propylcarbamoyl)piperidine-1-carboxylate (8) (577.6 mg, 68% yield). 1H NMR (400 MHz, d4-
MeOD) δ 8.01 (s, 1H), 7.75 (s, 1H), 7.62 (d, J = 8.7 Hz, 3H), 7.33-7.28 (m, 5H), 7.11 dd, J = 8.5, 
8.4 Hz, 1H), 4.21 (t, J = 6.5 Hz, 2H), 3.90 (brd, J = 11.6 Hz, 2H), 3.75 (s, 2H), 3.68 (s, 2H), 3.30 
(q, J = 6.4 Hz, 2H), 2.94 (s, 4H), 2.87 (s, 2H), 2.80 (s, 3H), 2.63 (brs, 4H), 2.54 (brs, 4H), 2.14-
2.01 (m, 5H), 1.45 (s, 9H), 1.18 (brd, J = 13.6 Hz, 2H). 13C NMR (100 MHz, d4-MeOD) δ176.9, 
162.7, 154.7, 147.4, 137.1, 136.2, 134.4, 134.3, 128.9 128.5, 128.4, 126.2, 124.4, 121.6, 120.8, 
115.8, 109.7, 79.8, 63.5, 56.4, 55.5, 53.1, 52.7, 44.7, 38.7, 37.2, 36.6, 34.6, 31.5, 30.1, 28.5. 






(trifluoromethoxy)phenyl)-1H-indol-1-yl)propylcarbamoyl)piperidine-1-carboxylate (8) (40 mg, 
0.049 mmol) was dissolved in 1,4-dioxane (0.5 mL) before the addition of HCl in 1,4-dioxane 
(0.1 mL of a 4 M solution). The resulting mixture was stirred for 6 h at 25 oC. Upon completion 



















mg, XS) was added. The crude material was purified by preparative TLC (15% MeOH in DCM) 
to provide 31MEW44 (18 mg, 51%). 1H NMR (400 MHz, d4-MeOD) δ 7.82 (s, 1H), 7.74 (d, J = 
8.7 Hz, 2H), 7.55 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 8.0 Hz, 2H), 7.31 (d, J = 8.2 Hz, 
2H), 7.21 (dd, J = 8.5, 7.5 Hz, 2H), 4.26 (t, J = 6.7 Hz, 2H), 3.75 (s, 2H), 3.60 (s, 2H), 3.24 (t, J 
= 6.6 Hz, 2H), 2.99-2.89 (m, 4H), 2.60 (brs, 4H), 2.49 (brs, 4H), 2.11-1.97 (m, 4H), 1.35 (brd, J 
= 13.9 Hz, 2H). 13C NMR (100 MHz, d4-MeOD) δ 179.4, 148.3, 138.1, 137.8, 136.4, 135.1, 
130.5, 129.7, 129.6, 128.1, 127.4, 125.4, 122.5, 121.9, 116.3, 110.8, 64.5, 57.2, 56.2, 53.9, 53.7, 





The compound prepared according to the protocols for 31MEW44. 1H NMR (400 MHz, d4-
MeOD) δ 7.44 (dd, J = 8.4, 1.0 Hz, 1H), 7.38 (td, J = 8.0, 6.1 Hz, 1H), 7.34-7.22 (m, 5H), 7.22-
7.15 (m, 1H), 7.08-6.98 (m, 2H), 6.94-6.87 (m, 2H), 4.34-4.21 (m, 2H), 4.06 (t, J = 5.5 Hz, 2H), 
3.56 (s, 2H), 2.73 (t, J = 5.5 Hz, 2H), 2.43 (s, 3H), 2.25-2.08 (m, 7H). 13C NMR (100 MHz, d4-













115.7, 112.6, 109.3, 59.5, 56.4, 53.7, 52.7, 51.3, 43.5, 39.7, 36.9, 31.1, 29.3. HRMS (m/z): 




36MEW3 was synthesized according to the same procedure as 31MEW44.  
1H NMR (400 MHz, Methanol-d4) δ 7.62 (s, 1H), 7.50 – 7.40 (m, 3H), 7.20 (d, J = 9.8 Hz, 1H), 
6.68 (d, J = 2.5 Hz, 1H), 6.64 (dd, J = 8.3, 2.5 Hz, 1H), 6.52 (d, J = 2.3 Hz, 2H), 6.40 (t, J = 2.3 
Hz, 1H), 4.55 (s, 3H), 4.29 (t, J = 6.8 Hz, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.77 (s, 6H), 3.73 (s, 
2H), 3.53 – 3.48 (m, 3H), 3.16 (p, J = 1.7 Hz, 1H), 2.77 – 2.48 (m, 11H), 2.36 (d, J = 7.5 Hz, 





























1H NMR (400 MHz, Methanol-d4) δ 7.66 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 7.5, 1.7 Hz, 1H), 7.54 
(s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.32 – 7.20 (m, 4H), 7.11 (dd, J = 8.3, 1.1 Hz, 1H), 7.05 (td, J = 
7.5, 1.2 Hz, 1H), 6.96 – 6.88 (m, 2H), 4.32 (t, J = 6.6 Hz, 2H), 4.12 (t, J = 5.5 Hz, 2H), 3.86 (s, 
3H), 3.71 (s, 2H), 3.25 – 3.17 (m, 4H), 2.83 (t, J = 5.5 Hz, 2H), 2.66 (s, 7H), 2.20 – 2.07 (m, 





32MEW56 was synthesized according to the same procedure as 31MEW44. 
1H NMR (400 MHz, Methanol-d4) δ 8.23 (d, J = 1.6 Hz, 1H), 7.97 (s, 1H), 7.93 – 7.83 (m, 2H), 
7.56 (d, J = 8.5 Hz, 1H), 7.32 (dd, J = 8.5, 1.5 Hz, 1H), 4.35 (t, J = 6.8 Hz, 1H), 3.86 (s, 1H), 
















To a solution of 5-chlorosalicyladehyde (82 mg, 0.56 mmol) in DMF (1 mL), K2CO3 (87 mg, 
0.63 mmol) was added and stirred for 10 min at 25 oC before the addition of 4-
(trifluoromethoxy)benzyl bromide (126 uL, 0.788 mmol). The resulting mixture was stirred at 25 
oC for 12 h. Upon completion, the reaction contents were diluted with saturated NaHCO3 and 
extracted with EtOAc (3X). The combined organic layers were washed once with brine, dried 
(Na2SO4), concentrated and purified by combiflash 0→ 30% EtOAc to provide 5-chloro-2-(4-
(trifluoromethoxy)benzyloxy)benzaldehyde (99 mg, 53% yield). 1H NMR (400 MHz, CDCl3) δ 
10.49 (s, 1H), 7.84 (d, J = 2.8 Hz, 1H), 7.55-7.45 (m, 3H), 7.34-7.23 (m, 3H), 7.01 (d, J = 8.9 Hz, 
1H), 5.20 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 188.1, 135.4, 134.23, 128.8, 128.3, 126.1, 





























43MEW63 was synthesized using the same procedures as 34MEW95. 
1H NMR (400 MHz, Methanol-d4) δ 7.84 (s, 1H), 7.74 (d, J = 8.7 Hz, 2H), 7.49 (s, 1H), 7.43 – 
7.29 (m, 5H), 7.29 – 7.17 (m, 2H), 6.96 (s, 1H), 6.90 – 6.80 (m, 2H), 6.59 (d, J = 2.3 Hz, 2H), 
6.40 (d, J = 2.4 Hz, 1H), 5.00 (s, 2H), 4.25 (t, J = 6.9 Hz, 2H), 3.81 (s, 3H), 3.79 (s, 2H), 3.75 (s, 
6 H), 3.62 (s, 2H), 3.53 – 3.47 (m, 3H), 3.19 – 2.91 (m, 6H), 2.63 (s, 4H), 2.50 (s, 4H), 2.16 – 





35MEW12 was synthesized according to the same procedures as 34MEW95.1H NMR (400 
MHz, Methanol-d4) δ 7.51 – 7.41 (m, 3H), 7.41 – 7.28 (m, 3H), 7.28 – 7.20 (m, 4H), 7.20 – 7.13 
(m, 2H), 7.13 – 7.06 (m, 2H), 7.06 – 6.98 (m, 3H), 6.93 – 6.86 (m, 2H), 5.11 (s, 2H), 4.26 (t, J = 
6.9 Hz, 2H), 4.06 (t, J = 5.5 Hz, 2H), 3.56 – 3.49 (m, 4H), 3.33 – 3.08 (m, 10H), 2.72 (t, J = 5.5 





















43MEW65 was synthesized using the same procedures as 34MEW95. 
1H NMR (400 MHz, Methanol-d4) δ 8.03 (s, 2H), 7.93 (s, 1H), 7.86 – 7.81 (m, 1H), 7.77 – 7.70 
(m, 2H), 7.51 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.40 – 7.34 (m, 2H), 7.26 (dddd, J = 23.7, 16.0, 
8.2, 1.3 Hz, 7H), 7.00 – 6.93 (m, 2H), 5.20 (s, 2H), 4.27 (t, J = 6.8 Hz, 2H), 3.78 (s, 2H), 3.62 (s, 
2H), 3.48 (s, 3H), 3.11 – 2.99 (m, 2H), 2.99 – 2.89 (m, 2H), 2.63 (s, 4H), 2.50 (s, 4H), 2.11 (t, J 




















43MEW73was synthesized using the same procedures as 34MEW95. 
1H NMR (400 MHz, Methanol-d4) δ 8.65 (d, J = 2.2 Hz, 1H), 7.91 (dd, J = 8.1, 2.2 Hz, 1H), 7.85 
(s, 1H), 7.76 – 7.69 (m, 2H), 7.53 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.42 – 7.33 (m, 4H), 7.33 – 
7.22 (m, 4H), 7.21 – 6.99 (m, 4H), 4.59 (p, J = 6.3 Hz, 1H), 4.30 (t, J = 6.9 Hz, 2H), 3.79 (d, J = 
7.6 Hz, 4H), 3.69 (s, 2H), 2.61 (d, J = 29.0 Hz, 8H), 2.28 – 2.08 (m, 4H), 1.94 (d, J = 15.8 Hz, 





















To a solution of tert-butyl 4-amino-4-(3-(4-((4-(2-(4-chlorophenoxy)ethyl)piperazin-1-
yl)methyl)-3-(3-fluorophenyl)-1H-indol-1-yl)propylcarbamoyl)piperidine-1-carboxylate  
 (29 mg, 0.0443 mmol) in DCE (1 mL), 5-chloro-2-(4-
(trifluoromethoxy)benzyloxy)benzaldehyde (44 mg, 0.133 mmol,), and MgSO4 (10 mg) were 
added and stirred at 40 oC for 1 h prior to the addition of sodium triacetoxyborohydride (19 mg, 
0.0886 mmol,). The resulting mixture was stirred for an additional 8 h at 40 oC before being 
concentrated and purified directly by preparative TLC (2% MeOH in DCM). The Boc group of 
the product was then removed (using the protocol for 31MEW44) to provide 34MEW95 (14 mg, 
33% yield over two steps). 1H NMR (400 MHz, d4-MeOD) δ 7.41-7.29 (m, 5H), 7.29-7.13 (m, 
8H), 7.12-6.97 (m, 4H), 6.92-6.86 (m, 2H), 5.71 (s, 1H), 4.95 (q, J = 11.1 Hz, 2H), 4.14 (q, J = 
7.1 Hz, 2H), 4.05 (t, J = 5.5 Hz, 2H), 3.53 (s, 2H), 3.44 (ddd, J = 14.7, 9.1, 6.3 Hz, 1H), 3.16 


























5H), 1.71 (d, J = 14.1 Hz, 1H). 13C NMR (100 MHz, d4-MeOD) δ 175.6, 157.5, 155.8, 136.8, 
135.2, 130.4, 130.2, 129.7, 129.3, 128.9, 128.8, 128.7, 127.5, 126.2, 126.1, 126.0, 125.4, 125.3, 
122.2, 121.1, 120.8, 117.0, 116.9, 116.7, 115.6, 114.0, 112.4, 112.2, 108.9, 69.5, 65.2, 59.7, 58.8, 
56.7, 53.0, 51.8, 43.3, 40.5, 40.4, 38.4, 31.2, 29.7, 27.3. HRMS (m/z): [M+H]+ cald for 




















Chapter 3: Cell-based and in vivo evaluation of 31MEW44 
The data presented in this chapter is part of a submitted manuscript: Welsch M.E., Kaplan A., 
Chambers J.M., Pagano N.C., Yang W.S., M.S. Martin, Badgley M.A., Olive K.P., Ferrando A., 
Stockwell B.R., Multivalent inhibitors of RAS GTPases designed using PAINT 
 
I. Introduction 
Based on the near identical sequences within the D38 and A59 sites among the different 
RAS isoforms, we speculated that 31MEW44 would function as a pan-RAS inhibitor. Ample 
evidence exists that tumors with mutated RAS proteins are addicted to these oncogenic isoforms 
[12, 86]. Thus, a pan-RAS inhibitor such as 31MEW44 might have an acceptable therapeutic 
window in vivo to be used as a pharmacological agent against RAS mutant cancers. This chapter 
describes the characterization of 31MEW44 to inhibit RAS signaling pathways in cell culture by 
examining a variety of different cellular markers of RAS modulation, ranging from levels of 
downstream phosphorylated proteins to altering the transcriptional effects of RAS activation. 
With evidence of in vitro RAS inhibition and anticancer activity, 31MEW44 was then evaluated 
in three different murine models for its ability to attenuate cancer progression. 
 
II. Cell-based evaluation 
IIa. Evaluation in a panel of cancer cell lines 
To see 31MEW44 would be selectively lethal to mutant RAS-dependent cancers it was 
evaluated in a panel of 10 mutant RAS cell lines and 4 wild-type cell lines (testing in the mutant 
RAS lines performed by Nen Pagano, Fig. 3.1a). As one would expect, two most resistant lines 
(SW982 and SW872) both possessed wild-type RAS and mutant BRAFV600E: a downstream RAS 
effector. In the mutant RAS lines there was a very wide range in sensitivity observed. We 
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hypothesized that this was due to their degree of dependency on mutant RAS. To examine if this 
was the case, an siRNA knockdown of the mutated isoform was performed in each of the lines 
tested (siRNA knockdown experiment performed by Nen Pagano). Plotting the percent viability 
with mutant RAS knockdown against the percent viability with 31MEW44 treatment confirmed 
that a correlation was indeed present. This was much stronger at the lower tested concentration: 
R2 = 0.30 at 5 µM 31MEW44 treatment and R2 = 0.70 at 2.5 µM (Fig. 3.1b). This can be 
interpreted as the lower concentration being more functionally equivalent to a knockdown. The 
higher concentrations would also result in inhibition of the active wild-type forms of RAS (more 
analogous to a multiple isoform knockdown). This idea is supported by the fact that the slope is 
much closer to 1 at the lower concentrations; 2.5 µM gave a slope of 1.2 compared to 1.7 at 5 
µM- indicating more of a functional equivalence at the lower concentration. Table 3.1 shows a 
table of EC50 values for 31MEW44, 34MEW43, and 34MEW95 in a panel of cell lines. 
	  
Figure	  3.1	  |	  Effect	  of	  31MEW44	  on	  the	  viability	  of	  a	  panel	  of	  cancer	  cell	  lines	  and	  correlation	  to	  RAS	  dependency.	  
(a)	  Effect	  of	  5	  μM	  31MEW44	   treatment	  on	   the	  viability	  of	  a	  panel	  of	   cancer	   cell	   lines.	  Cell	   lines	  were	   treated	   in	  6-­‐well	  
format	  for	  24	  h.	  (b)	  Correlation	  of	  cell	   line	  sensitivity	  of	  mutant	  RAS	  knockdown	  to	  2.5	  and	  5	  μM	  31MEW44	  treatment.	  
The	   knockdown	   viability	   was	  measured	   72	   h	   after	   reverse	   transfection	   with	   siRNA	  when	   siDeath	   control	   resulted	   in	  
complete	   loss	   of	   viability.	   Knockdown	   was	   confirmed	   by	   qPCR	   of	   the	   mutated	   isoform.	   *siRNA	   experiments	   and	  




Table	   3.1	   |	   Table	   of	   growth	   inhibition	   EC50	   values	   for	   31MEW44,	   34MEW43,	   and	   34MEW95	   in	   a	   panel	   of	   RAS	  
mutated	  cancer	  cells.	   	  Compounds	  were	  tested	  in	  triplicate	  in	  384-­‐well	  format,	  over	  a	  15-­‐point	  dilution	  series	  for	  48	  h.	  
ND=not	  determined.	  *Determined	  EC50	  values	  for	  31MEW44	  performed	  by	  Nen	  Pagano	  and	  myself. 
IIb. Prevention of anchorage-independent growth 
To see if this growth inhibition was effective under more physiologically relevant 
conditions, the ability of 31MEW44 to prevent tumor growth in an anchorage-independent 
fashion was assessed. This was examined by seeding the breast cancer MDA-MB-231 cell line 
(KRASG13D) and the colorectal line SW480 (KRASG12V) in low-adherence plates, resulting in 
aggregation into tumor-like spheres. Vehicle-treated cells grew into multicellular tumor-
spheroids (Fig. 3.2), whereas compound treated decreased in size in a dose-dependent manner. 
Thus, these compounds are effective at inhibiting tumor cell growth in 3D cultures.   
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Figure	   3.2	   |	   Inhibitors	   prevent	   anchorage	   independent	   growth.	   (a)	   Images	  of	  MDA-­‐MB-­‐231	  cells	  after	  72	  h	   in	   low	  
adherence	  plates	  forming	  three	  dimensional	  multicellular	  spheroids	  when	  untreated	  or	  treated	  with	  31MEW44	  at	  20	  μM	  
with	   the	  dose-­‐response	  curves	   for	  31MEW44	  treatment	  of	  MDA-­‐MB-­‐231	  and	  SW480	  cells.	   (b)	  Dose	  response	  curves	  of	  
34MEW43	  and	  34MEW95	  in	  MDA-­‐MB-­‐231	  cells. 
IIc. Induction of apoptosis 
The mechanism of lethality after loss of RAS expression is thought to be caspase-
dependent apoptosis [15]. To see if the compounds induced activation of caspases HT-1080 cells 
were treated with 31MEW44, 34MEW43, and 34MEW95. Activity was then measured by 
incubation of the lysate with a pro-fluorescent substrate for caspases 3 and 7 (rhodamine 110 bis-
N-CBZ-L-aspartyl-L-gluramyl-L-valyl-aspartic acid amide). In response to inhibitor treatment 
there was an observed increased fluorescence relative to DMSO treated, consistent with 
activation of caspases 3 and/or 7. The fluorescence level was similar to that of the known 
apoptosis-inducing agent staurosporine (Fig. 3.3). 
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Figure	   3.3	   |	   Induction	   of	   caspase	   3/7	   activation	   by	   inhibitors.	  HT-­‐1080	   cells	  were	   treated	  with	   31MEW44	  5	   μM,	  
34MEW43	  10	  μM,	  35MEW95	  5	  μM	  or	  staurosporin	  5	  μM	  for	  24	  h.	  Cells	  were	  then	  lysed	  and	  treated	  with	  a	  pro-­‐fluorescent	  
caspase	   3/7	   substrate	   (rhodamine	   110	   bis-­‐N-­‐CBZ-­‐L-­‐aspartyl-­‐L-­‐gluramyl-­‐L-­‐valyl-­‐aspartic	   acid	   amide)	   for	   16	   h	   and	  
measured.	  
	  
IId. Overexpression of mutant RAS and effectors  
If 31MEW44 was killing cells through RAS inhibition, overexpression of activated RAS 
or its downstream effectors would confer a degree of resistance to a cell line sensitive to the 
inhibitor. To examine this, HT-1080 cells (NRASQ61K) were transfected with pBABE-puro 
vectors containing KRASG12V, PI3KE545K, BRAFV600E or the empty vector using a retrovirus. 
Following puromycin selection, a portion of the PI3KE545K transfected cells underwent a second 
transfection with pBABEneo BRAFV600E. With 5 µM treatment of 31MEW44 for 24 h, resistance 
was observed in all cases relative to the empty vector, with the most resistant line being the 
BRAFV600E and PI3KE545K sequentially transfected line (Fig. 3.4).  
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Figure	  3.4	  |	  Effect	  of	  KRAS	  and	  effector	  overexpression	  on	  31MEW44	  sensitivity.	  (a)	  HT-­‐1080	  cells	  were	  retrovirally	  
transfected	  with	  a	  pBABE-­‐puro	  empty	  vector	  or	  vector	  containing	  KRASG12V,	  PI3KE545K,	  or	  BRAFV600E.	  Following	  selection	  
with	   puromycin,	   a	   population	   of	   the	   PI3KE545K	   transfected	   cells	   were	   transfected	   a	   second	   time	   with	   a	   pBABE-­‐neo-­‐
BRAFV600E	  vector	  and	  selected	  with	  geneticin.	  Stable	  cell	  lines	  were	  then	  treated	  with	  31MEW44	  for	  24	  h	  in	  6-­‐well	  format.	  
(b)	   Western	   blot	   of	   downstream	   phosphorylated	   AKT	   (S473)	   and	   ERK1/2.	   (c)	   qPCR	   confirmation	   of	   effector	  
overexpression.	  	  qPCR	  confirmation,	  (c),	  performed	  by	  Nen	  Pagano.	  
IIe. Disruption of RAS signaling pathways 
The ability of 31MEW44, 34MEW43, and 34MEW95 to disrupt RAS-RAF-MEK-ERK 
signaling was first examined in BJeLR cells (HRASG12V) by measuring phosphorylated ERK1/2 
levels following inhibitor treatment. All three compounds effectively decreased the ratio of 
pERK1/2 to total ERK1/2 in a dose-dependent manner (Fig. 3.5a). To confirm that this decrease 
correlated with disruption of the interaction between RAS and RAF in cells, a RAS pull-down 
assay was performed using agarose beads with the RAS binding domain of CRAF. This 
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indicated a dose-dependent decrease in CRAF-RBD-bound RAS (Fig. 3.5b), supporting the 
notion that these compound inhibited the interaction directly. This inhibitory effect was evident 
as well with the RAS-PI3K-AKT pathway, which exhibited a dose-dependent decrease in 
phosphorylated AKT (Fig. 3.5c). To provide further confirmation of direct disruption of RAS-
RAF and RAS-PI3K, a co-immunoprecipitation with cRAF and PI3Kγ using an HRAS antibody, 
was performed in the presence and absence of 31MEW44. Compound administration indeed 
decreased levels of co-immunoprecipitated CRAF and PI3K, suggesting direct inhibition (Fig. 
3.5d). To test if 31MEW44 is capable of preventing the interaction of RAS and RALGDS (a 
guanine dissociation stimulator of RALA), a RALA activation assay using RALBP1 was 
performed. Consistent with inhibition of the RAS-RALGDS interaction, we observed decreased 
levels of active GTP-bound RALA in a dose dependent manner (Fig. 3.5e). 
	   	  
Figure	  3.5	  |	  Disruption	  of	  RAS-­‐effector	  signaling	  pathways	  by	  inhibitors.	  (a)	  Effect	  of	  inhibitors	  on	  ERK1/2	  
activation.	  BJeLR	  cells	  were	  treated	  were	  treated	  with	  inhibitors	  at	  2	  μM	  and	  8	  μM,	  U0126	  at	  8	  μM,	  or	  BEZ-­‐235	  at	  0.2	  μM	  
for	  24	  h	  under	  serum	  free	  conditions.	  The	  lysate	  was	  analyzed	  for	  phosphorylated	  and	  total	  ERK.	  (b)	  Ability	  of	  inhibitors	  
to	  prevent	  the	  RAS-­‐RAF	  interaction.	  BJeLR	  cells	  were	  treated	  under	  the	  conditions	  described	  in	  (a).	  The	  cells	  were	  then	  
lysed	  and	  the	  lysate	  was	  then	  incubated	  with	  CRAF	  RBD-­‐agarose	  beads	  for	  2	  h	  before	  being	  washed	  2X	  with	  PBS,	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denatured	  and	  subsequently	  detected	  by	  western	  blotting.	  (c)	  Effect	  of	  inhibitors	  on	  AKT	  activation.	  BJeLR	  cells	  were	  
treated	  under	  the	  conditions	  described	  in	  (a)	  and	  the	  lysate	  was	  analyzed	  for	  total	  and	  phosphorylated	  AKT.	  	  (d)	  Co-­‐
immunoprecipitation	  of	  RAS	  with	  CRAF	  and	  PI3Kγ.	  Cells	  were	  treated	  with	  31MEW44	  for	  3	  h	  in	  10%	  FBS	  in	  DMEM	  before	  
being	  lysed	  and	  immunoprecipitated	  with	  an	  anti-­‐HRAS	  antibody.	  	  (e)	  Effect	  of	  31MEW44	  on	  RAS-­‐RALGDS	  pathway.	  
BJeLR	  were	  seeded	  in	  2%	  FBS	  in	  DMEM	  18	  h	  prior	  to	  treatment	  with	  31MEW44	  and	  U0126	  in	  2%	  FBS	  in	  DMEM	  for	  3	  h.	  
Cells	  were	  then	  lysed	  and	  the	  lysate	  was	  incubated	  with	  RALBP1	  agarose	  beads	  for	  2	  h	  before	  being	  washed	  2X	  with	  PBS,	  
denatured	  and	  subsequently	  detected	  by	  western	  blotting. 
IIf. Transcriptional analysis of RAS activation 
To determine mRNA expression differences that manifest upon RAS inhibition BJeLR 
(HRASG12V) and BJeHLT (wt HRAS), engineered isogenic fibroblasts that differ only by 
HRASG12V overexpression, were utilized. If 31MEW44 was inhibiting RAS, the expression 
levels of genes associated with RAS activation in BJeLR cells treated with 31MEW44 should be 
approaching levels found in the BJeHLT line.  
The expression of urokinase-type plasminogen activator (uPA) is associated with 
invasion, metastasis and angiogenesis via the breakdown of various components of the 
extracellular matrix [95, 96]. The overexpression of uPA is facilitated by RAS activation through 
the RAS-RALGDS-RAL pathway [95, 96]. uPA expression levels were analyzed, via qPCR, in 
BJeLR (DMSO treated) versus BJeLR (31MEW44 treated at 5 µM and 25 µM) and BJHLT 
(DMSO treated); a dose-dependent decrease was found in uPA expression upon 31MEW44 
treatment, similar to the levels found in BJeHLT cells (Fig. 3.6). Another RAS effector is the 
GEF TIAM1, which subsequently activates the small GTPase RAC [95, 97, 98]. RAC activation 
leads to overexpression of matrix metalloprotease 9 (MMP9) that plays a key role in metastasis 
[95, 97, 98]. Again, dose dependent downregulation of MMP9 expression was observed upon 
31MEW44 treatment. Levels of the transcription factor CMYC are strongly correlated with the 
proliferation status of cells. Its expression is known to be upregulated by activation of the RAS-
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RAF-MEK-ERK signaling module [95, 99]. Upon 31MEW44 treatment of BJeLR cells, we 
observed a dose-dependent reduction in CMYC expression (Fig. 3.6). Finally, the metabolic shift 
of transformed cells to the aerobic metabolism of glucose is well established [95]. Associated 
with this change is the upregulation of lactate dehydrogenase (LDH), which converts the end 
product of glycolysis (pyruvate) into lactate, a change that has been observed in RAS 
transformed cells [95, 100]. Treatment of 31MEW44 decreased these elevated levels of LDH, 
dose-dependently, in BJeLR cells. Thus, 31MEW44 reverses the transcriptional changes 
associated with RAS activation, consistent with the notion that it is a RAS inhibitor (Fig. 3.6).  
	  
Figure	  3.6	  |	  Analysis	  of	  genes	  linked	  to	  RAS	  activation.	  BJeLR	  cells	  were	  treated	  for	  1	  h	  with	  31MEW44	  at	  5	  μM	  and	  25	  
μM.	  Cells	  were	  subsequently	  lysed,	  the	  RNA	  was	  extracted,	  converted	  to	  cDNA	  and	  analyzed	  by	  qPCR.	  qPCR	  
measurements	  were	  taken	  in	  duplicate.	  	  	  	  
In addition to altering genes associated with RAS activation, we hypothesized that in 
response to RAS inhibition cells would attempt to compensate by expressing additional RAS 
proteins. To examine this, five cell lines were treated with 31MEW44 for 4 and 24 h: Mia-paca-2 
(KRASG12C), NCI-H441 (KRASG12V), NCI-H23 (KRASG12C) BJeLR (HRASG12V), and HT1080 
(NRASQ61K). A time dependent increase in RAS expression was observed in all cases of 
31MEW44 treatment, supporting the idea that the inhibitor would cause the upregulation of RAS 
expression (experiment performed by Nen Pagano, Fig. 3.7). 
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Figure	  3.7	  |	  Expression	  levels	  of	  mutant	  RAS	  with	  31MEW44.	  Cells	  were	  treated	  with	  31MEW44	  at	  10	  μM	  for	  4	  or	  24	  
h.	   In	   each	   line	   tested	   a	   time	   dependent	   upregulation	   in	   expression	   was	   observed.	   	   Nen	   Pagano	   performed	   this	  
experiment 
III. In vivo evaluation 
IIIa. Metabolic stability and in vivo pharmacokinetics of 31MEW44 
To see if 31MEW44 would be a suitable candidate for in vivo testing its metabolic 
stability was initially assessed in silico using P450 Site of Metabolism (Schrödinger, inc.). The 
results indicated virtually no accessibility of the heme group of cytochrome P450 to potentially 
reactive segments of 31MEW44 (Fig. 3.8). To test this experimentally 31MEW44 was incubated 
with purified mouse liver microsomes and its degradation was followed by LC-MS (performed 
by Alliance Pharma). The positive control compound, 7-ethoxycoumarin, was determined to 
have a half-life of 3.9 minutes, while all of 31MEW44 remained after a 45-minute incubation 
(Fig. 3.9), in good agreement with the SOM calculations. Its in vivo pharmacokinetics were then 
assessed by analyzing plasma samples of male C57BL6 adult mice with the compound 
administered both orally (PO) and intravenously (IV). After monitoring the concentration of 
31MEW44 over 12 hours, oral delivery yielded a half-life of 3.1 hours, while intravenous 
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delivery showed almost no elimination, suggesting a half-life >12 hours (Fig. 4.10) (performed 
by Alliance Pharma).  
	  
Figure	   3.8	   |	   Site	   of	   metabolism	   calculations	   on	   31MEW44.	   Shown	   is	   the	   overall	   reactivity	   of	   31MEW44,	   the	  
accessibility	  of	  the	  heme	  group	  of	  CYP450,	  and	  the	  intrinsic	  reactivity	  of	  31MEW44.	   
	  
Figure	   3.9	   |	   Metabolic	   stability	   and	   pharmacokinetics	   of	   31MEW44.	   (a)	   Stability	   of	   31MEW44	   in	   human	   liver	  
microsomes.	   31MEW44	   and	   7-­‐ethoxycoumarin	   were	   incubated	   for	   45	   min	   with	   microsomal	   protein	   and	   an	   NADPH	  
generating	   system.	   (b)	   Pharmacokinetics	   of	   31MEW44.	   A	   total	   of	   42	   male	   C57BL6	   adult	   mice	   were	   dosed	   orally	   or	  
intravenously	  with	  31MEW44	  in	  10%	  NMP/90%	  PEG-­‐400	  at	  30	  mg/kg.	  Concentration	  in	  the	  plasma	  was	  then	  measured	  
over	  the	  course	  of	  12	  h.	  These	  experiments	  were	  performed	  by	  Alliance	  Pharma 
IIIb. Evaluation in a tumor xenograft model 
The in vivo efficacy of 31MEW44 in a tumor xenograft mouse model was then assessed 
using the MDA-MB-231 cell line in 8-week-old nude mice. Over 15 days they received either 10 
doses of vehicle orally, 10 doses of 31MEW44 (180 mg/kg) orally, or 4 doses of 31MEW44 (30 
mg/kg) intravenously and 6 doses of 31MEW44 (30 mg/kg) intraperitoneal. No toxicity was 
observed with either treatment, monitored by body weight loss. Treatment with 31MEW44, 
Overall Score Heme accessibility Intrinsic reactivity
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either orally or the combination of intravenous and intraperitoneal injections, resulted in almost 
complete elimination of the tumor (Fig.  3.10a).  
Next, to see if 31MEW44 was able to enter a xenograft and inhibit RAS signaling a short 
pharmacodynamic study was performed. MDA-MB-231 tumors were grown to a larger size than 
the therapeutic study (~130 cubic millimeters) and mice were dosed daily, intraperitoneal (IP) 
with 31MEW44 at 30 mg/kg or vehicle (5% DMSO in HBSS at pH 4) for six consecutive days. 
Segments of the xenografts were then analyzed for phosphorylated ERK levels (Fig. 3.10b). 
Overall, 31MEW44-treated mice showed tumor pERK levels ~70% lower than those of the 
vehicle-treated. 
	  
Figure	  3.10	  |	  Effect	  of	  31MEW44	  on	  a	  MBA-­‐MB-­‐231	  mouse	  tumor	  xenograft.	  (a)	  Efficacy	  of	  31MEW44	  in	  an	  MDA-­‐MB-­‐
231	  xenograft.	  Eight-­‐week-­‐old	  nude	  female	  mice	  were	  injected	  with	  7	  million	  MDA-­‐MB-­‐231	  cells.	  After	  tumors	  reached	  an	  
average	  size	  of	  58	  cubic	  millimeters	  they	  were	  treated	  with	  vehicle	  (PO,	  10	  doses,	  10%	  DMSO	  in	  HBSS	  pH	  4),	  31MEW44	  
(PO,	  180	  mg/kg,	  10	  doses),	  or	  by	  a	  combination	  of	  intravenous	  and	  intraperitoneal	  injections	  of	  31MEW44	  (30	  mg/kg,	  4	  
IV	  doses,	  6	  IP	  doses)	  over	  two	  weeks.	  (b)	  Effect	  of	  31MEW44	  on	  phosphorylated	  ERK1/2	  levels	  in	  an	  MDA-­‐MB-­‐231	  tumor	  
xenograft. 
 
IIIc. Evaluation in patient-derived T-ALL model 
Encouraged by these results we next sought to evaluate 31MEW44 in a more clinically 
relevant, patient-derived model. It was first tested in patient-derived T-cell acute lymphoblastic 
leukemia (T-ALL) samples cultured in vitro (this experiment was performed and analyzed by Dr. 
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Marta Sanchez-Martin and Professor Adolfo Ferrando). Two of the samples tested had mutant 
NRAS (G13V and G13D), along with four samples possessing wild-type NRAS (Fig. 3.13).  
31MEW44 showed a high degree of selectivity for the mutant NRAS cells, which retaining only 
20-40% viability after 5 µM treatment, while no observed decrease in viability was observed in 
the four cell lines tested with wild-type NRAS.  
	  
Figure	  3.11	  |	  Effect	  of	  31MEW44	  on	  the	  viability	  of	  patient-­‐derived	  T-­‐ALL	  cells.	  T-­‐ALL	  samples	  isolated	  from	  patients	  
and	  cultured	  in	  vitro.	  PDTALL6,	  9,	  13	  and	  19	  (all	  wild-­‐type	  RAS),	  PDTALL22	  (NRAS	  G13V),	  PDTALL	  (NRAS	  G13D).	  This	  
experiment	  was	  performed	  and	  analyzed	  by	  Dr.	  Marta	  Sanchez-­‐Martin	  and	  Professor	  Adolfo	  Ferrando	   (Columbia	  
University) 
To see if this translated into in vivo efficacy, the patient derived sample PDTALL22 from 
the initial in vitro evaluation was used as a luciferase expressing xenograft. Mice were dosed 
with 31MEW44 (30 mg/kg, IP) once daily (on days 0, 4, 5, 7, and 8) and imaged for luciferase 
on days 0 (before treatment), 4, and 8 (Fig. 3.12a). A substantial decrease in the overall 
luciferase signal was observed with 31MEW44 treatment (Fig. 3.12b). Examination of the spleen 
revealed a consistent decrease in size with the 31MEW44 treated mice relative to the vehicle, 
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along with a reduction in the percent of human CD45+ cells (Fig. 3.12c). These experiments 
were performed and analyzed by Dr. Marta Sanchez-Martin and Professor Adolfo Ferrando. 
	  
Figure	  3.12	  |	  Effect	  of	  31MEW44	  on	  a	  patient	  derived	  T-­‐ALL	  xenograft.	  (a)	  Effect	  of	  31MEW44	  on	  a	  patient-­‐derived	  T-­‐
ALL	  sample	  PDTALL22	  as	  a	   luciferase	  expressing	  primograft.	  Mice	  were	   treated	  with	  31MEW44	  (30	  mg/kg)	  or	  vehicle	  
intraperitoneal	  once	  daily	  on	  days:	  0,	  1,	  4,	  5,	  and	  7.	  Representative	  images	  of	  mice	  from	  each	  treatment	  group	  at	  days,	  0,	  4	  
and	  8	  (final	  day)	  of	  the	  study.	  (b)	  Average	  effect	  of	  31MEW44	  and	  vehicle	  on	  the	  overall	  luciferase	  signal.	  (c)	  Bar	  graph	  
representing	   the	   average	   mouse	   spleen	   weight	   (left).	   Percentage	   of	   human	   CD45+	   cells	   in	   the	   spleen	   of	   vehicle	   and	  
31MEW44-­‐treated	  mice	  (right).	  These	  experiments	  were	  performed	  and	  analyzed	  by	  Dr.	  Marta	  Sanchez-­‐Martin	  and	  
Professor	  Adolfo	  Ferrando	  (Columbia	  University) 
IIId. Evaluation in the KPf/fC mouse model  
 To explore the utility of 31MEW44 for the treatment of pancreatic cancer, it was next 
evaluated in the genetically engineered KrasLSL.G12D/+Tp53fl/flPdx1-Cre (KPf/fC) mouse model 
[102]. This model allows for both the pancreas specific expression of KrasG12D and deletion of 
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Tp53.  Significant toxicity was observed with 31MEW44 and the study was terminated after five 
days of treatment at 30 mg/kg, once per day. Analysis of the tumor samples showed a substantial 
reduction in both phosphorylated Erk1/2 and phosphorylated Akt (S473), along with a modest 
increase in cleaved caspase-3 (Fig. 3.13). This toxicity was not observed when 31MEW44 was 
tested with wild-type mice, as monitored by body weight. This genotype selective toxicity can be 
attributed, at least in part, to being on-target. The KPC mice have the deletion of one Kras allele 
in the tissue that does not express Cre recombinase. As a result these mice would be more 
sensitive to a pan-RAS inhibitor, such as 31MEW44. These experiments were performed and 
analyzed by Michael Badgely and Professor Kenneth Olive. 
	  
Figure	  3.13	  |	  Effect	  of	  31MEW44	  on	  RAS	  signaling	  pathways	  in	  the	  KPf/f	  C	  mouse	  model.	  (a)	  Pre-­‐treatment	  analysis	  
(biopsy,	   bx)	   of	   tissue	   samples	   taken	   from	   KPf/fC	  mice	   by	   western	   blotting	   for	   phosphorylated	   ERK1/2,	   total	   ERK1/2,	  
phosphorylated	   AKT	   (S473),	   and	   total	   AKT	   (left).	   Samples	   were	   taken	   prior	   to	   treatment	   from	   each	   of	   three	   mice	  
receiving	  either	  31MEW44	  (30	  mg/kg)	  or	  vehicle	  dosed	  once	  daily,	   intraperitoneal.	  Post-­‐treatment	  analysis	   (necropsy,	  
nx)	   of	   tissue	   samples	   taken	   from	   KPf/fC	   mice	   by	   western	   blotting	   for	   phosphorylated	   ERK1/2,	   total	   ERK1/2,	  
95	  
phosphorylated	  AKT	  (S473),	  and	  total	  AKT	  (right).	  (b)	  Analysis	  of	  phosphorylated	  ERK1/2	  and	  total	  ERK1/2,	  detected	  by	  
immunohistochemistry.	   Shown	   are	   images	   from	   representative	   sections	   of	   the	   biopsy	   and	   necropsy	   samples	   from	  
31MEW44	   and	   vehicle	   treated	   mice.	   This	   experiment	   was	   performed	   and	   analyzed	   by	   Michael	   Badgely	   and	   Prof.	  
Kenneth	  Olive	  (Columbia	  University).	  The	  western	  blot	  on	  the	  samples	  provided	  by	  Michael	  Badgely	  was	  performed	  
Yan	  Zhang.	   
 
IV. Discussion 
The evaluation of 31MEW44 in panel of cancer cell lines showed a correlation of 
mutated RAS dependence to compound sensitivity, as well as selectivity over the wild-type lines.  
Evidence of the disruption of the two canonical effector pathways, RAS-RAF and RAS-PI3K, 
was shown in BJeLR cells by decreases in the levels of downstream-phosphorylated ERK1/2 and 
AKT, respectively. Support of the hypothesis that 31MEW44 disrupts the RAS-RAF interaction 
directly was demonstrated with a RAS pull-down using agarose beads with the RBD of CRAF. 
To provide further confirmation, a co-immunoprecipitation was performed with an HRAS 
antibody detecting levels of PI3Kγ and CRAF with 31MEW44 treatment. The decrease in the co-
immunoprecipitated PI3K and CRAF further supported that direct RAS-effector abrogation is 
occurring. The disruption of the RAS-RALGDS-RAL pathway was investigated through a 
RALA activation assay. This assay showed a decrease of active RALA with 31MEW44 
treatment, indicating disruption of the RAS-RALGDS interaction.  
To show evidence of RAS inhibition on the transcriptional level, the expression of six 
genes associated with RAS-RAF, RAS-TIAM1 and RAS-RALGDS pathways was examined. In 
all cases, inhibitor treatment of the overexpressed HRASG12V-containing BJeLR line altered 
expression such that it approached levels found in the isogenic BJeHLT line with endogenous 
levels of wild-type RAS. Additionally, a panel of five mutant RAS cell lines was all shown to 
96	  
have increased levels of mutant RAS expression with inhibitor treatment in a time dependent 
manner. Our hypothesis is that this consistent upregulation of RAS expression could be a 
response of the cell to compensate for less functional RAS due to its inhibition by 31MEW44.  
To determine if 31MEW44 would be a suitable in vivo candidate, its metabolic stability 
was first assessed in silico using site of metabolism. It was predicted to be highly metabolically 
stable and these results were supported experimentally through incubation with drug 
metabolizing enzyme rich, liver microsomes. The in vivo pharmacokinetics showed suitable 
clearance of the compound for in vivo studies both through oral delivery and intravenously. 
Encouraged by the results of the metabolic stability and pharmacokinetics, 31MEW44 was tested 
in an MDA-MDA-231 xenograft that resulted in an almost complete elimination of the tumors in 
the 31MEW44 treated mice. In a separate study, 31MEW44 showed evidence of inhibiting RAS 
signaling by decreasing phosphorylated ERK1/2. To examine how 31MEW44 would perform in 
a more clinically relevant model it was evaluated in patient derived T-ALL samples. An even 
higher degree of selectivity for the RAS mutant samples was observed compared to the standard 
cell lines previously tested. This motivated the testing of 31MEW44 in a xenograft of one of the 
patient derived samples. After only an 8-day study it demonstrated an overall decrease in tumor 
burden and of human CD45+ cells invading the spleen, further demonstrating the therapeutic 
utility of 31MEW44. 
KRAS mutations are found in an astonishing 90% of pancreatic cancer [10]. 
Chemotherapeutic agents are also known to have difficulty entering pancreatic tissue, as it is 
poorly vascularized [103]. To see if 31MEW44 would be useful in the treatment of pancreatic 
cancer, it was evaluated in the genetically engineered KPf/fC mouse model. Toxicity was 
observed with 31MEW44 treatment and the study was terminated after five days. We 
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hypothesize that a portion of the toxicity is due to on-target RAS inhibition. The KrasG12D allele 
is preceded by a lox-stop-lox sequence, which prevents it from being expressed in tissue that 
does not have Cre protein present (non-pancreatic tissue). Thus, these mice would be more 
sensitive to pan-RAS inhibition. This was supported by lack of toxicity observed when wild type 
mice were tested with 31MEW44. Analysis of the tissue samples of the treated mice showed 
decreases in downstream-phosphorylated ERK1/2 and AKT (S473), indicating abrogation of the 
RAS-RAF and RAS-PI3K pathways, respectively. The abrogation of RAS signaling by 
31MEW44 suggests that it could be used as a potential therapeutic agent. Further evaluation in a 
model that doesn’t require the loss of a functional RAS allele is necessary to further explore the 
















Cell viability assays 
All cell culture assays were incubated at 37°C with 5% CO2, using media recipes specified on 
www.atcc.org. 
384-well format viability assays 
Cells were trypsinized, counted, and seeded into 384-well plates at 1,000 cells/well. After 16 h, 
compounds (from 10 mM stocks in DMSO) were arrayed in an 8- or 16-point dilution series in 
384-well polypropylene plates. Compound solutions were transferred at a 1:5 dilution into the 
assay plates. After 48 h, a 50% Alamar blue solution was added to a final concentration of 10% 
Alamar blue. After 6 h of incubation, fluorescence intensity was determined using a Victor3 
plate reader (Perkin Elmer) with a 535 nm excitation filter and a 590 nm emission filter. All 
compound measurements were performed in triplicate.  
 
6-well format viability assays 
Cells were trypsinized, counted, and seeded into 6-well plates at 200,000 cells per well 16 h prior 
to use. Media was then aspirated and replaced with 2 mL of media containing compounds at the 
indicated concentrations (from 10 mM stocks in DMSO). After 24 h, cells were trypsinized and 




BJeLR cells were seeded in DMEM and 10% FBS with 1% penicillin and streptomycin (PS) or 
DMEM and 2% FBS with 1% penicillin and streptomycin (PS), 16 h prior to use. The medium 
was then aspirated and compounds added as solutions in serum free medium (DMEM with 1% 
PS) or DMEM and 2% FBS with 1% penicillin and streptomycin (PS) to the dishes and treated at 
the indicated time points. Following treatment, the medium was aspirated from each dish and 
cells were washed twice with PBS. Cells were lysed with 60 µl buffer (50  mM HEPES, 40  mM 
NaCl, 2  mM EDTA, 0.5% Triton-X, 1.5 mM sodium orthovanadate, 50 mM NaF, 10 mM 
sodium pyrophosphate, 10   mM sodium β-glycerophosphate and protease inhibitor tablet 
(Roche), pH  7.4). Unlysed cells and debris were pelleted for 12 min at 12,000 rpm at 4 oC. 
Samples were separated using SDS-polyacrylamide gel electrophoresis and transferred to a 
polyvinylidene difluoride membrane. Transfer was performed using the iBlot system 
(Invitrogen). Membranes were treated with Li-COR odyssey blocking buffer for 1 h at 25 oC, 
then incubated with primary antibody (1:1000) in a 1:1 solution of PBS-T and Li-COR odyssey 
blocking buffer overnight at 4 °C. Following 3x5 min washes in PBS-T, the membrane was 
incubated with secondary antibodies (1:2000) in a 1:1 solution of PBS-T and Li-COR Odyssey 
blocking buffer for 45 min at 25 oC. Following three 5 min washes in PBS-T, the membrane was 
scanned using the Li-COR Odyssey Imaging System. Antibodies for pERK1/2, ERK1/2, pAKT 
ser473, AKT, pan-RAS, RALA, PI3Kgamma (Cell Signaling), and RAF-1 (Santa Cruz) were 
detected using a goat anti-rabbit or goat anti-mouse IgG antibody conjugated to an IRdye at 
800CW and 680CW conjugated, respectively (Li-COR biosciences).  
 
Multicellular tumor spheroids  
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Multicellular tumor spheroids (MCTSs) were grown in 96-well Corningware Ultra Low 
Attachment (ULA) Plates (CLS 3474). 100 µL of cell suspension containing 2 X 104 cells/ml 
were added to each well of the ULA plate containing 100 µL of a 2X solution of the desired 
concentration of compounds. Cells were incubated at 37 °C, 5% CO2 for 72 h to allow for MCTS 
formation. After 72 h, 50 uL of a 50% solution of alamar blue and medium was added and 
incubated for 12 h prior to measurements on a Victor3 plate reader as previously described. 
 
Caspase 3/7 activation assay 
HT-1080 cells were seeded into 384-well plates at 1,000 cells/well. After 16 h, compounds (as 
50 mM stocks in DMSO) were arrayed in a dilution series in 384-well polypropylene plates. 
Compound solutions were transferred at a 1:5 dilution into the assay plates for a total volume of 
40 µL. After 24 h, 8 µL of a 1:100 solution of rhodamine 110 bis-(N-CBZ-l-aspartyl-l-glutamyl-
l-valyl-aspartic acid amide) to lysis buffer (APO-1, Promega) was added and the plate was 
wrapped in aluminum foil and incubated at room temperature for 16 h. Fluorescence intensity 
was then determined using a Victor3 plate reader (Perkin Elmer) with a 490 nm excitation filter 
and a 535 nm emission filter.  
 
Cell-based RAS pulldown 
BJeLR cells were seeded 16 h prior to use in 10% FBS in DMEM. The medium was then 
aspirated and replaced with serum-free media containing the inhibitors (from 10 mM DMSO 
stocks) and cells were incubated for 24 h. The medium was removed, washed with cold PBS, 
lysed and spun down at 13,000 rpm at 4 °C to remove unlysed cells and debris. The lysate was 
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incubated with Raf-1 RBD agarose beads (EMD milipore) for 2 h with rotation at 4 °C. The 
solution was then spun down at 1500g and the supernatant removed. The beads were washed 2X 
with PBS, resuspended in 2.5 X SDS, and then analyzed by western blotting procedure.  
 
Determining RAS dependency using siRNAs targeting RAS isoforms (this protocol was 
developed by Nen Pagano) 
Small interfering RNAs (siRNAs) targeting each RAS isoform were purchased from Dharmacon 
Technologies.  
 
siRNA Catalog numbers 
siDEATH: AllStars Hs Cell Death Control siRNA; Cat # 1027299 from QIAGEN 
 
siHRAS: ON-TARGETplus SMARTpool human HRAS siRNA; Cat # L-004142-00-0005 from 
GE Dharmacon 
 
siKRAS: ON-TARGETplus SMARTpool human KRAS siRNA; Cat # L-005069-00- 
0010 from GE Dharmacon 
 
siNRAS: ON-TARGETplus SMARTpool human NRAS siRNA; Cat # L-003919-00-0005 from 
GE Dharmacon 
 
siNon-Targetting: ON-TARGETplus Non-targetting Pool siRNA; Cat # D-001810-10-20 from 
GE Dharmacon 
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Reverse transfection was performed by preparing a solutions of 1 mL of Opti-MEM (Invitrogen) 
with 6 µL of lipo-RNAiMAX (Invitrogen) and 5 µL of RNAi solution (10 µM stock), and by 
incubating the mixture (1 mL/well) in a 6-well plate for 30 min at 37 °C. While the siRNA 
complex was forming, 0.2 million cells were suspended in 1 mL of 2X serum-containing media. 
The cell solution (1mL) was transferred to the each well of the 6-well plate containing siRNA 
complex (1mL), and the 6-well plate was returned to the culture incubator. At 24, 48, 72 and 96 
h post transfection cells were trypsinized and viability was determined using trypan blue 
exclusion assay. 
 
Confirming RAS knockdown using RT-qPCR experiment 
Cells were detached from the 6-well plate, and 0.5 million cells were collected as a pellet by 
centrifuging 1,000 rpm for 5 min. Total cellular RNA sample was prepared using RNAeasy 
extraction kits (QIAgen) according to manufacturer’s instruction. The resulting RNA sample was 
reverse-transcribed using a High Capacity cDNA Reverse Transcription kit (Life Technologies). 
The cDNA samples were mixed with TaqMan® probes for each RAS isoform gene, and arrayed 
on 96-well plate in triplicates. The plate was loaded onto ViiA7 Real-Time PCR system (Life 
Technologies) for qPCR reaction. Comparative analysis (ΔΔCt analysis) was performed with 
ACTB (human actin b), an internal reference gene.  
 
Immunoprecipitations 
BJeLR cells were seeded 16 h prior to use in 10% FBS in DMEM. Media was aspirated and 
replaced with media containing 31MEW44 (from a 10 mM DMSO stock). After 6 h cells were 
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washed 2X with ice cold buffer (25 mM tris, 100 mM NaCl, 1 mM TCEP, 5 mM MgCl2, 0.1% 
tween-20 and 1 protease inhibitor/25 mL). Cells were scrapped, pelleted at 13,000 rpm for 10 
min at 4 oC, then passed through a 26 gauge needle several times. The solution was spun down a 
second time at 13,000 rpm for 15 min at 4 oC, to remove unlysed cells and debris. HRAS 
antibody (Santa cruz, SC-520) was then added to the lysate (1:100) and the solution was rocked 
at 4 oC for 16 h. Protein A agrose beads were then added and the solution was rotated at 4 oC for 
an additional 6 h. The solutions were spun down at 1500xg for 2 min and the supernatant was 
removed by syringe. The beads were washed 2X by this process with buffer, then resuspended in 
2.5X SDS.  
 
RALA activation assay 
BJeLR cells were seeded 16 h prior to use in 2% FBS in DMEM. Media was aspirated and 
replaced with media containing 31MEW44 (from a 10 mM DMSO stock). After 6 h cells were 
washed 2X with ice cold buffer (25 mM tris, 100 mM NaCl, 1 mM TCEP, 5 mM MgCl2, 0.1% 
tween-20 and 1 protease inhibitor/25 mL). Cells were scrapped, pelleted at 13,000 rpm for 10 
min at 4 oC, then passed through a 26 gauge needle several times. The solution was spun down a 
second time at 13,000 rpm for 15 min at 4 oC, to remove unlysed cell and debris. RALBP1 
agarose beads (EMD Millipore) were then added to the lysate and the solution was rotated at 4 
oC for 2 h. The solutions were spun down at 1500 xg for 2 min and the supernatant was removed 
by syringe. The beads were washed 2x by this process with buffer, then resuspended in 2.5X 
SDS.  
Gene expression analysis by RT-qPCR 
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Cells from six-well plates were trypsinized and centrifuged at 3,000 rpm for 3 min. The cell 
pellet was then lysed and the RNA was extracted using the QIAshreader and RNAeasy extraction 
kits (QIAGEN) according to the manufacturer’s protocol. 2 µg of RNA from each sample was 
then converted to cDNA using the TaqMan RT Kit (Applied Biosystems). Primers for 
Quantitative PCR (qPCR) were designed with Primer Express. qPCR was performed using 
Power SYBR Green Master Mix (Applied Biosystems) in a 96-well format, in triplicate, using an 
Applied Biosystems 7300 Cycler set to absolute quantification. Expression changes were 
computed using the DDCt method with GAPDH as an internal reference gene. Urokinase-type 
plasminogen activator (uPA) Forward 5’ GGATGTGCCCTGAAGGACAA 3’, reverse 5’ 
TGCGGATCCAGGGTAAGAAG 3’; matrix metalloprotease 9 (MMP9) forward 5’ 
GAGTGGCAGGGGGAAGATGC 3’, reverse 5’ CCTCAGGGCACTGCAGGATG 3’; lactate 
dehydrogenase (LDH) forward 5’ GCCCGACGTGCATTCCCGATTCCTT 3’, reverse 5’ 
GACGGCTTTCTCCCTCTTGCTGACG 3’; CMYC forward 5’ 
TCAAGAGGTGCCACGTCTCC 3’, reverse 5’ TCTTGGCAGCAGGATAGTCCTT 3’. 
 
RAS, PI3K and BRAF overexpression. 
Phoenix-AMPHO (ATCC: CRL-3213) cells were seeded in a 6-well plate at 600,000 cells/well 24 
h prior to use 10% FBS and 1% PS in DMEM. A solution of lipofectamine 2000 (6 µL) in 100 
µL opti-mem media (reduced serum media) and the plasmid (2.5 µg) in 100 µL opti-mem media 
were combined and incubated 5 min at 25 oC, then added to 1.8 mL of opti-mem in each well. 
After 12 h, the media was replaced with 10% FBS and 1% PS in DMEM. The next day the 
supernatant was collected three times spaced 4 h apart and polybrene was added (1/1000). The 
supernatant was filtered (0.45 µm) and added to HT1080 cells seeded at 100,000 cells per well 
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(6-well dish) in 2 mL portions spaced 4 h apart. After 48 h, the cells were trypsinized and re-
seeded in medium containing puromycin (2 µg/mL). After 6 d of selection the cells were 
analyzed for expression using the aforementioned qPCR procedure. 2 mL solutions of the 
inhibitors were added to a 6-well plate of the transfected HT-1080 cells (100,000 cells/well) and 
treated for 24 h. The cells were then trypsinized, re-suspended in 1 mL of medium and viability 
was measured by VI-CELL (Beckman Coulter) through mixing with trypan blue. 
 
 
pBABE-puro was a gift from Hartmut Land & Jay Morgenstern & Bob Weinberg (Addgene 
plasmid # 1764) 
Ref: Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug 
selection markers and a complementary helper-free packaging cell line. Morgenstern JP, Land 
H. Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 
 
pBABE puro KRAS V12 was a gift from William Hahn (Addgene plasmid # 9052) 
Ref: unpublished viral vectors 
 
pBabe-Puro-BRAF-V600E was a gift from William Hahn (Addgene plasmid # 15269) 
Ref: Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. Boehm JS, 
Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, 
Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-
Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, 
Lander ES, Polyak K, Hahn WC. Cell. 2007 Jun 15. 
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pBabe puro HA PIK3CA E545K was a gift from Jean Zhao (Addgene plasmid # 12525) 
Ref: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases 
in human mammary epithelial cells. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts 
TM. Proc Natl Acad Sci U S A. 2005 Dec 20. 102(51):18443-8.  
 
pBABEbleo-Flag-BRAFV600E was a gift from Christopher Counter (Addgene plasmid # 53156) 
Ref: Copper is required for oncogenic BRAF signalling and tumorigenesis. Brady DC, Crowe 
MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, 
Counter CM. Nature. 2014 Apr 9. doi: 10.1038/nature13180. 
 
Microsomal stability (this protocol was developed by Alliance Pharma) 
Test compounds (0.5 µM) were incubated at 37 ºC for up to 45 min in 50 mM of potassium 
phosphate buffer (pH 7.4) containing microsomal protein (0.5 mg/mL) and an NADPH 
generating system (0.34 mg/mL β-nicotinamide adenine dinucleotide phosphate (NADP), 1.56 
mg/mL glucose-6-phosphate, 1.2 units/mL glucose-6-phosphate dehydrogenase).  At 0, 5, 15, 30 
and 45 min intervals an aliquot was taken and quenched with acetonitrile (ACN) containing 
internal standard.  No-cofactor controls at 45 min were prepared.  Following completion of the 
experimentation, the samples were analyzed by LC-MS/MS using a Shimadzu HPLC and an 
Applied Biosystem API4000. 
 
In vivo pharmacokinetic analysis (this protocol was developed by Alliance Pharma) 
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27 mg of 31MEW44, was dissolved in 5.4 mL of 10% NMP/90% PEG-400 to yield a dosing 
solution with a final concentration of 5 mg/mL. The dose formulation was prepared freshly in the 
morning of dosing day. A total of 42 male C57 adult mice, approximately 25 grams of body 
weight, were administered at 20 mg/kg dose level via a single IV bolus injection or a single oral 
gavage. Blood samples (approximately 400 µL) were collected from three mice per time point 
via terminal brachial bleed at pre-dose and 30 min, 1h, 2 h, 4h, 8h and 12 h post-dose. Blood 
samples were placed into tubes containing K2 EDTA anti-coagulant, and centrifuged at ~2,100 g 
(rcf) for 10 min at 4 oC to separate plasma.  Following centrifugation, the resulting plasma was 
transferred to clean tubes and stored frozen at -80 °C. The mouse plasma samples (50 µL) were 
aliquoted, spiked with internal standard (250 ng/mL tolbutamide), and then extracted with 
protein precipitation. The supernatant of each sample was diluted and injected into LC-MS/MS 
system. The data acquisition and processing were performed using Sciex API 5500 mass 
spectrometer with Analyst 1.6.2 software.  The standard curve range for the plasma samples 
were analyzed using a calibration curve of 0.5-5000 ng/mL. The pharmacokinetic (PK) analysis 




Athymic nude mice (eight weeks; Charles River Laboratories) were injected with 7 million 
MDA-MB-231 cells subcutaneously. After 3 d, mice were separated into treatment groups of 
roughly equal tumor size (58 mm3) and dosed with 180 mg/kg 31MEW44 orally (12 mg/mL, 
10% DMSO, pH 4), vehicle orally, or by a combination of intraperitoneal and intravenous 
injections at 30 mg/kg (4 mg/mL, 5% DMSO in HBSS at pH 4). Over 14 d mice received a total 
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of 10 doses of 31MEW44 or vehicle orally, or six intraperitoneal injections and 4 intravenous 
injections. Tumor size was measured by electronic caliper every 2 d and calculated using the 
formula: 0.523 X Length X width^2. 
 
Pharmacodynamic study 
Athymic nude mice (eight weeks; Charles River Laboratories) were injected with 8 million 
MDA-MB-231 cells subcutaneously. After 4 d, mice were separated into treatment groups of 
roughly equal tumor size (128 mm3) and population, and dosed with 30 mg/kg 31MEW44 in 5% 
DMSO HBSS at pH 4 or vehicle (5% DMSO HBSS at pH 4) intraperitoneal, once per day for 6 
d. Tumor size was measured by electronic caliper every 2 d and calculated using the formula: 
0.523 X Length X width2.  
 
Mice were euthanized using a CO2 gas chamber before xenograft dissection. Tumors were then 
weighed, frozen and stored at -80 oC. Segments of the tumor were taken (~60 mg) and suspended 
in 120 uL lysis buffer. Xengrafts were then lysed by sonication (40 amp for 10-15 seconds) and 
samples were centrifuged at 14,000 rpm at 4 oC for 30 min to remove unlysed cells and debris. 
The supernatant was then analyzed by western blotting using the aforementioned protocol. 
 
Culture conditions and viability measurements in patient derived T-ALL samples (this 
protocol was developed by Dr. Marta Sanchez-Martin) 
Patient Samples 
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T-ALL samples were provided by Columbia Presbyterian Hospital, the Eastern Cooperative 
Oncology Group (ECOG), University of Padova, and Hospital Central de Asturias with informed 
consent and analyzed under the supervision of the Columbia University Medical Center 
Institutional Review Board committee. 
Primary cell co-culture and in vitro cell viability assays. 
For the analysis of 31MEW44 on primary T-ALL patient samples, we cultured cells in MEMa 
medium supplemented with 10% FBS, 10% human heat-inactivated serum, 1% 
penicillin/streptomycin, 1% GlutaMAX, human IL-7 (10 ng/mL), human SCF (50 
ng/mL),human FLT3-ligand (20 ng/mL), and insulin (20 nmol/L) on a feeder layer of MS5 
stromal cells overexpressing the NOTCH ligand Delta-like 1 as described by Amstrong et al. 
(25). In these experiments, T-ALL lymphoblasts were cultured in triplicate and treated with 
either vehicle, DMSO, or 31MEW44 (doses raging from 1 to 5 µM). We harvested the cells 72 h 
after treatment and analyzed cell viability using the BD cell viability kit with liquid counting 
beads (BD Bioscience) gating out stroma cells (GFP+), dead cells and particles (PI +). We 
acquired data using a FACSCanto II flowcytometer (BD Bioscience) and analyzed it using 
FlowJo software (Tree Star, Inc.). Viability data is represented as % relative to vehicle treatment. 
Sequencing 
A region of 124bp from coding exon1 of the human NRAS gene, including G12-G13 mutation 
hotspot, was amplified from the genomic DNA of six primary T-ALL samples by polymerase 
chain reaction and was analyzed by direct dideoxynucleotide sequencing using primers FW: 5’-
GCTGGTGTGAAATGACT-3’ and. RV: 5’-GCTACCACTGGGCCTCACCT-3’. 
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COSMIC 
PDTALL 22 synonymus variants GCA/GCT (A); GGT/GTT (G13) (G13V). 
PDTALL26 missense variant GGT/GAT (G13) (G13D). 
 
Patient-derived xenograft (this protocol was developed by Dr. Marta Sanchez-Martin) 
Animals were maintained in the animal facility at the Irving Cancer Center at Columbia 
University Medical Campus; and all animal procedures were approved by the Columbia 
University IACUC. To generate primary xenografts, cells from T-ALL sample PD22, harboring 
a mutated allele of NRAS, were transplanted via intravenous injection into lethally irradiated 
primary recipients as previously described (Chiang et al., 2008). Upon detection of human 
lymphoblasts (human CD45+ cells) in peripheral blood, mice were sacrificed; lymphoblasts 
isolated from the spleens were transduced with retroviral particles expressing a fusion protein 
between the red cherry fluorescent protein and luciferase (MigR1 CherryLUC), and re-injected 
in sublethally irradiated mice (Piovan et al., 2013). 
Mice transplanted with retrovirally transduced cells were imaged regularly until luciferase 
activity was detected. Tumor cells were harvested from the spleens of these mice, and injected 
into secondary recipients. Secondary recipients were randomized into two groups of 5 mice with 
equal load of luciferase. Animals were treated I.P. with vehicle or 31MEW44 30 mg/kg in 5% 
DMSO in HBSS at pH 4., once daily on days 0; 1; 4; 5; 7 and 8, and imaged at day 0 (before 
treatment), at day 4 and at day 8. Mice were sacrificed at day 8; spleen weight and presence of 
human CD45 + cells in the spleen (lymphoblasts) were documented together with changes in 
luciferase signal over treatment.  
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Chiang, M.Y., Xu, L., Shestova, O., Histen, G., L'Heureux, S., Romany, C., Childs, M.E., 
Gimotty, P.A., Aster, J.C., and Pear, W.S. (2008). Leukemia-associated NOTCH1 alleles are 
weak tumor initiators but accelerate K-ras-initiated leukemia. The Journal of clinical 
investigation 118, 3181-3194. 
  
Piovan, E., Yu, J., Tosello, V., Herranz, D., Ambesi-Impiombato, A., Da Silva, A.C., Sanchez-
Martin, M., Perez-Garcia, A., Rigo, I., Castillo, M., et al. (2013). Direct reversal of 
glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer cell 24, 
766-776. 
 
KPf/fC mouse study (this protocol was developed by Michael Badgely) 
KRASLSLG12D; p53fl/fl; Pdx1-Cre (KPF/FC) mice have been previously described [1]. Animals 
were housed in a barrier facility and monitored daily prior to enrollment on studies. All 
experiments were carried out in compliance with established IACUC guidelines of Columbia 
University.  
Animal surgery  
KPF/FC were palpated twice weekly to assess for tumor formation. Upon discovery of a palpable 
mass deemed amenable to surgery, tumors were accessed by abdominal laparotomy as 
previously described for biopsy procedures [2]. In short, mice were anesthetized with 
isofluorane, prepared for aseptic surgery, and injected with buprenorphine intra-operatively to 
initiate post-operative analgesia. Following visual identification, tumors were held in place with 
a pair of biopsy forceps while a small-diameter biopsy punch (2-mm diameter, Zivic Instruments 
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PUN2000) was used to cleanly remove a tissue sample. The resultant wound was filled with an 
absorbable, gelatin compressed sponge to staunch possible bleeding. Incisions were sutured 
closed and the mouse was allowed to recover from 24-48 hours prior to study initiation. 
 
Sample processing and storage 
Biopsy samples derived from small animal surgery were divided in two specimens. The first was 
stored in 10% buffered formalin phosphate overnight at 4ºC and then placed in 70% ethanol for 
extended storage prior to processing and embedding in paraffin wax blocks. The second was 
embedded in O.C.T. compound and subsequently frozen atop a bath of LN2 prior to long-term 
storage at -80ºC. Tumor samples taken at necropsy were processed and stored identically to those 
described above.  
 
Immunohistochemistry 
Paraffin embedded samples were sectioned at 5µM thickness and mounted on positively charged 
sample slides. These slides were heated at 60ºC for 15-30 minutes and subsequently rehydrated 
by standard protocols. Unmasking was performed in 10 mM citrate buffer, pH 6 for 5 minutes in 
a pressure cooker at high temperature, followed by peroxidase quench in 3% hydrogen peroxide 
for 20 minutes. Blocking was carried out using 1.5% horse serum and 2% animal free blocker 
(Vector Labs) in TBS-T for 1 hour at room temperature. Slides were incubated with primary 
antibody (cleaved caspase-3, catalog no. 9664; ERK, catalog no. 4695; pERK, catalog no. 4376. 
All antibodies from Cell Signaling) overnight at 4ºC. Slides were then allowed to equilibrate to 
room temperature prior to washing with TBS-T and incubation with secondary antibody 
(ImmPress polymer reagent, Vector Labs). Signal was developed with ImmPACT DAB 
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Peroxidase Substrate (Vector Labs). Slides were counterstained with hematoxylin for 30 
seconds. For quantification of cleaved-caspase 3 staining, all available 40x fields on three 
separate sections of biopsy samples and twenty total 40x fields from two separate sections of 
necropsy samples were analyzed for each study mouse.  
 
Drug studies 
Mice were dosed once daily with 30mg/kg of 31MEW44 by way of intraperitoneal injection. 
Mice were monitored closely for changes in health status and were sacrificed after 5 days on 
















Chapter 4: Structure-activity relationship studies and optimization of experimental cancer 
therapeutics  
 Medicinal chemistry in the absence of target binding site information is a time-
consuming and challenging endeavor, as innumerable synthetic modifications could be 
potentially made to a given structure. The approach described in this chapter first entails 
breaking down a given molecule into segments based on synthetic disconnection points. Subtle 
changes are introduced initially and coupled with iterative rounds of biological evaluation to 
obtain a structure-activity relationship (SAR). This preliminary information is then used as the 
basis for the design of more elaborate modifications that can then be made to the molecule. 
Prioritization of these possibilities is based on synthetic difficulty, reagent cost, and likelihood of 
a favorable improvement of the activity and/or the ADMET properties of the molecule. This is 
approach has been implemented in the optimization of two experimental cancer therapeutics, 
erastin and J9, discovered in the Stockwell lab. 
 
I. Erastin background  
The small molecule erastin was discovered from a high-throughput screen for compounds 
that exhibit mutant RAS-selective lethality [104]. A library of 23,550 molecules was screened 
using isogenic, engineered mutant and wild type RAS expressing cell lines [104]. Investigation 
into the mechanism of action of erastin showed that it elicits a novel, non-apoptotic, iron 
dependent form of cell death in cancer cells that has been coined ferroptosis [105]. This has been 
found to occur through the inhibition of the antiporter system xc-, which exchanges extracellular 
cystine for intracellular glutamate [105-107]. The ability to study ferroptosis in vivo has been 
limited by erastin’s metabolic stability, aqueous solubility, and potency. The goal of this study 
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was to obtain a thorough structure-activity relationship profile to improve these properties for in 
vivo testing, and help learn more about erastin’s novel mechanism of cell death. 
 
II. Erastin chemistry and biological evaluation 
Towards this goal, the search began with an achiral analog that lacked the methyl group 
at the chiral center and had an isopropoxy group in place of the ethoxy group on the aromatic 
ring extending off of the quinazolinone nitrogen (dierastin) (Fig. 4.1). To synthesize this target a 
route was designed that proved to accommodate a broad range of substrates and facilitated the 
rapid synthesis of multiple new analogs (Scheme 4.1). Anthranillic acid was first acetylated with 
chloroacetyl chloride. The product was then heated in the presence of 2-isopropoxyaniline and 
phosphorous trichloride to form the quinazolinone core. The chlorine on the methyl group of the 
quinazoline was then displaced by an SN2 reaction using excess piperazine. The remaining free 
amine of piperazine was then was then attached to 4-chlorophenoxy acetylchloride in a 
nucelophillic acyl substitution to form the final target compound. This analog retained erastin’s 
activity and was used as the basis for further analog development.  
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Dierastin was broken down to exist as five functional regions (Fig. 4.1). To examine if 
the replacement of the quinazolinone scaffold (region A) with other biologically active scaffolds 
would improve activity, quinoline (scheme 4.2) and indole (scheme 4.3) analogs were 
synthesized. The quinoline core was synthesized using a Meth-Cohn type quinoline synthesis 
from acetyl aniline (2), which provided 2-chloroquinoline-3-carboxaldehyde (3). This was then 
reduced to 4 and protected with TBS prior to a Suzuki coupling at the 2-position to yield 5. The 
alcohol was subsequently deprotected with TBAF and converted to a bromide (8), which was 
then displaced by piperazine by an SN2 reaction. This allowed for the final attachment of the 4-
chlorophenoxy-acetyl group to provide quinolone dierastin (10, scheme 4.2). 
Scheme 4.1 | General analog synthetic route.  (a) TEA (1.1 eq), chloroacetyl chloride (1.1 eq), THF, 0oC to 25oC, 6 h; 
(b) PCl3 (1.2 eq), EDIPA (1.0 eq), then aniline (1.1 eq), dioxane, 25oC to 70oC, 6 h; (c) piperazine (3.0 eq), THF, 25oC, 14 
h; (d) EDIPA (1.2 eq), 4-DMAP (0.5 eq),  acyl chloride (1.2 eq), CH2Cl2 0oC to 25oC, 3 h -or- EDIPA (1.2 eq), carboxylic 
acid (1.1 eq), HBTU (1.2 eq), 30 min, then 3, DMF, 12 h; e) alkyl halide (1.5 eq), K2CO3 (1.2 eq), 60oC, DMF 24 h; (f) 






























































The indole analog was synthesized starting with 1H-indole-2-methanol (1, scheme 4.3). 
Following protection of the alcohol with TBS, the indole core was brominated at the 3-position 
with NBS. The brominated indole NH-group was then protected with BOC to allow for a Suzuki 
coupling, which provided 4. This more hindered alcohol was then deprotected with HF-pyridine 
and oxidized using DMP to an aldehyde (6). Introduction of the aldehyde enabled attachment of 
piperazine through a reductive amination (7). The amended piperazine could then attack 4-
chlorophenoxyacetyl chloride. Deprotection of the BOC group with TFA provided the final 
indole analog (9, scheme 4.3). 
NH2
H


























Scheme 4.2 | Synthesis of quinoline dierastin.  (a) EDIPA (1.2 eq), acetyl chloride (1.2 eq), CH2Cl2 , 0oC to 25oC, 6 h; (b) POCl3 (9.5 eq), 
DMF (3.3 eq), 0oC to 70oC, 12 h; (c) NaBH4 (2.0 eq), MeOH:CH2Cl2 (1:2), 0oC, 1 h; (d) EDIPA (1.5 eq), TBS-Cl (1.5 eq), CH2Cl2, 25oC, 12 h; (e) 
Pd(PPh3)4 (10%), 2-Isopropoxyphenylboronic acid (1.5 eq) in EtOH, NaCO3 (2M, aq) (10.0 eq), dioxane 25oC to 80oC, 24 h; (f) TBAF (1.1 eq), 
CH2Cl2 , 0oC, 1 h; (g) PBr3 (3.0 eq), CH2Cl2 , 0oC, 30 min, 25oC, 2 h; (h) piperazine (3.0 eq), THF, 25oC, 14 h; (i) EDIPA, 4-DMAP,  4-
chlorophenoxy acetylchloride, CH2Cl2 0oC to 25oC, 3 h.










Additional modifications to the quinazolinone core (region A) consisted of more subtle 
changes by incorporating various anthranillic acid derivatives into scheme 4.1. This synthetic 
scheme also allowed for changes in the piperazine portion (region B) by using methylamine and 
dimethylethylenediamine as replacement linkers between regions A and the acetylchlorophenoxy 
group. To examine the role of region C, analogs were synthesized replacing the carbonyl with a 
methylene, or the phenoxy oxygen with either a methylene or an NH-group. Additional subtle 
modifications were made to the chlorophenoxy ring by either removal of the chlorine, movement 
to the 3-position, or replacement with a fluorine. Modifications to region E were accomplished 
through the incorporation of either 3-isopropoxyaniline or 5-bromo-2-isopropoxyaniline and 









































Scheme 4.3 | Synthesis of indole dierastin. (a) EDIPA (1.5 eq), TBS-Cl (1.2 eq), 
DMF, 25oC, 12 hr; (b) NBS (1.0 eq), DMF 0oC, 1 hr; (c) Boc2O (1.8 eq), 4-DMAP 
(0.2 eq), CH2Cl2, 25oC, 12 hr; (d) Pd(PPh3)4 (10%), 2-Isopropoxyphenylboronic 
acid (1.5 eq) in EtOH, NaCO3 (2M, aq) (10.0 eq), dioxane 25oC to 80oC, 24 hr; (e) 
HF-py (xs), 25oC, 6 hr; (f) DMP (1.8 eq), NaHCO3 (10 eq), CH2Cl2, 25oC, 3 hr; (g) 
piperazine (10.0 eq), ZnCl2 (0.2 eq), NaBH3CN in MeOH,  40oC, 6 hr; (h) EDIPA, 4-
DMAP,  4-chlorophenoxy acetylchloride, CH2Cl2 0oC to 25oC, 3 hr; (i) TFA:  CH2Cl2 












This set of analogs was evaluated in HT1080 cells +/- betamercaptoethanol (BME) to see 
whether lethality involved inhibition of system xc- [106] (These experiments were performed by 
Professor Scott Dixon). BME has been found to rescue the cells from the inhibition of system xc- 
by erastin through forming a mixed disulfide with cystine [105, 108]. This facilitates cysteine 
transport into the cell by an alternative mechanism [108]. Glutamate release was also assessed in 
parallel using an aplex red assay system in human CCF-STTG1 astrocytoma cells, as an 
additional indicator of system xc- inhibition [106] (This experiment was perfomed by Dr. Ajit 
Thomas and Professor Barbra Slusher). Overall the lethality in HT-1080 cells correlated 
substantially with glutamate release in CCF-STTG1 cells (R2 = 0.86), supporting the hypothesis 
that system xc- inhibition is quantitatively linked to ferroptosis [106]. 
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Figure 4.2 | Structure-activity relationship of initial analog set. (a) Synthetic modifications made to dierastin broken down by 
molecular region. (b) Lethal potency of analogs in HT-1080 cells with and without β-mercaptoethanol (β-ME). Glutamate release 
inhibition in CCF-STTG1 cells. (c) Dose-response curves of representative analogs in BJeLR and BJeH cells. *Figure from 
Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and 
ferroptosis. Elife 2014, 1–25 (2014). The evaluation of the analogs shown in HT1080 cells was performed by Professor Scott 
Dixon (Stanford University). The glutamate release assay in CCF-STTG1 cells was performed by Dr. Ajit Thomas and 
Professor Barbra Slusher (Johns Hopkins University). 
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The results indicate losses of potency with replacement of the quinazolinone scaffold, 
particularly with the indole analog (4, Fig. 4.2). Small groups attached to the quinazolinone 
scaffold were generally tolerated with a slight loss in activity (6-10, Fig. 4.2). Any change 
introduced in regions B or C (11-15, Fig. 4.2) resulted in a significant loss of potency. The two 
most sensitive regions were D and E. Any small change in the phenoxy ring (region D, 16-18, 
Fig. 4.2) caused an almost complete loss in potency, even with replacement of the chlorine for 
fluorine (16). This was disappointing as this segment is extremely hydrophobic and would have 
been ideal to modify to improve aqueous solubility. In region E, modifications to the 5-position 
of the ring caused a roughly 5-fold increase in lethality with the most active analog being the 
introduction of an aromatic ring (21, Fig. 4.2). The improvement of potency attained with the 
addition of the furan ring, suggests that hydrophilic moieties could be introduced at that position 
to further increase aqueous solubility as well as activity.  
Three positions on dierastin were chosen as points of attachment for hydrophillic 
moieties based on the initial SAR profile (Fig. 4.2), cost of reagents, and synthetic accessibility. 
The synthetic strategy that proved to be the most fruitful was the incorporation of bromine off of 
either the quinazolinone scaffold or the aniline ring. This could then be converted to a vinyl 
group through a Stille coupling and oxidatively cleaved using sodium periodate and osmium 
tetraoxide to yield an aldehyde (scheme 4.4). This enabled the incorporation of an amine group 
through a reductive amination at the final step. Moieties could also be introduced through a 
nucleophillic substitution of the nitro precursor to the aniline (scheme 4.5) and then incorporated 
into the general synthetic route (scheme 4.1). 
 The evaluation of this analog set was performed in the engineered cell lines, used in the 
original screen: BJeLR (HRASG12V) and BJeH (wt HRAS) (analogs off of the 6-position of the 
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quinazolinone scaffold tested by Dr. Kathryn Lemberg). The most substantial increases in 
potency and selectivity were found with analogs modified at the 5-position of the aniline ring, 
where seven of the eight tested showed an improvement in potency over erastin (Fig. 4.3).  
 
 
Scheme 4.4 | Synthesis of  analogs with methylamino groups on the 5 position of the aniline ring. (a) tributylvinyltin (1.5 eq), 
PdCl2(PPh3)2 (5%), dioxane, 70oC, 24 h; (b) OsO4 (3%), NaIO4 (2.0 eq), dioxane:water (3:1), 25oC, 24 h; (c) amine (6.0 eq), mol sieves, 































































Scheme 4.5 | Synthesis of 4-substituted anilines. (a) 2-iodopropane (2.0 eq), 
K2CO3 (1.2 eq), DMF, 50oC, 12 hr; (b) NaH (1.2 eq), 2-(dimethylamino)ethan-1-ol 
(1.5 eq), then 4-fluoro-2-isopropoxy-1-nitrobenzene, 0oC to 25oC, 7 h (c) 50oC, 8 










Figure	  4.3	  |	  Activity	  of	  analogs	  designed	  to	  improve	  aqueous	  solubility.	  The	  EC50	  value	  represents	  the	  lethality	  in	  
BJeLR	  cells	  after	  48	  h	  treatment.	  The	  selectivity	  score	  is	  the	  ratio	  of	  the	  EC50	  in	  BJeLR	  to	  BJeH	  *Analogs	  off	  of	  the	  6-­‐
position	  of	  the	  quinazolinone	  scaffold	  tested	  by	  Dr.	  Kathyrn	  Lemberg. 
Interestingly, the most potent compound of the set was one of the synthetic intermediates, 
aldehyde erastin (AE, Fig. 4.3). This showed an increase in potency of over 200-fold and an 
increase in selectivity of 5-fold over the original erastin structure. We speculated that this is due 
to the aldehyde moiety making a reversible covalent bond with a lysine residue in the target, 
through the formation of an imine. This hypothesis is supported by the fact that the moieties 
incorporated at the same position that showed the most favorable activity all had a group that 
could act as a hydrogen bond acceptor in addition to the newly amended nitrogen. For example 
the diethylamine analog (12MEW12) showed similar activity to erastin, while the morpholine 
group (11MEW75) showed an almost 14-fold improvement in potency and almost twice the 









































































































Compound    EC50 (BJeLR)    Selectivity score*
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still problematic and further characterization was focused on 11MEW75. This analog appeared 
to be the best balance of improved potency, selectivity, and aqueous solubility. Figure 4.4 shows 
the morpholine moiety attached at three different positions on the ring with the corresponding 
potency and selectivity. Movement of the morpholine substituent one position over resulted in a 
36-fold decrease in potency, indicating a very specific target interaction. 
	  
Figure	  4.4	  |	  Effect	  of	  the	  movement	  of	  the	  methylmorpholino	  substituent	  on	  activity.	  The	  EC50	  value	  represents	  the	  
lethality	  in	  BJeLR	  cells	  after	  48	  h	  treatment.	  The	  selectivity	  score	  is	  the	  ratio	  of	  the	  EC50	  in	  BJeLR	  to	  BJeH	  	  
 
Off of the quinazolinone scaffold, the amino group at the 6-position (6MEW160) showed 
a two-fold increase in potency and >25 fold increase in selectivity. To see if the combination of 
the amino group and the methylmorpholino moiety would further improve activity, an analog 






























this decreased both the potency and selectivity of 11MEW75. 
	  
Figure	  4.5	  |	  Effect	  of	  the	  addition	  of	  an	  amino	  group	  to	  11MEW75	  on	  activity.	  The	  EC50	  value	  represents	  the	  lethality	  
in	  BJeLR	  cells	  after	  48	  h	  treatment.	  The	  selectivity	  score	  is	  the	  ratio	  of	  the	  EC50	  in	  BJeLR	  to	  BJeH. 
To verify that 11MEW75 indeed acts through the same mechanism as erastin, a 
suppression experiment was performed using known compounds that prevent erastin induced cell 
death [105]. HT1080 cells were cotreated with deferoxamine (DFOM, an iron chelator), U0126 
(a MEK1/2 inhibitor), and butylated hydroxyanisole (BHA, an antioxidant). Each compound 
resulted in complete suppression of erastin and 11MEW75 induced cell death up to 10 µM, 













































Figure	  4.6	  |	  Confirmation	  that	  11MEW75	  acts	  through	  the	  same	  mechanism	  as	  erastin.	  Dose-­‐response	  curves	  of	  
erastin	  and	  11MEW75	  in	  HT-­‐1080	  in	  the	  presense	  of	  DFOM,	  U0126,	  and	  BHA.	  	  	   
Both AE and 11MEW75 were tested in an HT1080 (NRASQ61K) xenograft, and both 
compounds did not show any significant efficacy (data not shown, xenograft performed by Dr. 
Wan Yang). We speculated that this inactivity could be still due to insufficient aqueous solubility 
and drug metabolism. Reexamining the panel of analogs, compound 15MEW33 (PE) had 
comparable potency to 11MEW75. Measuring the aqueous solubility indicated that a substantial 
increase in solubility was gained with this subtle change of the oxygen for a secondary amine 
(Fig. 4.7a). The metabolic stability of erastin and PE was then assessed by incubation with liver 
microsomes (Alliance Pharma). The results show a substantial improvement compared to erastin, 
which is degraded within minutes (Fig. 4.7b).  














































Figure 4.7 | Aqueous solubility and metabolic stability of selected analogs. (a) Measured aqueous solubility of erastin and 
selected analogs. (b) Metabolic stability of midazolam (positive control), erastin, and PE.  *6.6b from Yang, W. S. et al. 
Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014). Experiment performed by Alliance Pharma. 
 
To see if this improvement translated to in vivo efficacy, PE was then evaluated in an 
HT-1080 xenograft (performed by Dr. Wan Yang).  There was indeed a significant decrease in 
tumor size of PE treated mice over the vehicle treated (Fig. 4.8a) [107]. Analysis of the tumor 
samples showed an increase in mouse liver Ptgs2 expression, a gene associated with ferroptosis; 
thus confirming that the cells were undergoing ferroptotic cell death (Fig. 4.8b) [107].  
	  
Figure	  4.8	  |	  Activity	  of	  PE	  in	  an	  HT-­‐1080	  mouse	  tumor	  xenograft.	  (a)	  (left)	  Representative	  pictures	  of	  vehicle	  and	  PE	  
treated	  HT-­‐1080	  xenografts.	  (right)	  Tumor	  xenograft	  size	  after	  a	  13-­‐day	  study	  of	  vehicle	  and	  PE	  treated	  mice	  (40	  mg/kg	  
s.c.	  twice	  a	  week	  for	  one	  week,	  then	  30	  mg/kg	  I.V.	  every	  other	  day	  for	  6	  days).	  (b)	  Expression	  of	  Ptgs2	  in	  mouse	  liver	  by	  
qPCR.	  Shown	  are	  the	  averages	  of	  vehicle,	  PE,	  and	  doxorubicin	  treated	  mouse	  samples.	  *Figure from Yang, W. S. et al. 
Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014). These experiments were performed by Dr. 










































III. J9 background  
Acute lymphoblastic leukemia (ALL) is typically treated by chemotherapy with 
glucocorticoids (GCs), such as dexamethasone [109]. Resistance to GC therapy results in a much 
higher risk of relapse and is particularly prevalent in T-cell acute lymphoblastic leukemia (T-
ALL) [109]. To address this, a screen was performed of 9,517 ‘drug like’ compounds to discover 
a molecule that reverses GC resistance [109]. This was accomplished using a human T-ALL cell 
line with a t(7;9)(q34;34) translocation expressing constitutively active NOTCH1 (CUTLL1 
cells), which has been shown to cause resistance of GC in thymocytes [110]. The compound J9 
was discovered in this screen and was shown to inhibit CUTLL1 cell growth with an EC50 of 28 
µM in the presence of 1 µM dexamethasone, in contrast to an EC50 of 294 µM in the absence of 
dexamethasone (Fig. 4.9) [109]. The goal of this study was to further improve the potency of J9 
for in vivo studies in order to better understand to mechanism of action of this reversal of GC 
resistance, and for use as a potential therapeutic agent. 
 
IV. J9 chemistry and biological evaluation 
	  
Figure	  4.9	  |	  Activity	  and	  structure	  of	  J9.	  	  (a)	  Diagram	  of	  the	  function	  of	  J9.	  (b)	  Dose-­‐response	  curves	  of	  CUTLL1	  cells	  48	  
h	  after	  treatment	  of	  J9	  with	  and	  without	  dexamethasone	  (1	  μM).	  	  (c)	  Structure	  of	  J9	  and	  how	  the	  molecule	  was	  broken	  










Cantley,	  A.	  M.	  et	  al.	  Small	  molecule	  that	  reverses	  dexamethasone	  resistance	  in	  t-­‐cell	  acute	  lymphoblastic	  leukemia	  
(T-­‐ALL).	  ACS	  Med.	  Chem.	  Lett.	  5,	  754–759	  (2014). 
 
The synthesis of J9 was accomplished through an LDA facilitated addition of 4-
methylpicoline to ethylcyclopropyl carboxylate (scheme 4.6). The pyrimidine moiety was then 
formed by the attack of dimethylformamide dimethyl acetal by the alpha carbon of the newly 
formed ketone, and subsequent cyclization in the presence of guanidine hydrochloride.  
 
Using this route, the amine group (in region A) was first replaced with a methyl group by 
using acetimidamide in place of guanidine hydrochloride in step c. This isosteric replacement 
resulted in a loss of all activity (compound 20, Fig 4.10). The role of the cyclopropane group 
(region B) was then explored by the incorporation of various esters into step a, scheme 7.1.  All 
changes, even as subtle as replacement with a cyclobutane (17, Fig. 4.10) or isopropyl group (14, 
Fig. 4.10), resulted in inactivity. Region C was initially investigated by the movement of the 
nitrogen to the 3- and 2-positions, which also diminished activity. To examine how the 
amendment of substituents with hydrogen bond accepting ability would affect activity, 4-fluoro 
and 4-methoxy analogs were synthesized (6 and 7, Fig. 4.10). This accomplished by converting 





















X,Y or Z = N








Scheme 4.6 | General J9 analog syntheic route. a) LDA (1.1 eq) 0oC, 1 h, then desired ester (1.3 
eq), 0-25oC, 6 h, THF; b) N,N-dimethylformamide dimethyl acetal (2.0 eq), 90oC, 5 h, neat; c) 
guanidine hydrochloride (1.1 eq), sodium ethoxide (1.1 eq), then iii., 40oC, 4 h, EtOH; d) Pd(PPh3)4 
(5%), sodium carbonate (2M, 5.0 eq),R2-B(OH)2 (1.5 eq), 80oC, 12 h dioxane -or- tributylvinyl tin (1.5 
eq) 80oC, 12 h dioxane.
if W=Br
a) b) c) d)
i. ii. iii. iv. v.
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phenylacetyl chloride. The resulting ketone was then incorporated into scheme 4.6. Again, these 
analogs lost all activity.  Next, substituents were amended at the 2- and 3- positions of the 
pyridine ring (region C) by the incorporation of a halogenated 4-methyl picoline into scheme 4.6, 
with a Suzuki or Stille coupling at the final step to provide 9-11 and 13, Fig. 4.10. Subsitutents at 
the 2-position resulted in either a loss of activity or a loss of selectivity for dexamethasone 
treatment. At the 3-position, bromine and furan rings improved both the potency and selectivity 
for dexamethasone treatment (Fig. 4.10 and Fig. 4.11), with the bromine analog (J9A) being the 
most selective of all the analogs tested. Fluorine or chlorine substituents at the same position 
were completely inactive, indicating a highly specific receptor interaction.   
Figure	  4.10	  |	  Structure-­‐activity	  relationship	  of	  J9.	  Shown	  is	  the	  growth	  inhibition	  EC50	  of	  CUTLL1	  cells	  48	  h	  after	  
treatment	  of	  the	  indicated	  analog	  with	  and	  without	  dexamethasone	  (1	  μM).	  *Testing	  in	  CUTLL1	  cells	  performed	  by	  
Alexandra	  Cantley.	  This	  figure	  is	  taken	  from	  Cantley,	  A.	  M.	  et	  al.	  Small	  molecule	  that	  reverses	  dexamethasone	  




Figure	  4.11	  |	  Growth	  inhibition	  of	  J9A	  and	  J9B.	  Dose-­‐response	  curves	  of	  J9A	  and	  J9B	  in	  CUTLL1	  cells	  with	  and	  without	  
dexamethasone	  (1	  μM).	  	  *Testing	  in	  CUTLL1	  cells	  performed	  by	  Alexandra	  Cantley.	  This	  figure	  is	  taken	  from	  Cantley,	  
A.	  M.	  et	  al.	  Small	  molecule	  that	  reverses	  dexamethasone	  resistance	  in	  t-­‐cell	  acute	  lymphoblastic	  leukemia	  (T-­‐ALL).	  
ACS	  Med.	  Chem.	  Lett.	  5,	  754–759	  (2014).	   
 
V. Discussion 
 Through systematically modifying the dierastin scaffold positions were identified that 
were amenable to the introduction of hydrophilic moieties. The attachment of hydrophilic groups 
at the 5-position of the aniline ring improved aqueous solubility, potency, and selectivity. 
Despite promising results in cell culture, the two most potent analogs (AE and 11MEW75) 
unfortunately showed no activity in a mouse xenograft. The panel of analogs was reassessed and 
the compound PE was then selected. PE proved to be substantially more soluble and 
metabolically stable than the other analogs. This indeed showed activity in xenograft model and 
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an upregulation in expression of the ferroptosis marker Ptgs2, highlighting the importance of 
ADME property optimization.  
J9 proved to be highly sensitive to the majority of the synthetic modifications made, 
indicating a very specific target interaction. Introduction of bromine at the 3-position of the 
pyridine ring was found to improve both the potency and selectivity. This position was also 
found to be highly sensitive, as replacement with other halogens eliminated activity. 
Interestingly, a furan ring at this position also improved the potency of the compound, suggesting 
perhaps larger substituents would also be tolerated. This could position could be potentially used 
as point of attachment for groups to be used for target identification to help understand the 
mechanism of action of the glucocorticoid resistance reversal. Identification of this target could 















The synthesis and characterization of: AE, PE, and MEII were published and adopted from Yang, 
W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014). 
 
The synthesis and characterization of: 13MEW76, 6MEW78, 7MEW81, 10MEW79, 6MEW160, 
14MEW31, 14MEW32, 8MEW98, 35MEW26, 35MEW27, 15MEW81, 35MEW14, 35MEW22, 
35MEW39, 35MEW38, 35MEW13, 13MEW16, 21MEW26, 35MEW28, and 35MEW29 were 
published and adopted from Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate 
exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014, 1–25 (2014). 
 
General erastin analog synthetic route.  (a) TEA (1.1 eq), chloroacetyl chloride (1.1 eq), THF, 
0oC to 25oC, 6 hr; (b) PCl3 (1.2 eq), EDIPA (1.0 eq), then 2-isoproxyaniline (1.1 eq), dioxane, 
25oC to 70oC, 6 hr; (c) piperazine (3.0 eq), THF, 25oC, 14 hr; (e) EDIPA, 4-DMAP, 4-
chlorophenoxy acetylchloride, CH2Cl2 0oC to 25oC, 3 hr. 
 
1-isopropoxy-2-nitrobenzene (general procedure 1) 
2-Iodopropane (14.4 mL, 143.8 mmol, 2.0 eq) was added to a stirred solution of 2-nitrophenol 
(10 g, 71.9 mmol) and potassium carbonate (14.9 g, 108 mmol, 1.5 eq) in DMF (160 mL) and the 
mixture was subsequently heated to 500C for 12 hrs.  Upon completion the reaction contents 




























dried (Na2SO4), concentrated and purified by combiflash 0-20% EtOAc to afford 1-isopropoxy-
2-nitrobenzene (11.7 g, 90% yield). 1H NMR (400 MHz, CDCl3): δ 7.71 p.p.m. (d app, J= 8.4 
Hz, 1H), 7.46 (t app, J=8 Hz, 1H), 7.07 (d app, J=8.4 Hz, 1H), 6.97-6.93 (m, 1H), 4.66 (h, J=1.5 
Hz, 1H), 1.35-1.33 (m, 6H); 13C NMR (125 MHz): δ 141.0, 133.7, 125.2, 120.0, 116.1, 72.5,  
HRMS (m/z): [M+] cald for C9H11NO3  181.19, found 182.08 
 
2-isopropoxyaniline (general procedure 2) 
To a solution of 1-isopropoxy-2-nitrobenzene (11.7 g, 64.6 mmol) in methanol (300 mL) Pd/C 
(10%) (5% wt, 0.585 g) was added and stirred under hydrogen (1 atm) for 72 hr. Upon 
completion the reaction was filtered over celite, concentrated, and purified by combiflash 0-
>30% EtOAc to afford 2-isopropoxyaniline (7.88 g, 81% yield). 1H NMR (400 MHz, CDCl3): δ 
6.80-6.79 p.p.m. (m, 2H), 6.78-6.75 (m, 2H), 4.59 (h, 1.5 Hz, 1H), 3.85 (s, 1H), 1.42 (d, J=6 Hz, 
2H); 13C NMR (125 MHz): δ 145.4, 137.4, 121.1, 118.4, 115.4, 113.7, 70.6 HRMS (m/z): [M+] 
cald for C9H13NO 151.21, found 151.47 
 
Bromo-isopropoxy amine (general procedure 3) 
To a solution of 4-bromo-1-isopropoxy-2-nitrobenzene (prepared using general procedure 1, 
84%, 17.54 g, 67.4 mmol) in THF (270 mL), HCl (1 M aq, 270 mL, 270 mmol, 4.0 eq), and 
stannous chloride (38 g, 282 mmol, 3.0 eq) were added and heated to 500C for 24 hr.  Upon 
completion the mixture was quenched with saturated aqueous sodium bicarbonate, filtered over 
celite and the crude product was extracted twice with ethyl acetate. The combined organic layers 
were dried (Na2SO4), concentrated and purified by combiflash 0->30% EtOAc to yield bromo-
isopropoxy amine (9.93 g, 64% yield) 1H NMR (400 MHz, CDCl3): δ 6.82 p.p.m. (d, J=2.4 Hz, 
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1H), 6.77 (dd, J1=8.5 Hz, J2=2.4 Hz, 1H), 6.63 (d, J=8.6 Hz, 1H), 4.46 (hept, J=1.5 Hz, 1H), 
1.33 (d, J=6.0, 6H), 13C NMR (125 MHz): δ 114.4, 138.9, 120.6, 117.6, 114.8, 113.2, 71.0 
HRMS (m/z): [M+] cald for C9H13NOBr 230.1, found 229.01 
 
2-(2-chloroethanamido)benzoic acid (general procedure 4) 
A solution of chloroacetyl chloride (2.09 mL, 26.25 mmol, 1.2 eq) in THF (40 mL) was added 
dropwise, over about 1 hr, to a solution of triethyl amine (3.05 mL, 21.9 mmol, 1.0 eq) and 
anthranillic acid (3.00 g, 21.9 mmol) in THF (120 mL) at 00C. The mixture was slowly warmed 
250C and stirred for an additional 4 hr. Upon completion, the reaction contents were diluted with 
EtOAc and washed with 1 M HCl and water.  The organic layer was dried (Na2SO4), the solvent 
was removed, and the crude solid was triturated with dichloromethane to afford 2-(2-
chloroethanamido)benzoic acid (3.20 g, 68% yield). 1H NMR (400 MHz, C6D6OS): δ 11.81 
p.p.m. (s, 1H), 8.53 (d, J=8.4 Hz, 1H), 8.02 (dd, J1= 7.9, J2=1.5 ), 7.63 (m, 1H), 7.21 (m, 1H), 
4.45 (s, 2H). 13C NMR (125 MHz): δ 169.8, 165.7, 140.4, 134.6, 131.6, 123.9, 120.3, 117.3, 
43.9; HRMS (m/z): [M+] cald for C9H8ClNO3 213.62, found 213.02 
 
2-(chloromethyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one (general procedure 5) 
EDIPA (0.326 mL, 1.87 mmol, 1.0 eq) was added to a solution of 2-(2-
chloroethanamido)benzoic acid (0.400 g, 1.87 mmol) at 250C in dioxane (10 mL) and stirred for 
2 minutes before the dropwise addition of phosphorous trichloride (0.309 mL, 2.25 mmol, 1.2 
eq). After 5 minutes of stirring, O-isopropoxyaniline (0.311 g, 2.06 mmol, 1.1 eq) was added and 
the resulting mixture was heated to 700C and stirred for an additional 6 hr. Upon completion the 
reaction was carefully quenched with saturated aqueous NaHCO3, diluted with water, and 
136	  
extracted 3 times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, 
and the crude material was purified by combi flash 0->50% EtOAc in hexanes to provide 2-
(chloromethyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one (333 mg, 54% yield). 1H NMR 
(400 MHz, CDCl3): δ 8.32 p.p.m. (m, 1H), 7.89 (m, 1H), 7.54 (m, 1H), 7.38 (dd, J1=7.7, J2=1.6, 
1H), 7.11 (m, 1H), 4.58 (hept, J= 1.5 Hz, 1H), 4.38 (d, J=12 Hz, 1H), 4.19 (d, J=12 Hz, 1H), 
1.26 (d, J=6.1, 3H), 1.17 (d, J=6.1, 1H), 13C NMR (125 MHz): δ 161.6, 153.0, 152.4, 147.2, 
134.5, 131.1, 130.8, 127.6, 127.5, 127.3, 125.3, 121.4, 121.0, 114.3, 71.2, 43.7, 22.2, 21.8; 
HRMS (m/z): [M+] cald for C18H17ClN2O2 328.79, found 329.1 
 
3-(2-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one (general procedure 
6) 
Piperazine (263 mg, 3.06 mmol, 3.0 eq) was added to a solution of 2-(chloromethyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (0.335 g, 1.01 mmol) in THF (5 mL) and the resulting 
mixture was stirred at 250C for an additional 14 hr. The reaction mixture was then concentrated 
and purified directly by combiflash 0->20% MeOH in DCM to provide 3-(2-isopropoxyphenyl)-
2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one (0.301 g, 77% yield). 1H NMR (400 MHz, 
CDCl3): δ 8.30 p.p.m. (m, 1H), 7.78 (m, 2H), 7.49 (m, 1H), 7.42 (m, 1H), 7.30 (m, 1H), 7.07 (m, 
2H), 4.56 (h, J=1.5 Hz, 1H), 3.26 (s, 1H), 2.85 (m, 3 H), 2.65 (s, 3H), 2.52 (m, 2H), 2.37 (m, 
1H), 2.23 (m, 2H). 13C NMR (125 MHz): δ 162.1, 153.7, 153.0, 147.2, 134.2, 132.1, 131.1, 
130.9, 130.4, 127.4, 127.1, 126.8, 126.4, 121.3, 120.5, 120.4, 114.3, 71.1, 71.0, 61.5, 53.3, 51.3, 




isopropoxyphenyl)quinazolin-4(3H)-one (general procedure 7) 
EDIPA (0.166 mL, 0.954 mmol, 1.2 eq) was added to a solution 3-(2-isopropoxyphenyl)-2-
(piperazin-1-ylmethyl)quinazolin-4(3H)-one which was then cooled to 00C, before the sequential 
addition of 4-chlorophenoxyacetyl chloride (0.196 g, 0.954 mmol, 1.2 eq) and 4-DMAP (49 mg, 
0.390 mmol, 0.5 eq). The mixture was slowly warmed to 250C and stirred for an additional 3 hrs. 
Upon completion, the reaction was quenched with saturated aqueous NaHCO3 and extracted 3 
times with dichloromethane. The combined organic layers were dried (Na2SO4), concentrated, 
and the crude material was purified by combi flash 0->5% MeOH in DCM to provide 2-((4-(2-(4 
chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one 
(270 mg, 62 % yield). 1H NMR (400 MHz, CDCl3): δ 8.32 p.p.m. (dd, J1= 8.0 Hz, J2= 0.8 Hz, 
1H), 7.83-7.75 (m, 2H), 7.54-7.47 (m, 1H), 7.45-7.42 (m, 1H), 7.30-7.23 (m, 3.5 H), 7.10-7.06 
(m2H), 6.89-6.86 (m, 2H), 4.64 (s, 1H), 4.57 (h, J=1.5, 1H), 3.51-3.44 (m, 4 H), 3.28 (s, 2H), 
2.54-2.42 (m, 2H), 2.30-2.26 (m, 2H), 1.21 (d, J=6 Hz, 3H), 1.13 (d, J=6 Hz, 3 H); 13C NMR 
(125 MHz): δ 166.1, 162.1, 156.6, 134.5, 130.9, 130.7, 129.7, 127.6, 127.3, 126.8, 126.5, 121.5, 
120.7, 116.1, 114.6, 71.4, 68.0, 61.0, 53.1, 52.8, 45.3, 42.1, 22.4, 22.0; HRMS (m/z): [M+] cald 














































AE and PE synthesis. (a) tributylvinyl tin (1.5 eq), PdCl2(PPh3)2 (5%), dioxane, 70oC;  (c) 
piperazine (6.0 eq), ZnCl2 (0.1 eq), 1,2-dichloroethane, 25oC, 3 hr, then NaBH3CN in MeOH, 




To a degassed solution of 3-(5-bromo-2-isopropoxyphenyl)-2-((4-(2-(4-
chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)quinazolin-4(3H)-one (Synthesized using the 
procedures described in scheme 2 using bromo-isopropoxy amine), (6.67 g, 10.8 mmol) in 
dioxane (100 mmol) PdCl2(PPh3)2 (5%, 0.378 g, 0.539 mmol) was added and the resulting 
mixture was stirred for 10 min before the addition of tributylvinyl tin (4.73 mL, 16.2 mmol, 1.5 
eq). The reaction was heated to 700C and stirred for 24 hr, cooled to room temp and a solution of 
KF (2 M, 16.2 mmol, 8.1 mL, 1.5 eq) was added and then stirred for an additional 12 hr. Upon 
completion the reaction was filtered and filtrate was diluted with saturated aqueous NaHCO3 and 
extracted 3 times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, 
and the crude material was purified by combi flash 0->5% DCM in methanol to provide 2-((4-(2-
(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-isopropoxy-5-vinylphenyl)quinazolin-
4(3H)-one (4.47g, 72% yield). 1H NMR (400 MHz, CDCl3): δ 8.25 p.p.m. (d, J=2.0 Hz, 1H), 
7.86 (dd, J1= 8.5 Hz, J2= 3.0 Hz, 1H),  7.68 (d, J=8.5, 1H), 7.38 (dd, J1= 8.4 Hz, J2= 2 Hz, 
1H), 7.22 (m, 3 H), 7.00 (d, J= 8.6 Hz, 1 H), 6.85 (d, J=4.8 Hz, 2H), 6.81 (d, J=11 Hz, 1H), 5.88 
(d, 17.5 Hz, 1H), 5.36 (d, 11 Hz, 1H)4.62 (s, 2H), 4.52 (m, 1H), 3.70 (m, 4.5 H), 3.49 (m, 7H), 
2.46 (m, 7 H) 2.32 (m, 1H), 2.22 (m, 1H), 1.21 (d, J=6 Hz, 3H), 1.13 (d, J=6 Hz, 3 H). 13C NMR 
(125 MHz): δ 166.0, 161.9, 156.4, 153.1, 152.2, 146.7, 136.4, 135.7, 131.8, 131.0, 130.9, 130.3, 
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129.5, 127.7, 126.7, 126.2, 124.7, 121.3, 115.9, 115.5, 114.3, 112.4, 71.4, 67.9, 67.0, 62.4, 60.8, 





To a solution of 2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-isopropoxy-5-
vinylphenyl)quinazolin-4(3H)-one (0.625 g, 1.09 mmol) in dioxane:water (3:1, 20 mL) OsO4 
(3%, 0.0327 mmol) was added dropwise and the mixture was stirred for 10 min before the 
addition of NaIO4 (0.332 g, 2.18 mmol, 2.0 eq) in several portions over 30 min. The reaction 
was stirred for 24 hr and then diluted with saturated aqueous NaHCO3 and extracted 3 times 
with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, and the crude 
material was purified by combi flash 0->5% DCM in methanol to provide 3-(2-((4-(2-(4-
chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-4-oxoquinazolin-3(4H)-yl)-4-
isopropoxybenzaldehyde (0.4 g, 64% yield). 1H NMR (400 MHz, CDCl3): δ 9.92 p.p.m. (s, 1H), 
8.28 (dd, J1=7.9, J2=1.0 Hz, 1H), 7.96 (dd, J1=8.6, J2=2.0 Hz, 2H), 7.89 (m, 1H), 7.80 (m, 
1H), 7.78 (m, 1H), 7.51 (m, 1H) 7.22 (m, 3H), 7.16 (d, J= 8.4, 1H), 6.84 (d, J=8.4, 2H), 4.69 (m, 
1H), 4.60 (s, 2H), 3.69 (s, 4H), 3.58 (s, 1H), 3.42 (s, 4H), 2.22 (m, 2H), 2.42 (m, 2H), 2.145 (m, 
2H), 1.26 (d, J=6, 3H), 1.22 (d, J=6, 3H), 13C NMR (125 MHz): δ 189.6, 165.9, 161.7, 158.4, 
156.4, 152.6, 146.9, 134.6, 133.3, 133.2, 131.9, 129.7, 129.5, 129.4, 127.5, 127.3, 127.1, 127, 
126.7, 121.1, 115.9, 121.0, 115.9, 113.5, 72.8, 72.2, 67.8, 67.1, 61.1, 52.9, 52.5, 45.11, 41.9 




ylmethyl)phenyl)quinazolin-4(3H)-one (15MEW33, PE) 
To a solution of 3-(2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-4-oxoquinazolin-
3(4H)-yl)-4-isopropoxybenzaldehyde (70 mg, 0.122 mmol) in 1,2-dichloroethane (1 mL) and 
molecular sieves (50 mg), zinc chloride (0.1 eq, 1.7 mg 0.0122 mmol) and piperazine (63 mg, 
0.732 mmol 6.0 eq) were added sequentially. The resulting mixture was stirred at room temp for 
3 hr before the addition of a solution of sodium cyanoborohydride (16 mg, 0.244 mmol, 2.0 eq) 
in methanol (0.5 mL) which was stirred for an additional 1 hr at 250C before being heated to 
400C for 3 hr. Upon completion the reaction was filtered, concentrated and purified directly by 
combiflash 0->20% MeOH in DCM to provide 2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-
yl)methyl)-3-(2-isopropoxy-5-(piperazin-1-ylmethyl)phenyl)quinazolin-4(3H)-one (36 mg, 46% 
yield). 1H NMR (400 MHz, CDCl3): δ 8.25 p.p.m. (d, J= 8.0 Hz, 1H), 7.76 (m, 2H), 7.49 (m 
1H), 7.35 (m, 1H), 7.22 (m, 3H), 7.03 (d, J=8.4 Hz, 2H), 4.68 (s, 2H), 4.54 (m, 1H), 3.59 (m, 
3H), 3.44 (m, 3H), 3.27 (s, 2 H), 3.12 (m, 5 H), 2.62 (m, 6 H) 2.36 (s, 3H), 2.25 (s, 1H), 1.21 (d, 
J=6 Hz, 3H), 1.13 (d, J=6 Hz, 3 H), 13C NMR (125 MHz): δ 162.2, 156.4, 153.1, 152.3, 147.1, 
134.5, 131.2, 131.1, 129.6, 128.9, 127.5, 127.1, 127.0, 126.0, 121.1, 116.3, 114.4, 77.2, 71.3, 
67.4, 61.3, 60.8, 52.7, 49.5, 44.9, 44.2, 42.1, 22.2, 21.8; HRMS (m/z): [M+] cald for 
C35H41ClN6O4 645.19; found, 645.29 
 
2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-isopropoxy-5-
(morpholinomethyl)phenyl)quinazolin-4(3H)-one (11MEW75, MEII) 
Prepared from AE according to the procedure described for PE, 50% yield. 1H NMR (400 MHz, 
CDCl3): δ 8.28 p.p.m. (dd, J1= 8 Hz, J2= 1 Hz, 1H), 7.77 (m, 2H) 7.49 (m, 1H), 7.38 (dd, J1= 
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8.4 Hz, J2= 2 Hz, 1H), 7.22 (m, 3 H), 7.00 (d, J= 8.6 Hz, 1 H), 6.85 (d, J=4.8 Hz, 2H), 4.60 (s, 
2H), 4.51 (m, 1H), 3.69 (m, 4H), 3.52 (m, 6.5 H), 3.27 (s, 2H), 2.52 (s, 1H), 2.50 (s, 4H), 2.38 (s, 
1H), 2.34 (s, 1H), 2.30 (s, 1H), 1.21 (d, J= 6.1 Hz, 3H), 1.13 (d, J=6.1, 3H), 13C NMR (125 
MHz): δ 166.0, 156.4, 153.3, 152.3, 147.1, 134.3, 130.9, 130.3, 129.5, 127.4, 127.1, 126.9, 
126.7, 126.2, 121.26, 121.2, 115.9, 114.2, 7.3, 67.9, 67.0, 62.4, 60.8, 53.6, 52.9, 52.7, 45.2, 42.0, 
22.3, 21.8; HRMS (m/z): [M+] cald for C35H50ClN5O5 646.18; found, 646.28 
 
Synthesis of 12MEW10 
 
4-isopropoxy-3-nitrobenzaldehyde was synthesized according to general procedure 1 from 4-
hydroxy-3-nitrobenzaldehyde (63% yield).  
 
4-(4-isopropoxy-3-nitrobenzyl)morpholine 
Morpholine (3.0 eq, 1.87 mL, 21.5 mmol) was combined with 4-isopropoxy-3-nitrobenzaldehyde 
(1.5 g, 7.7 mmol) in dichloroethane (20 mL) and stirred for 30 min at 50oC before the addition of 
sodium triacetoxy borohydride (2.28 g, 1.5 eq, 10.76 mmol). The resulting solution was stirred 
for an additional 7 hr until being diluted with saturated aqueous sodium bicarbonate and 
extraction 3 times with dichloromethane. The combined organic layers were dried (Na2SO4), 
concentrated, and the crude material was purified by combi flash 0->5% DCM in methanol to 
















2-isopropoxy-5-(morpholinomethyl)aniline was synthesized from 4-(4-isopropoxy-3-
nitrobenzyl)morpholine according to general procedure 2 (41% yield). 
 
 
2-(2-chloroacetamido)-5-nitrobenzoic acid (synthesized using general procedure 4) was 
combined with 2-isopropoxy-5-(morpholinomethyl)aniline according to general procedure 5 to 
provide 2-(chloromethyl)-3-(2-isopropoxy-5-(morpholinomethyl)phenyl)-6-nitroquinazolin-


























































using general procedures 6 and 7. 2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-
isopropoxy-5-(morpholinomethyl)phenyl)-6-nitroquinazolin-4(3H)-one was synthesized from 2-
(chloromethyl)-3-(2-isopropoxy-5-(morpholinomethyl)phenyl)-6-nitroquinazolin-4(3H)-one 
(200 mg, 0.289 mmol) was combined with 10% Pd/C (10 mg) in methanol (6 mL) and stirred 
under H2 (1 atm) overnight. The resulting solution was filtered over celite, concentrated and 
purified by combiflash 0->5% MeOH in DCM to provide 12MEW10 (80 mg, 42% yield). 1H 
NMR (300 MHz, CDCl3) δ 8.15 (d, J = 8.7 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.25 (dd, J = 9.5, 2.6 
Hz, 3H), 7.15 (s, 1H), 7.01 (dd, J = 8.7, 2.0 Hz, 2H), 6.92 – 6.84 (m, 2H), 4.64 (s, 2H), 4.52 (p, J 
= 6.1 Hz, 1H), 3.72 (t, J = 4.7 Hz, 4H), 3.26 (s, 2H), 2.49 (d, J = 4.8 Hz, 7H), 2.30 (d, J = 22.9 
Hz, 3H), 1.24 (d, J = 6.1 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H). 
 
12MEW61 
Was prepared according to the same synthetic sequence as 12MEW10 using anthranillic acid 2-
hydroxy-3-nitrobenzaldehyde.1H NMR (300 MHz, CDCl3) δ 8.33 (d, J = 7.9 Hz, 1H), 7.91 – 
7.73 (m, 2H), 7.67 – 7.46 (m, 2H), 7.27 – 7.18 (m, 4H), 6.93 – 6.76 (m, 2H), 4.62 (s, 2H), 4.17 – 
4.03 (m, 1H), 3.74 (t, J = 4.6 Hz, 4H), 3.42 (s, 3H), 2.72 – 2.37 (m, 6H), 2.07 (s, 3H), 1.16 (d, J 
= 6.1 Hz, 3H), 0.90 (d, J = 6.2 Hz, 3H). 
 
13MEW59 
Was prepared according to the same synthetic sequence as 12MEW10 using anthranillic acid and 
bis(2-methoxyethyl)amine. 1H NMR (300 MHz, CDCl3) δ 8.36 – 8.23 (m, 1H), 7.96 – 7.65 (m, 
2H), 7.49 (ddd, J = 8.1, 6.6, 1.8 Hz, 1H), 7.39 (dd, J = 8.5, 2.2 Hz, 1H), 7.27 – 7.15 (m, 3H), 
6.99 (d, J = 8.4 Hz, 1H), 6.92 – 6.78 (m, 2H), 4.63 (s, 2H), 4.58 – 4.43 (m, 1H), 3.70 (d, J = 4.8 
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Hz, 2H), 3.31 (d, J = 1.5 Hz, 8H), 2.75 (td, J = 5.9, 1.5 Hz, 4H), 2.39 (ddt, J = 26.7, 20.4, 5.4 Hz, 
4H), 1.22 (d, J = 6.1 Hz, 3H), 1.14 (d, J = 6.0 Hz, 3H). 
 
13MEW31 
Was prepared according to the same synthetic sequence as piperazine erastin using 3-
(methylamino)propanenitrile.1H NMR (300 MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.4 Hz, 1H), 7.94 
– 7.71 (m, 2H), 7.60 – 7.35 (m, 2H), 7.27 – 7.16 (m, 2H), 7.03 (d, J = 8.6 Hz, 1H), 6.99 – 6.80 
(m, 2H), 4.65 (s, 2H), 4.60 – 4.47 (m, 1H), 3.31 (s, 2H), 2.76 (td, J = 6.6, 3.4 Hz, 2H), 2.61 – 
2.20 (m, 9H), 1.24 (d, J = 6.0 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H). 
 
14MEW77 
Was prepared using the same sequence as piperazine erastin using 1-methylpiperazine. 1H NMR 
(300 MHz, CDCl3) δ 8.30 (d, J = 7.1 Hz, 1H), 7.89 – 7.69 (m, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.42 
– 7.33 (m, 1H), 7.26 – 7.20 (m, 3H), 7.01 (d, J = 8.6 Hz, 1H), 6.94 – 6.80 (m, 2H), 4.65 (s, 2H), 
4.53 (p, J = 6.0 Hz, 1H), 3.67 – 3.41 (m, 8H), 3.29 (s, 2H), 2.48 (d, J = 21.6 Hz, 10H), 1.23 (d, J 
= 6.0 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H). 
 
12MEW12 
Was prepared according to the same synthetic sequence as 12MEW10 using anthranillic acid and 
bis(2-methoxyethyl)amine.1H NMR (300 MHz, CDCl3) δ 8.29 (ddd, J = 8.0, 1.5, 0.7 Hz, 1H), 
7.90 – 7.65 (m, 2H), 7.49 (ddd, J = 8.1, 6.6, 1.7 Hz, 1H), 7.37 (dd, J = 8.5, 2.2 Hz, 1H), 7.27 – 
7.17 (m, 3H), 6.99 (d, J = 8.5 Hz, 1H), 6.90 – 6.81 (m, 2H), 4.63 (s, 2H), 4.59 – 4.45 (m, 1H), 
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3.59 – 3.44 (m, 8H), 3.28 (s, 2H), 2.53 (qd, J = 7.1, 1.7 Hz, 5H), 2.46 – 2.19 (m, 4H), 1.21 (d, J 
= 6.0 Hz, 3H), 1.14 (d, J = 6.0 Hz, 3H), 1.03 (t, J = 7.1 Hz, 6H). 
 
Synthesis of 11MEW16 
 
4-bromo-1-isopropoxy-2-nitrobenzene (prepared from general procedure 1 using 4-bromo-1-
hydroxy-2-nitrobenzene) (0.300 g,  1.15 mmol) was combined with 1-methylpiperazine (0.39 
mL, 3.46 mmol, 3.0 eq), sodium tert-butoxide (0.170 g, 1.73 mmol, 1.5 eq), BINAP (40 mg, 
5%), Pd2(dba)3 (50 mg, 5%) in toluene and heated to 80oC for 12 hr. Upon completion the 
reaction was diluted with brine and extracted 3 times with ethylacetate. The combined organic 
layers were dried (Na2SO4), concentrated and purified by combiflash 0->5% MeOH in DCM to 
provide 1-(4-isopropoxy-3-nitrophenyl)-4-methylpiperazine.  
 
11MEW16 
Using provide 1-(4-isopropoxy-3-nitrophenyl)-4-methylpiperazine, 11MEW16 was synthesized 
using general procedures 4-7. 
1H NMR (300 MHz, CDCl3) δ 8.43 – 8.16 (m, 1H), 7.91 – 7.69 (m, 2H), 7.50 (ddd, J = 8.1, 6.6, 
1.8 Hz, 1H), 7.27 – 7.19 (m, 2H), 7.00 (d, J = 1.6 Hz, 2H), 6.94 – 6.75 (m, 3H), 4.65 (d, J = 2.5 
Hz, 2H), 4.38 (p, J = 6.0 Hz, 1H), 3.50 (t, J = 9.2 Hz, 4H), 3.41 – 3.24 (m, 2H), 3.15 (dd, J = 6.2, 















dihydroquinazoline-6-carbaldehyde was synthesized using the same procedures as AE with 2-
amino-5-bromobenzoic acid. 9MEW73 was prepared using the reduction procedure described for 
(2-chloroquinolin-3-yl)methanol with 2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)-
3-(2-isopropoxyphenyl)-4-oxo-3,4-dihydroquinazoline-6-carbaldehyde. 1H NMR (300 MHz, 
CDCl3) δ 8.27 (s, 1H), 8.00 – 7.68 (m, 2H), 7.57 – 7.37 (m, 1H), 7.29 – 7.18 (m, 5H), 7.08 (dd, J 
= 7.6, 4.6 Hz, 2H), 6.97 – 6.79 (m, 2H), 4.85 (s, 2H), 4.64 (s, 2H), 4.61 – 4.50 (m, 1H), 3.51 (s, 
4H), 3.27 (s, 2H), 2.46 (d, J = 20.0 Hz, 2H), 2.22 (d, J = 15.3 Hz, 3H), 1.24 (d, J = 6.0 Hz, 3H), 













































9MEW35 was prepared using the same procedure as the synthesis of 1-(4-isopropoxy-3-
nitrophenyl)-4-methylpiperazine from 4-bromo-1-isopropoxy-2-nitrobenzene. 1H NMR (300 
MHz, CDCl3) δ 7.66 (dd, J = 5.9, 3.0 Hz, 2H), 7.53 – 7.37 (m, 2H), 7.28 – 7.20 (m, 3H), 7.06 
(dtd, J = 7.7, 3.4, 1.2 Hz, 2H), 6.91 – 6.81 (m, 2H), 4.63 (s, 2H), 4.60 – 4.48 (m, 1H), 3.48 – 3.40 
(m, 2H), 3.35 (q, J = 4.5, 3.9 Hz, 4H), 3.23 (s, 2H), 2.67 – 2.58 (m, 4H), 2.46 (t, J = 5.1 Hz, 2H), 
2.38 (s, 3H), 2.29 – 2.09 (m, 2H), 1.23 (d, J = 6.1 Hz, 3H), 1.16 (d, J = 6.0 Hz, 3H). 
 
10MEW53 
10MEW53 was prepared using the same procedure as the synthesis of PE, using 1-
methylpiperazine and 2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)-4-oxo-3,4-dihydroquinazoline-6-carbaldehyde. 1H NMR (300 MHz, 
Acetone-d6) δ 8.19 (d, J = 2.0 Hz, 1H), 7.81 (dd, J = 8.4, 2.0 Hz, 1H), 7.76 – 7.65 (m, 1H), 7.43 
(td, J = 8.0, 1.7 Hz, 1H), 7.27 – 7.18 (m, 3H), 7.11 – 7.00 (m, 2H), 7.00 – 6.78 (m, 2H), 4.63 (d, 
J = 1.5 Hz, 2H), 4.59 – 4.46 (m, 1H), 3.65 (s, 2H), 3.45 (s, 2H), 2.50 (s, 11H), 2.33 – 2.07 (m, 
8H), 1.24 (dd, J = 6.1, 1.6 Hz, 4H), 1.16 (dd, J = 6.0, 1.6 Hz, 3H). 
 
6MEW160 
To a solution of 2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)-6-nitroquinazolin-4(3H)-one (60 mg, 0.1 mmol) in methanol (1 mL) 10% 
palladium on carbon (3 mg) was added. The reaction was then stirred under hydrogen gas (1 
atm) for 12 hr. Upon completion the mixture was filtered over celite, concentrated, and purified 
by combiflash 0-> 5% MeOH in DCM to provide 6MEW160 (55 mg, 98% yield). 1H NMR (300 
MHz, chloroform-d) δ 7.85 p.p.m. (d, J = 2.5 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.47-7.35 (m, 
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2H), 7.29-7.20 (m, 4H), 7.06 (ddt, J = 6.7, 3.6, 1.8, 1.8 Hz, 2H), 7.00 (s, 1H), 6.90-6.79 (m, 2H), 
6.60 (s, 1H), 4.62 (s, 2H), 4.54 (p, J = 6.1, 6.1, 6.1, 6.1 Hz, 1H), 3.44 (tt, J = 7.3, 7.3, 3.0, 3.0 Hz, 
5H), 3.24 (s, 2H), 2.49 (ddd, J = 10.3, 6.4, 3.5 Hz, 1H), 2.40 (dt, J = 10.9, 4.8, 4.8 Hz, 1H), 2.31 - 
2.11 (m, 2H), 1.22 (d, J = 6.0 Hz, 4H), 1.14 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for 
C30H32ClN5O4 562.06, found 562.31. 
 
10MEW78 
10MEW78 was synthesized according to the same procedure as PE from 2-((4-(2-(4-
chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-isopropoxyphenyl)-4-oxo-3,4-
dihydroquinazoline-6-carbaldehyde and morpholine.1H NMR (300 MHz, CDCl3) δ 8.21 (d, J = 
1.9 Hz, 1H), 7.83 (dd, J = 8.4, 2.0 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.54 – 7.40 (m, 1H), 7.27 – 
7.19 (m, 2H), 7.07 (dt, J = 7.3, 3.2 Hz, 2H), 6.93 – 6.78 (m, 2H), 4.63 (s, 2H), 4.57 (p, J = 6.0 
Hz, 1H), 3.74 (t, J = 4.6 Hz, 4H), 3.65 (s, 3H), 3.49 (d, J = 14.6 Hz, 7H), 3.27 (s, 2H), 2.50 (t, J 
= 4.7 Hz, 6H), 2.21 (t, J = 11.5 Hz, 2H), 1.24 (d, J = 6.0 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H). 
 
9MEW90 
9MEW90 was synthesized according to the same procedure as PE from 2-((4-(2-(4-
chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-isopropoxyphenyl)-4-oxo-3,4-
dihydroquinazoline-6-carbaldehyde and diethylamine. 1H NMR (300 MHz, CDCl3) δ 8.20 (s, 
1H), 7.86 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.27 – 7.15 (m, 
3H), 7.08 (dd, J = 7.9, 3.2 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 4.63 (s, 2H), 4.57 (q, J = 6.0 Hz, 
1H), 3.71 (s, 2H), 3.51 (s, 5H), 3.27 (s, 2H), 2.57 (q, J = 7.2 Hz, 4H), 2.46 (d, J = 17.3 Hz, 2H), 





To a solution of 9MEW73 (30 mg, 0.052 mmol) and EDIPA (0.012 mL, 0.0686 mmol, 1.1 eq) in 
DCM (1 mL) at 0oC, phosphorous tribromide (0.017 mL, 0.062 mmol, 1.2 eq) was added. The 
resulting solution was stirred at 6 h at 0oC before being quenched with saturated sodium 
bicarbonate and extracted 3 times with dichloromethane. The combined organic layers were 
dried (Na2SO4), concentrated and purified by preparative TLC 2% MeOH in DCM to provide 6-
(bromomethyl)-2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (10 mg, 30% yield).  
To a solution of 6-(bromomethyl)-2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (20 mg, 0.0313 mmol) in DCM (1 mL) imidazole (21 
mg, 0.313 mmol, 10 eq) was added and stirred for 24 h. The resulting solution was concentrated 
and purified directly by preperative TLC 5% MeOH to provide 11MEW21 (17.2 mg, 88% yield). 
1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 2.1 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.66 – 7.57 (m, 
1H), 7.52 (dd, J = 8.5, 2.1 Hz, 1H), 7.45 (td, J = 8.0, 1.7 Hz, 1H), 7.28 – 7.17 (m, 3H), 7.17 – 
6.99 (m, 3H), 6.95 (q, J = 1.1 Hz, 1H), 6.93 – 6.79 (m, 2H), 4.63 (s, 2H), 4.57 (p, J = 5.9 Hz, 
1H), 3.48 (d, J = 13.6 Hz, 4H), 3.27 (s, 2H), 2.46 (t, J = 13.4 Hz, 2H), 2.22 (t, J = 10.2 Hz, 2H), 



































Analogs off of the 4-position of the aniline ring 
11MEW1 
11MEW1 was synthesized according to the same synthetic sequence as 12MEW10 using 
anthranillic acid and 3-hydroxy-4-nitrobenzaldehyde.1H NMR (300 MHz, CDCl3) δ 8.30 (ddd, J 
= 8.0, 1.5, 0.6 Hz, 1H), 7.86 – 7.69 (m, 2H), 7.50 (ddd, J = 8.2, 6.7, 1.6 Hz, 1H), 7.26 – 7.14 (m, 
3H), 7.12 – 6.97 (m, 2H), 6.96 – 6.82 (m, 2H), 4.63 (s, 2H), 4.58 (dt, J = 12.1, 6.0 Hz, 1H), 3.83 
– 3.64 (m, 4H), 3.55 (s, 6H), 3.28 (s, 2H), 2.68 – 2.37 (m, 7H), 2.35 – 2.25 (m, 1H), 2.20 (t, J = 
4.9 Hz, 1H), 1.25 – 1.20 (m, 3H), 1.15 (d, J = 6.0 Hz, 3H). 
 
10MEW7 
4-fluoro-2-isopropoxy-1-nitrobenzene (synthesized using general procedure 1) (2.0 g, 10 mmol) 
was combined with 1-methylpiperazine (2.2 mL, 20 mmol, 2.0 eq) and EDIPA (1.75 mL, 10.04 
mmol, 1.0 eq) in DMF (30 mL) and heated to 40oC for 12 hr. The resulting solution was diluted 
with saturated sodium bicarbonate and extracted 3 X with EtOAc. The combined organic layers 
were dried (Na2SO4), concentrated and purified by combiflash 0->10% MeOH in DCM to 
provide 1-(3-isopropoxy-4-nitrophenyl)-4-methylpiperazine (3.02 g, quantitative yield). 2-
isopropoxy-4-(4-methylpiperazin-1-yl)aniline was then synthesized from 1-(3-isopropoxy-4-
nitrophenyl)-4-methylpiperazine using general procedure 2. The combined organic layers were 
dried (Na2SO4), concentrated and purified by combiflash 0->10% MeOH in DCM to provide  
10MEW7 was synthesized using the general analog synthetic scheme with 2-isopropoxy-4-(4-
methylpiperazin-1-yl)aniline.1H NMR (300 MHz, CDCl3) δ 8.46 – 8.21 (m, 1H), 7.93 – 7.70 (m, 
2H), 7.49 (ddd, J = 8.1, 6.5, 1.9 Hz, 1H), 7.28 – 7.19 (m, 2H), 7.11 (d, J = 8.5 Hz, 1H), 6.96 – 
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6.77 (m, 2H), 6.73 – 6.47 (m, 2H), 4.65 (s, 2H), 4.50 (p, J = 6.0 Hz, 1H), 3.54 (d, J = 15.5 Hz, 
5H), 3.29 (t, J = 5.6 Hz, 5H), 2.61 (t, J = 5.1 Hz, 4H), 2.53 (d, J = 24.3 Hz, 3H), 2.39 (s, 4H), 
1.60 (s, 3H), 1.23 (d, J = 6.0 Hz, 3H), 1.14 (d, J = 6.0 Hz, 3H). 
 
The synthesis of the remaining analogs are described in Dixon, S. J. et al. Pharmacological 
inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. 
Elife 2014, 1–25 (2014). [106] 
 
10MEW91 
NaH (0.24 g (60% in mineral oil), 6 mmol, 1.2 eq) was added to a solution of 2-
(dimethylamino)ethan-1-ol (0.76 mL, 7.5 mmol, 1.5 eq) at 0oC in THF (15 mL). The mixture 
was stirred for 10 min before the dropwise addition of a solution of 4-fluoro-2-isopropoxy-1-
nitrobenzene (synthesized using general procedure 1) (1 g, 5 mmol) in THF (15 mL). The 
resulting mixture was stirred at 0oC for 1 hr before being warmed to 25oC and stirred for an 
additional 6 hr. Upon completion the reaction was diluted with saturated sodium bicarbonate and 
extracted 3 times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated 
and purified by combiflash 0->10% MeOH in DCM to provide 2-(3-isopropoxy-4-
nitrophenoxy)-N,N-dimethylethan-1-amine (0.5 g, 37% yield). 
1H NMR (300 MHz, CDCl3) δ 8.29 (dd, J = 8.0, 1.4 Hz, 1H), 7.85 – 7.66 (m, 2H), 7.48 (ddd, J = 
8.1, 6.6, 1.7 Hz, 1H), 7.27 – 7.20 (m, 2H), 7.16 (d, J = 8.5 Hz, 1H), 6.97 – 6.82 (m, 2H), 6.75 – 
6.49 (m, 2H), 4.64 (s, 2H), 4.50 (p, J = 6.0 Hz, 1H), 4.21 (t, J = 5.4 Hz, 2H), 3.65 (dq, J = 13.1, 
6.5 Hz, 3H), 3.26 (d, J = 1.6 Hz, 2H), 3.10 (q, J = 7.5 Hz, 2H), 2.93 (t, J = 5.2 Hz, 2H), 2.50 (s, 
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7H), 2.30 (d, J = 15.4 Hz, 2H), 1.50 (d, J = 6.7 Hz, 8H), 1.21 (d, J = 6.0 Hz, 3H), 1.14 (d, J = 6.0 
Hz, 3H). 
 
Quinoline Erastin– 6MEW78 
N-phenylethanamide.  Acetyl chloride (0.916 mL, 12.89 mmol, 1.2 eq) was added slowly to a 
solution of EDIPA (2.25 mL, 12.89 mmol, 1.2 eq) and aniline (0.98 mL, 10.74 mmol) at 0 °C. 
The resulting mixture was stirred for an additional hour at 0 °C then at 25 °C for 4 hours. Upon 
completion, the mixture was quenched with saturated aqueous NaHCO3 and extracted three 
times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, and the 
crude material was purified by combiflash 0-> 20% EtOAc in hexanes to provide N-
phenylethanamide (1.27 g, 88% yield). 
 
2-chloroquinoline-3-carbaldehyde. POCl3 (1.29 mL, 14.1 mmol, 9.5 eq) was added to DMF 
(0.379 mL, 4.89 mmol, 3.3 eq) at 0 °C. The mixture was stirred for an additional 5 min at 0 °C 
before the addition of N-phenylethanamide (200 mg, 1.48 mmol). The mixture was then heated 
to 75 °C and stirred for 12 hours. Upon completion, the reaction was quenched carefully with 
cold water and extracted three times with Et2O. The combined organic layers were dried 
(MgSO4), concentrated, and the crude material was purified by combiflash 0->30% EtOAc in 
hexanes to provide 2-chloroquinoline-3-carbaldehyde (139 mg, 49% yield). 
 
(2-chloroquinolin-3-yl)methanol. NaBH4 (0.849 g, 22.44 mmol, 2.0 eq) was added to a solution 
of 2-chloroquinoline-3-carbaldehyde (2.15 g, 11.22 mmol) in DCM:MeOH (2:1, 120 mL) at 0° C 
and stirred for 1 hour. Upon completion, the reaction was quenched with saturated aqueous 
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NH4Cl and extracted three times with dichloromethane. The combined organic layers were dried 
(Na2SO4), concentrated, and the crude material was purified by combiflash 0->50% EtOAc in 
hexanes to provide (2-chloroquinolin-3-yl)methanol (2.1 g, 97%).  
 
3-((tert-butyldimethylsilyloxy)methyl)-2-chloroquinoline was prepared according to the 
general TBS protection procedure (1.2 g, 29%) 
 
3-((tert-butyldimethylsilyloxy)methyl)-2-(2-isopropoxyphenyl)quinoline (Suzuki coupling 
procedure). Pd(PPh3)4 (187 mg, 0.162 mmol, 10%) was added to a solution of 3-((tert-
butyldimethylsilyloxy)methyl)-2-chloroquinoline (0.5 g, 1.62 mmol) in dioxane (10 mL) and 
stirred for 10 min at 25° C. To the resulting mixture, a solution of 2-isopropoxyphenylboronic 
acid (0.438 g, 2.43 mmol, 1.5 eq) in EtOH (4 mL) was added and the resulting mixture was 
stirred at 25 °C for 10 min before the addition of a 2 M aqueous solution of sodium carbonate 
(8.1 mL, 16.2 mmol, 10 eq). The resulting mixture was stirred at 25 °C for an additional 5 min, 
then heated to 80 °C for 24 hours. Upon completion, the mixture was diluted with water and 
extracted three times with EtOAc. The combined organic layers were dried (Na2SO4), 
concentrated, and the crude material was purified by combiflash 0->20% EtOAc in hexanes to 
provide 3-((tert-butyldimethylsilyloxy)methyl)-2-(2-isopropoxyphenyl)quinoline (0.57 g, 86% 
yield) 
 
(2-(2-isopropoxyphenyl)quinolin-3-yl)methanol. TBAF (1 M, 0.67 mL, 0.67 mmol, 1.1 eq) 
was added to a solution of (2-(2-isopropoxyphenyl)quinolin-3-yl)methanol in THF (6 mL) at 0 
°C. The resulting mixture was stirred at 0 °C for 1 hour. Upon completion, saturated aqueous 
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NH4Cl was added and extracted 3 times with EtOAc. The combined organic layers were dried 
(Na2SO4), concentrated, and the crude material was purified by combiflash 0->40% EtOAc in 
hexanes to provide (2-(2-isopropoxyphenyl)quinolin-3-yl)methanol (135 mg, 75%). 
 
3-(bromomethyl)-2-(2-isopropoxyphenyl)quinolone. PBr3 (0.130 mL, 1.38 mmol, 3 eq) was 
added to a solution of (2-(2-isopropoxyphenyl)quinolin-3-yl)methanol (135 mg, 0.45 mmol) in 
DCM (5 mL) at 0 °C. The resulting mixture was stirred at 0 °C for an additional 30 min, then at 
25 °C for 2 hr. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 
and extracted 3 times with EtOAc. The combined organic layers were dried (Na2SO4), 
concentrated, and the crude material was purified by combiflash 0-20% EtOAc in hexanes to 
provide 3-(bromomethyl)-2-(2-isopropoxyphenyl)quinoline (57 mg, 35%). 
 
2-(2-isopropoxyphenyl)-3-(piperazin-1-ylmethyl)quinoline (amine addition procedure). To a 
solution of 3-(bromomethyl)-2-(2-isopropoxyphenyl)quinoline (57 mg, 0.160 mmol) in THF, 2 
mL at 0 °C, piperzine (138 mg, 1.6 mmol, 10 eq) was added and stirred for 12 hours. The 
reaction mixture was then concentrated and purified directly by combiflash 0-20% MeOH in 
DCM to afford 2-(2-isopropoxyphenyl)-3-(piperazin-1-ylmethyl)quinoline (51 mg, 88% yield). 
 
6MEW78 - 2-(2-isopropoxyphenyl)-3-(piperazin-1-ylmethyl)quinoline (acyl chloride addition 
procedure). To a solution of 2-(2-isopropoxyphenyl)-3-(piperazin-1-ylmethyl)quinoline (51 mg, 
0.141 mmol), EDIPA (30 uL, 0.169 mmol, 1.2 eq) and 4-DMAP (3 mg, 0.0282 mmol, 0.2 eq) in 
DCM (2 mL) at 0 °C, a solution of 4-chlorophenoxy acetyl chloride (32 mg, 0.155 mmol, 1.1 eq) 
in DCM (1 mL) was added dropwise. The reaction slowly warmed to 25 °C and was stirred for 4 
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hours. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 and 
extracted three times with DCM. The combined organic layers were dried (Na2SO4), 
concentrated, and the crude material was purified by preparative TLC 5% MeOH in DCM (34 
mg, 45% yield) 1H NMR (300 MHz, chloroform-d) δ 8.29 p.p.m. (s, 1H), 8.23-8.04 (m, 1H), 
7.88 (dd, J = 8.0, 1.5 Hz, 1H), 7.71 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.57 (ddd, J = 8.1, 6.9, 1.2 Hz, 
1H), 7.47-7.31 (m, 2H), 7.27-7.19 (m, 2H), 7.09 (td, J = 7.5, 7.4, 1.0 Hz, 1H), 6.99 (d, J = 8.3 
Hz, 1H), 6.91 ? 6.82 (m, 2H), 4.64 (s, 2H), 4.43 (p, J = 6.0, 6.0, 6.0, 6.0 Hz, 1H), 3.85-3.37 (m, 
6H), 2.34 (m, 4H), 1.22 (d, J = 6.0 Hz, 3H), 1.03 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for 
C31H32ClN3O3 530.06, found 530.22. 
 
Synthesis of indole erastin 
7MEW81 - 2-((tert-butyldimethylsilyloxy)methyl)-1H-indole (TBS protection procedure).  
TBS-Cl (1.66 g, 11.04 mmol, 1.2 eq) was added to a solution of (1H-indol-2-yl)methanol (1.335 
g, 9.2 mmol) and EDIPA (2.4 mL, 13.8 mmol, 1.5 eq) in DMF (30 mL) at 25 °C. The mixture 
was stirred for an additional 5 hours at 25 °C. Upon completion, the reaction contents were 
diluted with water and extracted three times with Et2O. The combined organic layers were dried 
(MgSO4), concentrated, and the crude material was purified by combiflash 0-20% EtOAc in 
hexanes to provide 2-((tert-butyldimethylsilyloxy)methyl)-1H-indole (2.04 g, 85%) 
 
3-bromo-2-((tert-butyldimethylsilyloxy)methyl)-1H-indole.  NBS (0.34 g, 1.91 mmol) was 
added to a stirred solution of 2-((tert-butyldimethylsilyloxy)methyl)-1H-indole (0.5 g, 1.91 
mmol) in DMF at 0 °C. The mixture was stirred an additional 1 hour at 0 °C. Upon completion, 
the reaction contents were diluted with water and extracted 3 times with Et2O. The combined 
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organic layers were dried (MgSO4), concentrated, and the crude material was purified by 
combiflash 0->10% EtOAc in hexanes to provide 3-bromo-2-((tert-
butyldimethylsilyloxy)methyl)-1H-indole (0.514 g, 79%) 
 
Tert-butyl 3-bromo-2-((tert-butyldimethylsilyloxy)methyl)-1H-indole-1-carboxylate. Di-
tert-butyl dicarbonate (2.08 g, 9.52 mmol,1.8 eq) and 4-DMAP (0.129 g, 1.06 mmol, 0.2 eq) 
were added sequentially to a stirred solution of 3-bromo-2-((tert-butyldimethylsilyloxy)methyl)-
1H-indole (1.8 g, 5.29 mmol) in DCM (20 mL) at 25 °C. The mixture was stirred for an 
additional 12 hours. Upon completion, the reaction contents were diluted with DCM, poured into 
water, and extracted 2 times with DCM. The crude material was pushed forward to the next step 




carboxylate was prepared according to general Suzuki coupling procedure  (0.883 g, 79%). 
 
Tert-butyl 2-(hydroxymethyl)-3-(2-isopropoxyphenyl)-1H-indole-1-carboxylate. Hydrogen 
fluoride pyridine (0.66 mL, 70% as HF, 30% as py) was added to a solution of tert-butyl 2-((tert-
butyldimethylsilyloxy)methyl)-3-(2-isopropoxyphenyl)-1H-indole-1-carboxylate (0.3 g, 1.01 
mmol) in THF:pyridine (5:1, 10 mL) at 0 °C.  The resulting mixture was then brought to room 
temperature and stirred for an additional 6 hours. Upon completion, the reaction was quenched 
with saturated NH4Cl and extracted three times with EtOAc. The combined organic layers were 
dried (Na2SO4), concentrated, and the crude material was purified by combiflash 0-30% EtOAc 
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in hexanes to provide tert-butyl 2-(hydroxymethyl)-3-(2-isopropoxyphenyl)-1H-indole-1-
carboxylate (0.279 g, 73%).  
 
Tert-butyl 2-formyl-3-(2-isopropoxyphenyl)-1H-indole-1-carboxylate.  Dess-Martin 
periodinane (230 mg, 0.543 mmol, 1.8 eq) was added to a stirred suspension of sodium 
bicarbonate (242 mg, 2.88 mmol, 10.0 eq) and tert-butyl 2-(hydroxymethyl)-3-(2-
isopropoxyphenyl)-1H-indole-1-carboxylate (110 mg, 0.288 mmol) in DCM (3 mL). The 
mixture was stirred at 25 °C for 2 hours, and upon completion, a saturated aqueous solution of 
sodium sulfite (1 mL) was added and the mixture was stirred for an additional 5 min. This was 
followed subsequently by the addition of water and extraction with DCM three times. The 
combined organic layers were dried (Na2SO4), concentrated, and the crude material was purified 
by combiflash 0-40% EtOAc in hexanes to give tert-butyl 2-formyl-3-(2-isopropoxyphenyl)-1H-
indole-1-carboxylate (quantitative yield). 
 
Tert-butyl 3-(2-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)-1H-indole-1-carboxylate.  A 
solution of tert-butyl 2-formyl-3-(2-isopropoxyphenyl)-1H-indole-1-carboxylate (0.140 g, 0.369 
mmol) in DCM (1.5 mL)was added to a stirred solution of piperazine (0.318 g, 3.69 mmol, 10 
eq) in MeOH (1.5 mL) at 25 °C. After an additional 15 min of stirring a solution of ZnCl2 (10 
mg, 0.0738 mmol, 0.2 eq) and sodium cyanoborohydride (70 mg, 1.11 mmol, 3.0 eq) in MeOH 
(1.5 eq) was added. The resulting mixture was heated to 40 °C and stirred for 6 hours. Upon 
completion, the reaction was diluted with water and extracted three times with EtOAc. The 
combined organic layers were dried (Na2SO4), concentrated, and the crude material was purified 
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by combiflash 0->20% MeOH in DCM to provide tert-butyl 3-(2-isopropoxyphenyl)-2-
(piperazin-1-ylmethyl)-1H-indole-1-carboxylate (73 mg, 44% yield). 
 
Tert-butyl 2-((4-(2-(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)-1H-indole-1-carboxylate was prepared according to the general acyl 
chloride addition procedure (89 mg, 90%). 
 
7MEW81- 2-(4-chlorophenoxy)-1-(4-((3-(2-isopropoxyphenyl)-1H-indol-2-
yl)methyl)piperazin-1-yl)ethanone.  TFA (1 mL) was added to a solution of tert-butyl 2-((4-(2-
(4-chlorophenoxy)ethanoyl)piperazin-1-yl)methyl)-3-(2-isopropoxyphenyl)-1H-indole-1-
carboxylate (85 mg, 0.138 mmol) in DCM (1 mL) and the resulting solution was stirred at 25 °C 
for 24 hours. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 and 
extracted three times with EtOAc. The combined organic layers were dried (Na2SO4), 
concentrated, and the crude material was purified by combiflash 0->5% MeOH in DCM to 
provide 2-(4-chlorophenoxy)-1-(4-((3-(2-isopropoxyphenyl)-1H-indol-2-yl)methyl)piperazin-1-
yl)ethanone (50 mg, 70% yield). 1H NMR (300 MHz, chloroform-d) δ 8.61 p.p.m. (s, 1H), 7.52 
(d, J = 7.9 Hz, 1H), 7.40 (ddd, J = 7.3, 5.8, 1.5 Hz, 2H), 7.39-7.27 (m, 1H), 7.30-7.15 (m, 3H), 
7.17-6.99 (m, 3H), 6.94-6.81 (m, 2H), 4.66 (s, 2H), 4.35 (p, J = 6.1, 6.1, 6.1, 6.1 Hz, 1H), 3.93-
3.40 (m, 7H), 2.43 (d, J = 9.7 Hz, 4H), 1.24-1.00 (m, 6H). HRMS (m/z): [M+] cald for 





one.  To a solution of a solution of 3-(2-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-
4(3H)-one (200 mg, 0.53 mmol) and EDIPA (82 uL, 0.635 mmol, 1.2 eq) in DCM (5 mL) at 0 
°C, a solution of chloroacetyl chloride (50 uL, 0.635 mmol, 1.2 eq) was added and the resulting 
mixture was stirred at 25 °C for 4 hours. Upon completion, the reaction was quenched with 
saturated aqueous NaHCO3 and extracted three times with DCM. The combined organic layers 
were dried (Na2SO4), concentrated, and the crude material was purified by combiflash 0->5% 
MeOH in DCM to provide 2-((4-(2-chloroethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (210 mg, 73% yield) 
 
35MEW22 -  2-((4-(2-(4-chlorophenylamino)ethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one.  4-chloroaniline (29 mg, 0.230 mmol, 5.0 eq) was 
added to a solution of 2-((4-(2-chloroethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (21 mg, 0.0462 mmol) in DMF (0.5 mL) and the 
resulting mixture was stirred at 60 °C for 12 hours. Upon completion, the mixture was diluted 
with water and extracted three times with diethyl ether. The combined organic layers were dried 
(MgSO4), concentrated, and the crude material was purified by preparative TLC 5% MeOH in 
DCM to provide 2-((4-(2-(4-chlorophenylamino)ethanoyl)piperazin-1-yl)methyl)-3-(2-
isopropoxyphenyl)quinazolin-4(3H)-one (8 mg, 32% yield). 1H NMR (400 MHz, Chloroform-d) 
δ 8.32 p.p.m. (dq, J = 8.0, 1.6, 1.6, 1.5 Hz, 1H), 7.87-7.71 (m, 2H), 7.64-7.39 (m, 2H), 7.31 (s, 
1H), 7.19-6.96 (m, 5H), 6.56-6.46 (m, 2H), 4.91 (d, J = 6.0 Hz, 1H), 4.57 (dtd, J = 8.1, 6.3, 5.8, 
4.2 Hz, 1H), 3.80 (dt, J = 3.9, 1.8, 1.8 Hz, 2H), 3.58 (d, J = 5.6 Hz, 2H), 3.41-3.26 (m, 4H), 2.66- 
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2.43 (m, 2H), 2.28 (dt, J = 16.2, 7.1, 7.1 Hz, 2H), 1.26 (dt, J = 6.1, 1.8, 1.8 Hz, 4H), 1.17 (dt, J = 




was prepared according to the general amine addition procedure using N,N-dimethylethylene 
diamine in place of piperazine (27 mg, 56% yield). 
 
35MEW26 was prepared from 3-(2-isopropoxyphenyl)-2-
((methyl(2(methylamino)ethyl)amino)methyl)quinazolin-4(3H)-one (20 mg, 22% yield). 1H 
NMR (400 MHz, chloroform-d) δ 8.36-8.26 p.p.m. (m, 1H), 7.81-7.70 (m, 2H), 7.54-7.39 (m, 
2H), 7.27-7.16 (m, 3H), 7.09 (td, J = 7.9, 7.4, 4.1 Hz, 2H), 6.92-6.80 (m, 2H), 4.73 (s, 1H), 4.61 
(s, 1H), 4.57 (ddt, J = 9.2, 6.1, 3.1, 3.1 Hz, 1H), 3.49-3.30 (m, 4H), 3.01 (s, 1H), 2.90 (s, 2H), 
2.82-2.44 (m, 2H), 2.29 (d, J = 15.6 Hz, 3H), 1.25 (d, J = 3.7 Hz, 3H), 1.16 (dd, J = 6.3, 1.3 Hz, 
3H). HRMS (m/z): [M+] cald for C30H33ClN4O4 549.04, found 549.22 
 
3-(2-isopropoxyphenyl)-2-((methylamino)methyl)quinazolin-4(3H)-one.  
A 33% (wt) solution (EtOH) of methyl amine (0.15 mL) was added to a solution of 2-
(chloromethyl)-3-(2-isopropoxyphenyl)quinazolin-4(3H)-one (80 mg, 0.243 mmol) in THF (3 
mL) and the resulting mixture was stirred at 25 °C for 12 hr. Upon completion, the mixture was 
diluted with water and extracted 3 times with EtOAc. The combined organic layers were dried 
(Na2SO4), concentrated, and the crude material was purified by combi flash 0->10% MeOH in 
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DCM to provide 3-(2-isopropoxyphenyl)-2-((methylamino)methyl)quinazolin-4(3H)-one (43 
mg, 55% yield). 
 
35MEW27 was prepared from 3-(2-isopropoxyphenyl)-2-((methylamino)methyl)quinazolin-
4(3H)-one using general acyl chloride addition procedure (71 mg, 72% yield) Mixture of 
atropisomers 1H NMR (400 MHz, chloroform-d) δ 8.31 p.p.m. (d, J = 7.9 Hz, 2H), 7.80 (dddd, J 
= 12.6, 8.5, 7.2, 1.5 Hz, 2H), 7.64 (dd, J = 8.3, 1.1 Hz, 1H), 7.59-7.41 (m, 5H), 7.25 (dd, J = 8.2, 
6.1 Hz, 3H), 7.20-7.07 (m, 6H), 7.00-6.94 (m, 2H), 6.86-6.75 (m, 2H), 4.82 (s, 2H), 4.60 (d, J = 
7.6 Hz, 5H), 4.25 (s, 2H), 3.98 (d, J = 17.0 Hz, 1H), 3.22 (s, 3H), 3.06 (s, 3H), 1.30 (dd, J = 18.1, 
6.1 Hz, 7H), 1.18 (dd, J = 16.3, 6.0 Hz, 6H). HRMS (m/z): [M+] cald for C27H26ClN3O4 
491.97, found 492.13. 
 
35MEW14.  To a solution of 3-(2-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-
4(3H)-one (30 mg, 0.079 mmol) and potassium carbonate (13 mg, 0.094 mmol, 1.2 eq) in DMF 
(1 mL), 4-chlorophenyl 2-bromoethyl ether (28 mg, 0.118 mmol, 1.5 eq) was added. The 
resulting mixture was stirred at 60 °C for 24 hours. Upon completion, the mixture was diluted 
with saturated aqueous NaHCO3 and extracted three times with EtOAc. The combined organic 
layers were dried (Na2SO4), concentrated, and the crude material was purified preparative TLC, 
10% MeOH in DCM to provide 35MEW14 (11.8 mg, 28% yield). 1H NMR (400 MHz, 
chloroform-d) δ 8.32 p.p.m. (dd, J = 7.9, 1.1 Hz, 1H), 7.88-7.75 (m, 2H), 7.50 (dt, J = 8.1, 4.1, 
4.1 Hz, 1H), 7.43 (td, J = 8.1, 7.9, 1.7 Hz, 1H), 7.31 (dd, J = 7.7, 1.7 Hz, 1H), 7.27-7.20 (m, 2H), 
7.12-7.00 (m, 2H), 6.90-6.76 (m, 2H), 4.56 (p, J = 6.0, 6.0, 6.0, 6.0 Hz, 1H), 4.06 (t, J = 5.8, 5.8 
Hz, 2H), 3.26 (d, J = 1.4 Hz, 2H), 2.78 (t, J = 5.8, 5.8 Hz, 2H), 2.51 (s, 6H), 2.35-2.22 (m, 2H), 
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1.25 (d, J = 6.0 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for C30H33ClN4O3 
533.06, found 533.23. 
 
35MEW38 (amine coupling procedure).  HBTU (147 mg, 0.38 mmol, 1.5 eq) was added to a 
solution of 3-chlorophenoxy acetic acid (69 mg, 0.336 mmol, 1.3 eq) and EDIPA (67 uL, 0.38 
mmol, 1.5 eq) in DCM (3 mL) and stirred for 30 min at 25 °C. A solution of 3-(2-
isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one (100 mg, 0.258 mmol) in 
DCM (1 mL) was added and stirred for an additional 4 hours. Upon completion, the reaction was 
quenched with saturated aqueous NaHCO3 and extracted three times with DCM. The combined 
organic layers were dried (Na2SO4), concentrated, and the crude material was purified by combi 
flash 0->5% MeOH in DCM to provide 35MEW38 (120 mg, 85% yield). 1H NMR (400 MHz, 
chloroform-d) δ 8.38-8.27 p.p.m. (m, 1H), 7.87-7.68 (m, 2H), 7.51 (ddd, J = 8.2, 6.6, 1.7 Hz, 
1H), 7.43 (ddd, J = 8.3, 7.5, 1.7 Hz, 1H), 7.33-7.26 (m, 1H), 7.21 (t, J = 8.1, 8.1 Hz, 1H), 7.12-
7.04 (m, 2H), 6.97 (ddd, J = 8.0, 1.9, 0.9 Hz, 1H), 6.92 (t, J = 2.2, 2.2 Hz, 1H), 6.83 (ddd, J = 8.5, 
2.5, 0.9 Hz, 1H), 4.64 (s, 2H), 4.56 (p, J = 6.1, 6.1, 6.0, 6.0 Hz, 1H), 3.68-3.36 (m, 4H), 3.29 (s, 
2H), 2.49 (dddd, J = 26.4, 11.1, 6.1, 3.2 Hz, 2H), 2.32-2.12 (m, 2H), 1.24 (d, J = 6.1 Hz, 3H), 
1.16 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for C36H35ClN4O4 547.04, found 547.21 
 
35MEW39.  Prepared using the general amine coupling procedure from 3-(2-
isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one, (132 mg, 96% yield). 1H 
NMR (400 MHz, chloroform-d) δ 8.36-8.25 p.p.m. (m, 1H), 7.83 ? 7.72 (m, 2H), 7.50 (ddd, J = 
8.1, 6.8, 1.5 Hz, 1H), 7.47-7.38 (m, 1H), 7.29-7.22 (m, 1H), 7.11-7.02 (m, 2H), 7.01-6.91 (m, 
2H), 6.91-6.80 (m, 2H), 4.62 (s, 2H), 4.56 (p, J = 6.1, 6.1, 6.1, 6.1 Hz, 1H), 3.58 -3.39 (m, 5H), 
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3.27 (s, 2H), 2.47 (dddd, J = 29.4, 10.8, 6.2, 3.5 Hz, 2H), 2.35-2.13 (m, 2H), 1.23 (d, J = 6.0 Hz, 
3H), 1.15 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for C30H31FN4O4 530.59, found 531.24 
 
35MEW13.  Prepared using the general amine coupling procedure from 3-(2-
isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one (18 mg, 44% yield). 1H NMR 
(400 MHz, chloroform-d) δ 8.32 p.p.m. (ddd, J = 8.0, 1.4, 0.7 Hz, 1H), 7.84-7.74 (m, 2H), 7.52 
(ddd, J = 8.2, 6.7, 1.7 Hz, 1H), 7.44 (ddd, J = 8.4, 7.5, 1.7 Hz, 1H), 7.31 (dd, J = 7.1, 1.9 Hz, 
2H), 7.29-7.27 (m, 1H), 7.12-7.06 (m, 2H), 7.00 (td, J = 7.3, 7.3, 1.1 Hz, 1H), 6.97-6.87 (m, 2H), 
4.66 (s, 2H), 4.57 (p, J = 6.1, 6.1, 6.1, 6.1 Hz, 1H), 3.52 (ddt, J = 10.6, 7.6, 3.2, 3.2 Hz, 4H), 3.28 
(s, 2H), 2.56-2.40 (m, 2H), 2.32-2.15 (m, 2H), 1.25 (d, J = 6.1 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H). 
HRMS (m/z): [M+] cald for C30H32N4O4 512.6, found 513.25 
 
15MEW81.  Prepared using the general amine coupling procedure 3-(2-isopropoxyphenyl)-2-
(piperazin-1-ylmethyl)quinazolin-4(3H)-one (226 mg, 58% yield).1H NMR (400 MHz, 
chloroform-d) δ 8.36-8.30 p.p.m. (m, 1H), 7.86-7.74 (m, 2H), 7.52 (ddd, J = 8.2, 6.5, 1.8 Hz, 
1H), 7.47-7.38 (m, 1H), 7.29-7.22 (m, 3H), 7.18-7.11 (m, 2H), 7.11-6.98 (m, 2H), 4.57 (p, J = 
6.0 Hz, 1H), 3.52 (dt, J = 9.7, 4.6 Hz, 2H), 3.28 (s, 4H), 2.98-2.89 (m, 2H), 2.56 (t, J = 7.7 Hz, 
2H), 2.41 (t, J = 5.7 Hz, 2H), 2.25 -2.10 (m, 2H), 1.25 (d, J = 6.0 Hz, 3H), 1.17 (d, J = 6.0 Hz, 
3H). HRMS (m/z): [M+] cald for C31H33ClN4O3 545.07, found 545.23. 
 
35MEW28.  Prepared using general Suzuki coupling procedure from 21MEW26 (30 mg, 77% 
yield). 1H NMR (400 MHz, chloroform-d) δ 8.38-8.32 p.p.m. (m, 1H), 7.85-7.76 (m, 2H), 7.74-
7.67 (m, 2H), 7.60-7.53 (m, 4H), 7.53-7.47 (m, 2H), 7.44 (t, J = 7.6, 7.6 Hz, 2H), 7.36 (d, J = 7.1 
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Hz, 1H), 7.26-7.20 (m, 2H), 7.15 (d, J = 8.6 Hz, 1H), 6.87-6.78 (m, 2H), 4.68-4.62 (m, 1H), 4.60 
(s, 2H), 3.63-3.23 (m, 7H), 2.49 (ddt, J = 14.5, 10.6, 4.8, 4.8 Hz, 2H), 2.23 (ddd, J = 18.4, 11.4, 
5.5 Hz, 2H), 1.28 (d, J = 6.0 Hz, 3H), 1.21 (d, J = 6.1 Hz, 3H). HRMS (m/z): [M+] cald for 
C36H35ClN4O4 623.14, found 623.24. 
 
35MEW29.  Prepared using general Suzuki coupling procedure from 21MEW26 (65 mg, 54%). 
1H NMR (300 MHz, chloroform-d) δ 8.33 p.p.m. (ddd, J = 8.0, 1.5, 0.7 Hz, 1H), 7.85-7.72 (m, 
2H), 7.68 (dd, J = 1.5, 0.9 Hz, 1H), 7.57-7.48 (m, 2H), 7.47 (t, J = 1.7, 1.7 Hz, 1H), 7.42 (d, J = 
2.2 Hz, 1H), 7.27-7.20 (m, 2H), 7.08 (d, J = 8.6 Hz, 1H), 6.95-6.76 (m, 2H), 6.63 (dd, J = 1.9, 
0.9 Hz, 1H), 4.61 (s, 2H), 4.56 (q, J = 6.1, 6.1, 6.1 Hz, 1H), 3.51 -3.35 (m, 4H), 3.29 (d, J = 2.2 
Hz, 2H), 2.48 (dt, J = 11.0, 5.1, 5.1 Hz, 2H), 2.20 (tt, J = 10.8, 10.8, 5.1, 5.1 Hz, 2H), 1.25 (d, J = 
6.0 Hz, 3H), 1.18 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for C34H33ClN4O5 613.1, found 
613.22. 
 
14MEW31.  Prepared from 5-chloro-3-(2-isopropoxyphenyl)-2-(piperazin-1-
ylmethyl)quinazolin-4(3H)-one using general acyl chloride addition procedure (122 mg, 87% 
yield).1H NMR (300 MHz, chloroform-d) δ 7.70-7.59 p.p.m. (m, 2H), 7.50 (dd, J = 5.5, 3.6 Hz, 
1H), 7.47-7.39 (m, 1H), 7.28-7.23 (m, 2H), 7.13-7.03 (m, 2H), 6.92-6.82 (m, 2H), 4.64 (s, 2H), 
4.57 (p, J = 6.1, 6.1, 6.1, 6.1 Hz, 1H), 3.51 (d, J = 14.4 Hz, 4H), 3.25 (s, 2H), 2.48 (s, 2H), 2.25 
(s, 2H), 1.26 (d, J = 6.0 Hz, 3H), 1.19 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for 
C30H30Cl2N4O4 581.49, found 581.17 
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14MEW32.  Prepared from 8-chloro-3-(2-isopropoxyphenyl)-2-(piperazin-1-
ylmethyl)quinazolin-4(3H)-one using general acyl chloride addition procedure (77 mg, 55% 
yield). 1H NMR (300 MHz, chloroform-d) δ 8.23 p.p.m. (dd, J = 8.0, 1.5 Hz, 1H), 7.87 (dd, J = 
7.8, 1.5 Hz, 1H), 7.52-7.38 (m, 2H), 7.28-7.21 (m, 4H), 7.13-7.01 (m, 2H), 6.93-6.81 (m, 2H), 
4.66 (s, 2H), 4.64-4.47 (m, 1H), 3.54 (s, 4H), 3.33 (d, J = 3.0 Hz, 2H), 2.64 (s, 1H), 2.54 (s, 1H), 
2.44 (s, 1H), 2.33 (s, 1H), 1.26 (d, J = 6.1 Hz, 3H), 1.18 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] 
cald for C30H30Cl2N4O4 581.49, found 581.17 
 
13MEW16.  Prepared from 3-(3-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-
one using general acyl chloride addition procedure (100 mg, 54%). 1H NMR (400 MHz, 
chloroform-d) δ 8.37-8.27 p.p.m. (m, 1H), 7.82 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.76 (d, J = 8.4 
Hz, 1H), 7.54 (ddd, J = 8.2, 7.0, 1.4 Hz, 1H), 7.43 (t, J = 8.0, 8.0 Hz, 1H), 7.28- 7.18 (m, 2H), 
7.10-6.94 (m, 1H), 6.88 (dd, J = 9.3, 2.1 Hz, 4H), 4.65 (s, 2H), 4.58 (p, J = 6.1, 6.1, 6.0, 6.0 Hz, 
1H), 3.53 (dt, J = 22.0, 5.0, 5.0 Hz, 4H), 3.32 (s, 2H), 2.40 (ddt, J = 27.6, 9.7, 5.0, 5.0 Hz, 4H), 
1.38 (dd, J = 6.3, 1.5 Hz, 6H). HRMS (m/z): [M+] cald for C30H31ClN4O4 547.04, found 
547.21. 
 
13MEW76.  Prepared from 3-(2-isopropoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-
one using general acyl chloride addition procedure (270 mg, 62% yield). 1H NMR (300 MHz, 
chloroform-d) δ 8.32 p.p.m. (dd, J = 8.0, 1.4 Hz, 1H), 7.87-7.71 (m, 2H), 7.57-7.40 (m, 2H), 
7.28-7.21 (m, 3H), 7.13-7.00 (m, 2H), 6.91-6.84 (m, 2H), 4.64 (s, 2H), 4.61-4.48 (m, 1H), 3.50 
(s, 4H), 3.28 (s, 2H), 2.44 (s, 2H), 2.23 (s, 2H), 1.24 (d, J = 6.0 Hz, 3H), 1.16 (d, J = 6.0 Hz, 3H). 
HRMS (m/z): [M+] cald for C30H31ClN4O4 547.04, found 547.21. 
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21MEW26.  Prepared from 3-(5-bromo-2-isopropoxyphenyl)-2-(piperazin-1-
ylmethyl)quinazolin-4(3H)-one (1.87 g, 70% yield). 1H NMR (400 MHz, chloroform-d) δ 8.36-
8.26 p.p.m. (m, 1H), 7.81-7.70 (m, 2H), 7.54-7.39 (m, 2H), 7.27-7.16 (m, 3H), 7.09 (td, J = 7.9, 
7.4, 4.1 Hz, 2H), 6.92-6.80 (m, 2H), 4.73 (s, 1H), 4.61 (s, 1H), 4.57 (ddt, J = 9.2, 6.1, 3.1, 3.1 
Hz, 1H), 3.49-3.30 (m, 4H), 3.01 (s, 1H), 2.90 (s, 2H), 2.82-2.44 (m, 2H), 2.29 (d, J = 15.6 Hz, 
3H), 1.25 (d, J = 3.7 Hz, 3H), 1.16 (dd, J = 6.3, 1.3 Hz, 3H). HRMS (m/z): [M+] cald for 
C30H33ClN4O4 549.04, found 549.22 
 
 
10MEW79.  Prepared from 6-fluoro-3-(2-isopropoxyphenyl)-2-(piperazin-1-
ylmethyl)quinazolin-4(3H)-one using general acyl chloride addition procedure (0.296 mg, 69% 
yield). 1H NMR (400 MHz, chloroform-d) δ 7.95 p.p.m. (dd, J = 8.4, 3.0 Hz, 1H), 7.76 (dd, J = 
9.0, 4.8 Hz, 1H), 7.52 (td, J = 8.6, 8.5, 2.8 Hz, 1H), 7.48-7.41 (m, 1H), 7.28-7.17 (m, 3H), 7.16-
7.02 (m, 2H), 6.91-6.81 (m, 2H), 4.64 (s, 2H), 4.57 (p, J = 6.1, 6.1, 6.0, 6.0 Hz, 1H), 3.61-3.39 
(m, 4H), 3.27 (s, 2H), 2.46 (dq, J = 22.1, 7.0, 7.0, 4.7 Hz, 2H), 2.24 (ddt, J = 30.1, 10.7, 4.3, 4.3 
Hz, 2H), 1.25 (d, J = 6.1 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for 
C30H30ClFN4O4 565.04, found 565.2. 
 
8MEW98.  Prepared from 3-(2-isopropoxyphenyl)-6,7-dimethoxy-2-(piperazin-1-
ylmethyl)quinazolin-4(3H)-one using the general acyl chloride addition procedure (54 mg, 53% 
yield). 1H NMR (300 MHz, chloroform-d) δ  7.64 p.p.m. (s, 1H), 7.50 - 7.39 (m, 1H), 7.28 - 7.16 
(m, 5H), 7.13-7.02 (m, 2H), 6.92 - 6.82 (m, 2H), 4.64 (s, 2H), 4.57 (q, J = 6.1, 6.1, 6.0 Hz, 1H), 
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4.03 (d, J = 9.2 Hz, 5H), 3.50 (d, J = 17.6 Hz, 4H), 3.24 (d, J = 1.8 Hz, 2H), 2.46 (s, 2H), 2.20 (s, 
2H), 1.24 (d, J = 6.1 Hz, 3H), 1.17 (d, J = 6.0 Hz, 3H). HRMS (m/z): [M+] cald for 
C32H35ClN4O6 607.1, found 607.23. 
 
Methods for analog synthesis and testing are described in: Cantley, A. M. et al. Small molecule 
that reverses dexamethasone resistance in t-cell acute lymphoblastic leukemia (T-ALL). ACS 
Med. Chem. Lett. 5, 754–759 (2014). 
 
 1-cyclopropyl-2-(pyridin-4-yl)ethanone  
To a solution of 4-picoline (1.57 mL, 16.1 mmol) in THF at 0° C LDA (2 M, 8.86 mL, 17.7  
mmol, 1.1 mol equiv) was added dropwise over 5 minutes. After 1 h a solution of ethyl  
cyclopropyl carboxylate (2.49 mL, 20.9 mmol, 1.3 mol equiv) was added and stirred at 0 °C for 
30 min before being warmed to 25 °C and stirred for an additional 6 h. Upon completion, the 
reaction was quenched with water and the product was extracted with EtOAc (3 X). The 
combined organic layers were dried (sodium sulfate), concentrated, and the crude material was 
purified by combiflash 0-> 80% EtOAc in hexanes to provide  
1-cyclopropyl-2-(pyridin-4-yl)ethanone (0.505 g, 19.5 % yield). 1H NMR (400 MHz, 
Chloroform-d) δ 8.64-8.47 p.p.m. (m, 2H), 7.22-7.03 (m, 2H), 3.87 (s, 2H), 1.99 (tt, J = 7.8, 4.5 
Hz, 1H), 1.16-1.01 (m, 2H), 0.94 (dt, J = 8.1, 3.5 Hz, 2H). HRMS (m/z): [M+] cald for 






N,N-dimethylformamide dimethyl acetal (0.43 mL, 3.24 mmol, 2.0 mol equiv) was added  
2 (261 mg, 1.62 mmol) and heated to 90 °C, neat for 6 h. Upon completion excess reagent was 
evaporated and the residue was dissolved in water and extracted with DCM (3 X). The combined 
organic layers were dried (sodium sulfate), concentrated and the crude material was pushed 
forward to the next step.  
 
4-cyclopropyl-5-(pyridin-4-yl)pyrimidin-2-amine (1)  
To a solution of sodium ethoxide (242 mg, 3.51 mmol, 1.1 mol equiv) in ethanol 8 mL, 
guanidine hydrochloride (335 mg, 3.51 mmol, 1.1 mol equiv) was added and stirred for 30 min 
before the addition of a solution of (E)-1-cyclopropyl-3-(dimethylamino)-2-(pyridin-4-yl)prop-2-
en-1-one  (0.7 g, 3.24 mmol) in ethanol (2 mL) at 25 °C. The reaction was stirred at 40 °C for 4 
h. Upon completion, the reaction was diluted with water and extracted 3 times with ethyl acetate. 
The combined organic layers were dried (sodium sulfate), concentrated and purifed by 
combiflash 0->2% MeOH in DCM to provide 4-cyclopropyl-5-(pyridin-4-yl)pyrimidin-2-amine 
(360 mg, 16% yield). H1 NMR (400 MHz, Chloroform-d) δ 8.78 -8.59 p.p.m. (m, 2H), 8.08 (s, 
1H), 7.43-7.33 (m, 2H), 5.11 (s, 2H), 1.97 (tt, J = 8.0, 4.7 Hz, 1H), 1.30-1.18 (m, 2H), 0.96 (dq, J 
= 8.2, 3.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 169.75, 162.56, 156.86, 149.96, 145.04, 






To a stirred solution of 4-methoxyphenacetyl chloride (0.5 g, 2.71 mmol) and copper  
bromide (0.389 g, 1.0 mol equiv) in THF at 0 °C, cyclopropylmagnesium bromide solution (0.5 
M in THF, 6 mL, 2.98 mmol, 1.1 mol equiv) was added over 20 minutes. The resulting mixture 
was slowly warmed to room temp and stirred for an additional 4 h. Upon completion, the 
reaction was quenched with a saturated solution of ammonium chloride and the crude material 
was extracted three times with ethyl acetate. The combined organic layers were dried (sodium 
sulfate), concentrated, and purified by combiflash 0->50% EtOAc in hexanes to yield 1-
cyclopropyl-2-(4-methoxyphenyl)ethanone (136 mg, 26% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 7.20-7.08 p.p.m. (m, 2H), 6.97- 6.83 (m, 2H), 3.83 (s, 4H), 3.79 (s, 2H), 2.01- 
1.94 (m, 1H), 1.08-0.99 (m, 2H), 0.87 (dt, J = 8.1, 3.4 Hz, 2H). HRMS (m/z): [M+] cald for 
C12H14O2, 190.24, found 212.4.  
 
4-cyclopropyl-5-(pyridin-3-yl)pyrimidin-2-amine (2)  
Prepared according to scheme 1 using 3-picoline in place of 4-picoline in step (a). 1H NMR (400 
MHz, Chloroform-d) δ 8.69 p.p.m. (dd, J = 2.3, 0.9 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 8.07 
(s, 1H), 7.74 (dt, J = 7.8, 2.0 Hz, 1H), 7.39 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 5.10 (s, 2H), 1.90 (tt, J 
= 8.0, 4.7 Hz, 1H), 1.25-1.18 (m, 2H), 0.99-0.90 (m, 2H). HRMS (m/z): [M+] cald for 




4-cyclopropyl-5-(pyridin-2-yl)pyrimidin-2-amine (3)  
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Prepared according to scheme 1 using 2-picoline in place of 4-picoline in step (a). 1H NMR (400 
MHz, Chloroform-d) δ 8.72 p.p.m. (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 8.29 (s, 1H), 7.75 (td, J = 7.7, 
1.9 Hz, 1H), 7.49 (dt, J = 7.9, 1.1 Hz, 1H), 7.29- 7.16 (m, 1H), 5.20 (s, 2H), 2.25 (tt, J = 8.0, 4.7 
Hz, 1H), 1.21 (dq, J = 4.7, 3.6 Hz, 2H), 0.94 (dq, J = 8.1, 3.6 Hz, 2H). HRMS (m/z): [M+] cald 
for C12H12N4, 212.25, found 213.11.  
 
4-cyclopropyl-5-(quinolin-4-yl)pyrimidin-2-amine (4)  
Prepared according to scheme 1 using lepidine in place of 4-picoline in step (a). 1H NMR  
(400 MHz, Chloroform-d) δ 9.01 p.p.m. (d, J = 4.3 Hz, 1H), 8.21 (dt, J = 8.5, 1.0 Hz, 1H), 8.11 
(s, 1H), 7.84-7.71 (m, 2H), 7.57 (ddd, J = 8.3, 6.8, 1.2 Hz, 1H), 7.38 (d, J = 4.3 Hz,  5 H), 5.02 
(s, 2H), 1.50 (tt, J = 8.0, 4.6 Hz, 1H), 1.27-1.09 (m, 2H), 0.83 (dddd, J = 6.8, 5.7, 4.3, 1.9 Hz, 
2H). HRMS (m/z): [M+] cald for C16H14N4, 262.31, found 262.12.  
 
4-cyclopropyl-5-phenylpyrimidin-2-amine (5)  
Prepared according to scheme 1, using 1-cyclopropyl-2-phenylethanone (prepared using the 
procedure for 1-cyclopropyl-2-(4-methoxyphenyl)ethanone) for step (b) in place of 1-
cyclopropyl-2-(pyridin-4-yl)ethanone. 1H NMR (300 MHz, Chloroform-d) δ 8.08 p.p.m. (s, 1H), 
7.55-7.30 (m, 6H), 4.90 (s, 2H), 2.01 (ddd, J = 8.1, 4.8, 3.3 Hz, 1H), 1.25-1.13 (m, 2H), 0.99-




4-cyclopropyl-5-(4-methoxyphenyl)pyrimidin-2-amine (6)  
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Prepared according to scheme 1, using 1-cyclopropyl-2-(4-methoxyphenyl)ethanone for  step (b) 
in place of 1-cyclopropyl-2-(pyridin-4-yl)ethanone. 1H NMR (400 MHz, Chloroform-d) δ 8.03 
p.p.m. (s, 1H), 7.33-7.26 (m, 2H), 6.97 (d, J = 8.7 Hz, 2H), 4.93 (s, 2H), 3.84 (s, 3H), 1.98 (tt, J = 
8.0, 4.7 Hz, 2H), 1.24-1.06 (m, 2H), 0.88 (dq, J = 8.1, 3.5 Hz, 2H). HRMS (m/z): [M+] cald for 
C14H15N3O, 241.29, found 242.13.  
 
4-cyclopropyl-5-(4-fluorophenyl)pyrimidin-2-amine (7)  
Prepared according to scheme 1, using 1-cyclopropyl-2-(4-fluorophenyl)ethanone  (prepared 
using the procedure for 1-cyclopropyl-2-(4-methoxyphenyl)ethanone) for step  
(b) in place of 1-cyclopropyl-2-(pyridin-4-yl)ethanone. 1H NMR (400 MHz, Chloroform-d) δ 
8.04 p.p.m. (s, 1H), 7.42-7.32 (m, 2H), 7.14 (t, J = 8.7 Hz, 2H), 5.06 (s, 2H), 1.94 (tt, J = 8.0, 4.7 
Hz, 1H), 1.23-1.14 (m, 2H), 0.97-0.80 (m, 2H). HRMS (m/z): [M+] cald for C13H12FN3, 
229.25, found 229.10.  
  
5-(3-bromopyridin-4-yl)-4-cyclopropylpyrimidin-2-amine (8)  
Prepared according to scheme 1, starting from 3-bromo-4-methylpyridine for step (a) in place of 
4-picoline. 1H NMR (300 MHz, Chloroform-d) δ 8.86 p.p.m. (d, J = 0.6 Hz, 1H), 8.60 (d, J = 4.9 
Hz, 1H), 7.99 (s, 1H), 7.28 (d, J = 1.5 Hz, 2H), 5.01 (s, 2H), 1.59-1.47 (m, 1H), 1.36-1.06 (m, 
3H), 0.94 (d, J = 21.4 Hz, 2H). HRMS (m/z): [M+] cald for C12H11BrN4, 291.15, found 290.50.  
 
4-cyclopropyl-5-(3-vinylpyridin-4-yl)pyrimidin-2-amine (9)  
To a solution of 5-(3-bromopyridin-4-yl)-4-cyclopropylpyrimidin-2-amine (60 mg, 0.206 mmol) 
and tetrakis(triphenylphosphine)palladium(0) (0.0103 mmol, 5%), tributylvinyl tin (0.309 mmol, 
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1.5 mol equiv) was added and heated to 80 °C for 24 h. Upon completion, a 1 M solution of KF 
(0.309 mL, 0.309 mmol, 1.5 mol equiv) was added and stirred for 12 h at 25 °C. The mixture 
was then filtered over celite, diluted with water and extracted 3X with ethyl acetate. The 
combined organic layers were dried (sodium sulfate), concentrated, and purified by preparative 
TLC 2% MeOH in DCM to provide 4-cyclopropyl-5-(3-vinylpyridin-4-yl)pyrimidin-2-amine (15 
mg, 31% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.87 p.p.m. (s, 1H), 8.54 (dd, J = 5.0, 1.3 
Hz, 1H), 7.94 (d, J = 1.3 Hz, 1H), 7.17 (dd, J = 5.0, 0.8 Hz, 1H), 6.57 (dd, J = 17.7, 11.2 Hz, 1H), 
5.78 (dd, J = 17.7, 1.0 Hz, 1H), 5.33 (dd, J = 11.2, 1.0 Hz, 1H), 5.21-4.88 (m, 2H), 1.56 (ddd, J = 
9.2, 4.6, 3.2 Hz, 1H), 1.22-1.03 (m, 2H), 0.99- 0.76 (m, 2H). HRMS (m/z): [M+] cald for 
C14H14N4, 238.29, found 238.12.  
 
4-cyclopropyl-5-(3-phenylpyridin-4-yl)pyrimidin-2-amine (10)  
To a stirred solution of 5-(3-bromopyridin-4-yl)-4-cyclopropylpyrimidin-2-amine (60 mg, 0.206 
mmol), phenyboronic acid (38 mg, 0.309 mmol, 1.5 mol equiv), 
Tetrakis(triphenylphosphine)palladium(0) (0.0103 mmol, 5%), a 2M solution of sodium 
carbonate (0.525 mL, 1.03 mmol, 5.0 mol equiv) was added. The resulting mixture was heated to 
80 °C for 24 h. Upon completion, the reaction was diluted with water and extracted with ethyl 
acetate 3X. The combined organic layers were dried (sodium sulfate), concentrated and purified 
by preparative TLC, 1:1 ethylacetate in hexanes to yield 4-cyclopropyl-5-(3-phenylpyridin-4-
yl)pyrimidin-2-amine (35 mg, 58% yield). 1H NMR (300 MHz, Chloroform-d) δ 8.74-8.62 
p.p.m. (m, 2H), 7.85 (d, J = 1.2 Hz, 1H), 7.35-7.23 (m, 4H), 7.23 -7.11 (m, 2H), 4.99 (s, 2H), 
3.52-3.43 (m, 1H), 2.05 (d, J = 9.1 Hz, 1H), 1.43-0.45 (m, 5H). HRMS (m/z): [M+] cald for 
C18H16N4, 288.35, found 289.10.  
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4-cyclopropyl-5-(3-(furan-3-yl)pyridin-4-yl)pyrimidin-2-amine (11)  
Prepared from compound 8, according to the conditions described for compound 10. 1H NMR 
(300 MHz, Chloroform-d) δ 8.74 p.p.m. (d, J = 0.8 Hz, 1H), 8.58 (d, J = 5.0 Hz, 1H), 7.93 (s, 
1H), 7.38 (t, J = 1.7 Hz, 1H), 7.33-7.15 (m, 3H), 6.26 (dd, J = 1.9, 0.9 Hz, 1H), 5.01 (s, 2H), 1.50 
(td, J = 8.0, 3.9 Hz, 1H), 0.87 (dd, J = 84.0, 44.1 Hz, 5H). HRMS (m/z): [M+] cald for 
C16H14N4O, 278.31, found 279.10.  
 
5-(2-bromopyridin-4-yl)-4-cyclopropylpyrimidin-2-amine (12)  
Prepared according to scheme 1, starting from 2-bromo-4-methylpyridine for step (a) in  
place of 4-picoline. 1H NMR (300 MHz, Chloroform-d) δ 8.42 p.p.m. (dd, J = 5.1, 0.7 Hz, 1H), 
8.29 (d, J = 5.0 Hz, 1H), 8.05 (s, 1H), 7.56 (dd, J = 1.6, 0.7 Hz, 1H), 7.45-7.35 (m,  
1H), 7.37-7.27 (m, 1H), 7.17 (dd, J = 5.1, 1.5 Hz, 1H), 5.11 (d, J = 9.2 Hz, 2H), 1.91 (tt, J  
= 8.0, 4.7 Hz, 1H), 1.24 (ddt, J = 6.5, 4.6, 2.5 Hz, 3H), 1.10- 0.86 (m, 2H). 13C NMR (101 MHz, 
CDCl3) 169.80, 162.76, 156.87, 150.05, 148.01, 142.58, 128.25, 123.44, 121.20, 14.15, 11.46.  




4-cyclopropyl-5-(2-(furan-3-yl)pyridin-4-yl)pyrimidin-2-amine (13)  
Prepared from compound 12, using the conditions described for compound 10. 1H NMR (400 
MHz, Chloroform-d) δ 8.65 p.p.m. (dd, J = 5.1, 0.9 Hz, 1H), 8.14-8.06 (m, 2H), 7.57-7.50 (m, 
2H), 7.23 (dd, J = 5.1, 1.7 Hz, 1H), 6.94 (dd, J = 1.8, 0.9 Hz, 1H), 5.00 (s, 2H), 2.00 (tt, J = 8.0, 
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4.7 Hz, 1H), 1.30-1.15 (m, 3H), 1.07-0.94 (m, 2H). 13C NMR (101 MHz, CDCl3) 169.34, 
162.17, 156.89,150.63, 134.93, 131.03, 130.52, 130.36, 128.46, 123.45, 121.80, 14.01, 11.11. 
HRMS (m/z): [M+] cald for C16H14N4O, 278.31, found 278.01.  
 
4-isopropyl-5-(pyridin-4-yl)pyrimidin-2-amine (14)  
Prepared according to scheme 1, using ethyl isobutyrate for step (a) in place of ethyl cyclopropyl 
carboxylate. 1H NMR (400 MHz, Chloroform-d) δ 8.70-8.58 (m, 2H), 8.09 (s, 1H), 7.23-7.18 
(m, 2H), 5.06 (s, 2H), 3.03 (hept, J = 6.7 Hz, 1H), 1.18 (d, J = 6.7 Hz, 6H). HRMS (m/z): [M+] 
cald for C12H14N4, 214.27, found 214.12.  
 
4-methyl-5-(pyridin-4-yl)pyrimidin-2-amine (15)  
Prepared according to scheme 1, using ethyl acetate for step (a) in place of ethyl cyclopropyl 
carboxylate.1H NMR (300 MHz, Chloroform-d) δ 8.71- 8.58 p.p.m. (m, 2H), 8.14 (s, 1H), 7.24-
7.18 (m, 2H), 5.07 (s, 2H), 2.37 (s, 3H). HRMS (m/z): [M+] cald for C10H10N4, 186.21, found 
187.10.  
 
5-(pyridin-4-yl)pyrimidin-2-amine (16)  
Prepared from 2-amino 5-bromopyrimidine and 4-pyridinyl boronic acid, using the conditions 
described for compound 10. 1H NMR (400 MHz, Chloroform-d) δ 8.75-8.66 p.p.m. (m, 2H), 
8.63 (s, 2H), 7.47-7.38 (m, 2H), 5.37 (s, 2H). HRMS (m/z): [M+] cald for C9H8N4, 172.19, 
found 173.08.  
 
4-cyclobutyl-5-(pyridin-4-yl)pyrimidin-2-amine (17)  
175	  
Prepared according to scheme 1, using ethyl cyclobutanecarboxylate for step (a) in place of ethyl 
cyclopropyl carboxylate. 1H NMR (400 MHz, Chloroform-d) δ 8.70-8.60 p.p.m. (m, 2H), 8.08 
(s, 1H), 7.19- 7.11 (m, 2H), 5.11 (s, 2H), 3.70 -3.50 (m, 1H), 2.57-2.35 (m, 2H), 2.16-1.99 (m, 
2H), 1.99-1.83 (m, 2H). HRMS (m/z): [M+] cald for C13H14N4, 226.28, found 226.12.  
 
4-phenyl-5-(pyridin-4-yl)pyrimidin-2-amine (18)  
Prepared according to scheme 1, using ethyl benzoate for step (c) in place of ethyl cyclopropyl 
carboxylate. 1H NMR (400 MHz, Chloroform-d) δ 8.57- 8.48 p.p.m. (m, 2H), 8.37 (s, 1H), 7.43- 
7.30 (m, 5H), 7.10- 7.04 (m, 2H), 5.38 (s, 2H). HRMS (m/z): [M+] cald for C15H12N4, 248.28, 
found 247.10.  
 
4-(furan-2-yl)-5-(pyridin-4-yl)pyrimidin-2-amine (19)  
Prepared according to scheme 1, using ethyl 3-furoate for step (a) in place of ethyl cyclopropyl 
carboxylate. 1H NMR (400 MHz, chloroform-d) δ 8.74-8.64 p.p.m. (m, 2H), 8.21 (s, 1H), 7.45 
(dd, J = 1.8, 0.8 Hz, 1H), 7.27- 7.20 (m, 2H), 6.57 (dd, J = 3.6, 0.8 Hz, 1H), 6.41 (dd, J = 3.5, 1.7 




4-cyclopropyl-2-methyl-5-(pyridin-4-yl)pyrimidine (20)  
Prepared according to scheme 1, using acetamidine hydrochloride for step (c) in place of  
guanidine hydrochloride. 1H NMR (300 MHz, Chloroform-d) δ 8.77- 8.67 p.p.m. (m, 2H),  
8.34 (s, 1H), 7.40- 7.35 (m, 2H), 2.66 (s, 3H), 1.97 (tt, J = 8.0, 4.7 Hz, 1H), 1.35-1.23 (m,  
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2H), 1.07- 0.94 (m, 2H). HRMS (m/z): [M+] cald for C13H13N3, 211.22, found 212.12.  
 
4-cyclopropyl-5-(2-fluoropyridin-4-yl)pyrimidin-2-amine (21)  
Prepared according to scheme 1 using 2-fluoro-4-methylpyridine for step (a). 1H NMR  
(400 MHz, Chloroform-d) δ 8.29 (d, J = 5.2 Hz, 1H), 8.09 (s, 1H), 7.38-7.19 (m, 1H),  
7.01 (t, J = 1.6 Hz, 1H), 5.38-4.92 (m, 2H), 1.94 (td, J = 8.0, 4.0 Hz, 1H), 1.31-1.13 (m,  
2H), 1.07 ? 0.94 (m, 2H). HRMS (m/z): [M+] cald for C12H11FN4, 230.25, found 231.1.  
 
 5-(2-chloropyridin-4-yl)-4-cyclopropylpyrimidin-2-amine (22)  
Prepared according to scheme 1 using 2-chloro-4-methylpyridine for step (a). 1H NMR (400 
MHz, Chloroform-d) δ 8.45 (dd, J = 5.2, 0.7 Hz, 1H), 8.07 (s, 1H), 7.41 (dd, J = 1.5, 0.7 Hz, 1H), 
7.33-7.25 (m, 1H), 5.12 (s, 2H), 1.92 (tt, J = 8.0, 4.7 Hz, 1H), 1.34-1.16 (m, 2H), 1.00 (dt, J = 
8.0, 3.3 Hz, 2H). HRMS (m/z): [M+] cald for C12H11ClN4, 246.70, found 247.07.   
 
4-cyclopropyl-5-(2,6-dichloropyridin-4-yl)pyrimidin-2-amine (23)  
Prepared according to scheme 1 using 2,6-dichloro-4-methylpyridine for step (a). 1H NMR (400 
MHz, Chloroform-d) δ 8.06 (s, 1H), 7.34 (s, 2H), 5.16 (s, 2H), 1.89 (td, J = 8.0, 4.0 Hz, 1H), 
1.33-1.19 (m, 2H), 1.03 (dt, J = 8.0, 3.4 Hz, 2H). HRMS (m/z): [M+] cald for C12H10Cl2N4, 






Chapter 5: Conclusions and future directions 
 This thesis presents the development of two approaches for targeting protein-protein 
interactions and their application towards inhibiting RAS GTPases. The first utilizes a 
pharmacophore screen and focused in silico library design to find compounds that are capable of 
interacting with ‘hot spot’ residues at the protein-protein interface. The second entails the design 
of ligands making multiple contacts on a target using iterative cycles of in silico library design 
and molecular docking. The other portion of this thesis is focused on medicinal chemistry and 
strategies for the optimization of two anticancer agents.  
 
I. Pharmacophore strategy 
Ia. Summary 
 At the interface of two interacting proteins certain residues confer a larger portion of the 
overall binding affinity [87]. The pharmacophore approach described in this work attempts to 
encapsulate those interactions in the form of a searchable model to discover competitive 
inhibitors to the desired target.  
This model was designed based on key interactions of RAS with its three canonical 
effector proteins: RAF, PI3K, and RALGDS. The screening of existing chemical libraries was 
unsuccessful in yielding adequate matches to these properties, which motivated the rational 
design of molecular libraries to match target specific features. This yielded much closer matches 
and led to the discovery of compounds that were capable of binding to RAS as well as 





 The inhibition of protein-protein interactions has been historically challenging with β-
strand mediated interactions, such as those that RAS engages in, being particularly difficult [8]. 
This method can be applied to other protein-protein interactions if co-crystallographic and 
mutagenesis data is available. This approach could also be used in combination with molecular 
docking to yield compounds with higher affinity than the described pharmacophore hits in this 
work.  
 
II. PAINT strategy 
IIa. Summary 
 The pharmacophore approach motivated an alternative strategy in which multiple 
contacts are made on the surface of RAS- PAINT. The design process first entails the docking of 
ligands into sites on a desired target that typically lack the properties of a conventional drug 
binding site, with the idea being that multiple contact points would confer enough binding 
affinity to be in the ideal drug range. This initial screen is used to find enriched molecular 
architectures in the top scoring molecules. Once identified, in silico libraries are designed in a 
given site using the underlying structure but with ‘linkage mimics’ to an adjacent site and 
additional points of diversity based on synthetic modifications that can be made. This library is 
then docked and top scoring compounds are selected, and subsequently amended to the 
underlying enriched structure in the next site. The resulting two-site spanning library undergoes 
the same process of in silico design introducing points of diversity based on possible synthetic 
modifications. This process led to the discovery of the compound 31MEW44, which binds to 
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RAS with low micromolar affinity and has showed RAS inhibiting activity in cell culture as well 
as activity in three different murine cancer models.  
 
IIb. Significance 
 The hope of this work is that the PAINT process can be used as an inhibitor design 
platform and be applied to other challenging targets. With the improving accuracy of docking 
algorithms and ever increasing number of published protein structures, strategies such as PAINT 
could prove to be valuable methods for the discovery of new biological tools and therapeutic 
agents.  
This is the first reported instance of a direct RAS inhibitor showing efficacy in a patient 
derived mouse xenograft model and evidence of the inhibition of RAS signaling in a genetically 
engineered mouse model. This molecule can be used as a tool for studying RAS function both in 
vitro and in vivo, and may lead to a new cancer drug.  
 
IIc. Future directions 
 The improvement of the potency of 31MEW44 through more extensive medicinal 
chemistry efforts is warranted before therapeutic translation. This would be aided greatly by 
additional characterization of the mode of binding of 31MEW44, such as a crystal structure 
bound to RAS. Attempts at extending into the Y32 site were unsuccessful at significantly 
improving binding affinity. With more knowledge of the precise mode of binding, additional 
ways of amending groups into the Y32 site or another adjacent site could be accomplished and 
the potency further improved.  
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Another direction of this project is further studies in murine cancer models. The toxicity 
observed in the KPf/fC model suggests that 31MEW44 would be more effective in a model that 
doesn’t utilize the Cre-lox system to obtain tissue specific expression. Recent advances in mouse 
models using crisper-cas have been successful in achieving tissue specific expression, as well as 
the simultaneous editing of multiple genes with only a single transfection of embryonic stem 
cells [83]. Using a mouse model with this system would be ideal for further studies of the 
pharmacological utility of 31MEW44 or an improved analog. 
Most importantly, the hope of this work is that the strategies implemented can be applied 
to other challenging targets. Current efforts in the Stockwell lab by Michael Gaschler are 
towards the development of an inhibitor to RHEB GTPase using this approach. Some exciting 
preliminary data suggests that the PAINT approach is indeed applicable to RHEB and hopefully 
to other target types. 
 
III. Medicinal chemistry of erastin and J9 
IIIa. Summary 
 Described in this work is the systematic modification of two anti-cancer agents with 
novel mechanisms of action. Each molecule was broken down into regions based on synthetic 
disconnection points and underwent iterative cycles of analog synthesis and biological 
evaluation. The potency and selectivity of both molecules was improved and an analog of erastin 





IIIb. Significance and future directions 
 The discovery of erastin and elucidation of its mechanism of action led to the 
characterization of an entirely new form of cell death, ferroptosis. The next stage of this project 
is studying ferroptosis in vivo. While PE showed activity in a mouse xenograft, it did not show 
activity in the more sophisticated mouse models it was evaluated in, in work done by Michael 
Badgley and Professor Kenneth Olive. Further ongoing efforts in this area have been towards the 
development of more potent analogs by Dr. Marie-Helene Larraufie and the optimization of drug 
formulation conditions to enable more extensive in vivo studies of ferroptosis. 
 The high level of sensitivity of J9 activity to minor modifications to the structure suggests 
a fairly specific target interaction is being made. The SAR studies have identified a position on 
this molecule that could be amenable to the introduction of a chemical group to facilitate target 
identification. An example would be a bifunctional aromatic ring containing a 
trifluoromethylphenyl diazarine (TPD) and an alkyne [111]. TPD are photoactivatable groups 
that form a reactive carbene species, which can then form a covalent bond with the target of J9 
[111]. The identification could then be facilitated by the attachment of a detectable group (such 
as fluorescein or biotin) by bioorthogonal click chemistry with the alkyne, and undergo 
subsequent proteomic analysis. This type of approach could facilitate the identification of the 
target of J9 and a better understanding of the mechanism underlying the resensitization of 
resistant T-ALL cells to GC therapy. This could lead to the development an improved therapy for 











Appendix	  Figure	  1	   |	  Disruption	  of	  RAS-­‐RAF	  and	  RAS-­‐RALGDS	  interactions	  by	  31MEW78	  and	  31MEW79.	  (a)	  Pull-­‐
down	  of	  GTP-­‐loaded	  KRASG12D	  with	  CRAF-­‐RBD	  agarose	  beads	  in	  the	  presence	  of	  31MEW79	  and	  31MEW78.	  (b)	  Pull-­‐down	  
of	  GTP-­‐loaded	  KRASG12D	  with	  GST-­‐tagged	  RALGDS	  using	  glutathione	  beads.	  	  
	  
Appendix	   Figure	   2	   |	   Microscale	   thermophoresis	   of	   31MEW79	   and	   31MEW78.	   Microscale	   thermophoresis	   of	  

























Appendix scheme 1 | synthesis of 31MEW79: a) (R)-2-amino-5-(tert-butoxycarbonylamino)pentanoic 
acid (1.0 eq), EDIPA (1.2 eq), HBTU (1.2 eq), 0oC THF, 30 min, then 2-aminoindan (1.5 eq), 25oC, 12 
h; b) piperdine (4.0 eq), 25oC, THF, 24 h; c) EDIPA (1.1 eq), chloroacetyl chloride (1.1 eq), 0oC, THF, 6 





Appendix	   Figure	   3	   |	   Binding	   site	   characterization	   of	   31MEW79.	   (a)	  Microscale	   thermophoresis	  measurements	   of	  
31MEW79	  binding	   to GppNHp-loaded KRASG12D, KRASG12D D38A and KRASG12D I36N. (b) 1H-15N HSQC spectrum of 50 µM 
KRASG12D bound-to GppNHp in the absence (blue) and presence (red) of 250 µM inhibitor 31MEW79.  Magnification of I36, 
E37 and S39 in the top left corner. These residues are shrinking (I36 and E37), or shifting (S39)-upon compound treatment. *1H-
15N HSQC NMR experiment performed by Dr. Anna Kaplan (Columbia University) 
 
Appendix 1: methods for the synthesis of the pharamcophore compounds 
 
(R)-tert-butyl 4-amino-5-(2,3-dihydro-1H-inden-2-ylamino)-5-oxopentylcarbamate (2) 
To a solution of (R)-2-amino-5-(tert-butoxycarbonylamino)pentanoic acid (1.1 g, 2.42 mmol) 
and DIPEA (0.51 mL, 2.9 mmol) at 0 oC in THF (150 mL) HBTU (1.1 g, 2.9 mmol) was added. 
After 30 min of stirring, 2-aminoindan (1) (0.48 mL, 3.63 mmol) was added and the resulting 
mixture was slowly warmed to 25 oC and stirred for an additional 12 h. After consumption of 
(R)-2-amino-5-(tert-butoxycarbonylamino) pentanoic acid, piperdine (0.95 mL, 9.68 mmol) was 
added to the crude reaction mixture and stirred for an additional 12 h. Upon completion, the 
contents of the reaction were concentrated and purified by combiflash 0→20% MeOH in DCM 
to provide (R)-tert-butyl 4-amino-5-(2,3-dihydro-1H-inden-2-ylamino)-5-oxopentylcarbamate 







2.67 (m, 6H), 1.89-1.51 (m, 2H), 1.44 (s, 9H). 13C NMR (100 MHz, d4-MeOD) δ 157.2, 140.7, 
140.7, 127.0, 126.4, 124.5, 124.2, 78.6, 39.6, 39.1, 39.0, 37.9, 27.5. HRMS (m/z): [M+H]+ cald 





To a solution of (R)-tert-butyl 4-amino-5-(2,3-dihydro-1H-inden-2-ylamino)-5-
oxopentylcarbamate (0.5 g, 1.43 mmol) and DIPEA (0.25 mL, 1.58 mmol) at 0 oC in THF (30 
mL) a solution of chloroacetyl chloride (0.126 mL, 1.58 mmol) in THF (3 mL) was added slowly 
dropwise. The resulting mixture was slowly warmed to 25 oC and stirred for an additional 6 h. 
Upon completion, the reaction was diluted with saturated aqueous NaHCO3 and extracted 3 
times with EtOAc. The combined organic layers were dried (Na2SO4), concentrated, and the 
crude material was purified by combiflash 0→10% MeOH in DCM to provide (R)-tert-butyl 4-
(2-chloroethanamido)-5-(2,3-dihydro-1H-inden-2-ylamino)-5-oxopentylcarbamate (3) (0.13 g, 
0.306 mmol, 21% yield). 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.3 Hz, 1H), 7.27-7.11 (m, 
5H), 4.89 (t, J = 6.2 Hz, 1H), 4.69 (dt, J = 7.7, 5.4 Hz, 1H), 4.64-4.52 (m, 1H), 4.06-3.78 (m, 2H), 
3.29 (tt, J = 12.2, 6.8 Hz, 3H), 3.06 (dd, J = 13.5, 6.4 Hz, 1H), 2.83 (dt, J = 16.0, 6.3 Hz, 2H), 
1.90-1.75 (m, 1H), 1.67 (dd, J = 14.1, 7.1 Hz, 1H), 1.50 (p, J = 7.0 Hz, 2H), 1.40 (s, 9H). 13C 
NMR (100 MHz, CDCl3) δ 170.9, 166.3, 156.5, 140.7, 126.8, 124.7, 79.3, 52.2, 50.6, 42.4, 39.9, 














To a solution of homopiperzine (92.1 mg, 0.920 mmol) in THF at 0 oC,  a solution of (R)-tert-
butyl 4-(2-chloroethanamido)-5-(2,3-dihydro-1H-inden-2-ylamino)-5-oxopentylcarbamate (3) 
(64.9 mg, 0.153 mmol) in THF (X mL) was added. The resulting mixture was slowly warmed to 
25 oC and stirred for 24 h. Upon completion the reaction contents were concentrated and purified 
by combiflash 0→30% MeOH to provide (R)-tert-butyl 4-(2-(1,4-diazepan-1-yl)ethanamido)-5-
(2,3-dihydro-1H-inden-2-ylamino)-5-oxopentylcarbamate (4) (70 mg, 93% yield). 1H NMR (400 
MHz, d4-MeOD) δ 7.22 (dd, J = 5.4, 3.4 Hz, 2H), 7.16 (dt, J = 5.1, 3.7 Hz, 2H), 4.60 (tt, J = 7.4, 
5.6 Hz, 1H), 4.40 (dd, J = 8.2, 5.6 Hz, 1H), 3.60-3.47 (m, 1H), 3.33 (q, J = 1.6 Hz, 3H), 3.31-
3.18 (m, 4H), 3.06 (td, J = 6.9, 2.1 Hz, 2H), 3.03-2.92 (m, 8H), 2.92-2.82 (m, 3H), 2.78 (dt, J = 
10.0, 5.6 Hz, 4H), 1.95-1.73 (m, 4H), 1.73-1.62 (m, 1H), 1.56-1.47 (m, 2H), 1.44 (s, 9H). 13C 
NMR (100 MHz, d4-MeOD) δ 172.3, 171.9, 140.7, 140.7, 126.4, 124.2, 61.5, 56.6, 55.1, 52.3, 
50.6, 48.9, 39.0, 38.8, 30.6, 30.0, 27.4, 26.0 HRMS (m/z): [M+H]+ cald for C26H42N5O4, 

































oxopentylcarbamate (4) (50 mg, 0.103 mmol) was dissolved in TFA (0.5 mL) and stirred for 12 
h at 25 oC. Upon completion the TFA was removed and the residue was re-suspended in MeOH 
and solid K2CO3 (100 mg, XS) was added. The crude material was purified by preparative TLC 
(15% MeOH in DCM) to provide 31MEW79 (28 mg, 70% yield). 1H NMR (400 MHz, d4-
MeOD) δ 7.22 (dt, J = 7.6, 3.6 Hz, 2H), 7.19-7.09 (m, 2H), 4.59 (tt, J = 7.3, 5.6 Hz, 1H), 4.43 
(dd, J = 8.1, 5.3 Hz, 1H), 3.31-3.17 (m, 4H), 2.97 (dt, J = 8.4, 6.4 Hz, 4H), 2.93-2.72 (m, 4H), 
2.04 (p, J = 5.9 Hz, 2H), 1.92-1.81 (m, 1H), 1.74 (tdd, J = 15.0, 8.8, 5.5 Hz, 3H). 13C NMR (100 
MHz, d4-MeOD) δ 126.4, 124.2, 61.00, 54.6, 52.1, 50.8, 45.9, 44.6, 38.9, 38.8, 29.4, 25.5, 23.6. 
HRMS (m/z): [M+H]+ cald for C21H34N5O2, 388.2707, found 388.2726 
 
4-amino-N-(3-(4-((4-(2-(4-chlorophenoxy)ethyl)piperazin-1-yl)methyl)-3-(3-fluorophenyl)-
1H-indol-1-yl)propyl)piperidine-4-carboxamide: 31MEW78  
This compound was prepared using the protocols for 31MEW79.1H NMR (400 MHz, d4-MeOD) 
δ 7.34-7.15 (m, 4H), 4.40 (dd, J = 8.2, 5.0 Hz, 1H), 3.54-3.37 (m, 2H), 3.31 (dd, J = 10.3, 5.2 
Hz, 4H), 3.19 (q, J = 16.0 Hz, 2H), 2.94 (td, J = 6.9, 3.2 Hz, 2H), 2.80 (q, J = 6.7, 6.1 Hz, 5H), 












128.5, 128.1, 126.0, 60.1, 52.3, 49.5, 43.2, 40.5, 38.8, 34.9, 29.0, 23.5. HRMS (m/z): [M+H]+ 
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